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Antimicrobial Roles for iNKT Cells and GM-CSF  
in Mycobacterium Tuberculosis Infection 
 
ABSTRACT 
Despite effective antibiotics, Mycobacterium tuberculosis (Mtb), the causative agent of 
tuberculosis, still infects nearly one-third of the worldʼs population. While key immune factors 
including CD4+ T cells and IFNγ production have been identified, there are still many antimicrobial 
mechanisms yet to be explored. Here we characterized the role of invariant natural killer T (iNKT) 
cells and GM-CSF during Mtb infection. 
iNKT cells are activated during many infections, but their effector functions are unknown 
in most cases. We investigated how iNKT cells suppress intracellular Mtb replication. When co-
cultured with Mtb-infected macrophages, iNKT cell activation, as measured by CD25 upregulation 
and IFNγ production, was primarily driven by IL-12 and IL-18. In contrast, iNKT cell control of Mtb 
growth was CD1d-dependent, and did not require IL-12, IL-18, or IFNγ. In this model, 
conventional activation markers did not correlate with iNKT cell antimicrobial function during Mtb 
infection. iNKT cell control of Mtb replication was also independent of TNF and cytolytic activity. 
Dissociating cytokine-driven activation and CD1d-restricted effector function, we uncovered a 
novel mediator of iNKT cell antimicrobial activity: GM-CSF. iNKT cells produced GM-CSF in a 
CD1d-dependent manner during Mtb infection, and GM-CSF was both necessary and sufficient to 
control Mtb growth.  
We next investigated GM-CSF production by other T cell subsets during Mtb infection. 
GM-CSF production increased in the lung over the course of infection and both innate and 
adaptive T cells produced GM-CSF. Preliminary results from adoptive transfer experiments using 
WT and GM-CSF-/- T cells revealed that T cell-derived GM-CSF contributed to control of bacterial 
iv 
growth in vivo. In our last set of studies, we addressed the mechanism by which GM-CSF leads to 
antimicrobial activity in macrophages. We found that GM-CSF altered host lipid metabolism within 
macrophages and this likely contributed to control of bacterial growth in a PPARγ-dependent 
manner.  
 Together, these studies identified GM-CSF as a novel antimicrobial effector function for 
both iNKT cells and other T cell subsets during Mtb infection and described how GM-CSF altered 
the intracellular niche for Mtb, preventing bacterial growth. These studies highlight the role for 
non-classical effector functions during Mtb infection. 
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Introductory Note 
This thesis is focused on novel antimicrobial mechanisms that control Mycobacterium 
tuberculosis (Mtb) infection. While this research was initially directed towards understanding the 
role of iNKT cells during Mtb, subsequent results led to further investigation into a role for GM-
CSF. 
Chapter 1 includes an overview of both tuberculosis and iNKT cell biology. The 
introduction begins with a short summary of the global health perspective on tuberculosis and a 
brief synopsis of the history of tuberculosis disease. Next, there is an overview of what is 
currently known about the immune response to Mtb. Following this is an introduction into the 
biology of iNKT cells. To link these topics together, the chapter ends with a discussion on the role 
for iNKT cells during microbial infection. 
Studies on the activation and effector function of iNKT cells during Mtb infection are 
discussed in Chapter 2. This work led to the identification of GM-CSF as a novel iNKT cell 
antimicrobial effector function and was recently published in the journal PLoS Pathogens. After 
GM-CSF was identified as an iNKT cell effector function during Mtb, follow-up studies were 
performed to characterize the role of T cell-derived GM-CSF during infection and these are 
included in Chapter 3. This work includes studies of different T cell subsets that express GM-
CSF in the lung during infection and analysis of its contribution to bacterial control. Chapter 4 
links GM-CSF as a T cell effector function to a direct cellular mechanism of bacterial control 
through exploration of the effect of GM-CSF on host lipid metabolism.   
Chapter 5 contains a general discussion of results focusing on two main themes. First, 
iNKT cells offer a tremendous opportunity to study novel effector mechanisms during infection 
due to the multitude of functions they express and the distinct activation pathway for a given 
pathogen may be key to understanding this. Second, GM-CSF and its perturbation of host cell 
metabolism may provide insight into Mtb biology and generate new therapeutic targets that alter 
metabolic pathways at the host-pathogen interface.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
 
 
Tuberculosis: a global health problem  
History of tuberculosis 
Immunity to Mycobacterium tuberculosis* 
Biology of invariant natural killer T (iNKT) cells 
Role for iNKT cells during microbial infection 
 
* Some of the text in this section has been adapted from the authorʼs own writing published in: 
 
Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. In search of a 
new paradigm for protective immunity to TB. Nat Rev Micro 2014, 12: 289-299. 
 
 
	   2	  
Tuberculosis: a global health problem  
 
Tuberculosis (TB) is one of humankindʼs oldest infectious diseases1. Despite evolving 
alongside us for thousands of years, it continues to be an urgent global public health problem.  
Nearly one-third of the worldʼs population is infected each year, yet most of these infections 
remain in a latent state. Once latently infected, individuals carry about a 10% lifetime risk of 
reactivation of their infection, which accounts for the 8 million people per year who become 
actively sick with Mycobacterium tuberculosis (Mtb), the causative agent of TB, and over 1 million 
people who die from the disease each year2. Mtb causes the second greatest number of deaths 
worldwide of any infectious agent2. Only HIV/AIDS causes more deaths. In the United States, 
almost 10,000 cases and over 500 deaths are reported each year. 63% of these cases are from 
foreign-born persons. These rates continue to decline in the U.S. from a peak in 19923. 
Importantly, Mtb primarily causes disease and death in young adults, which leads to a significant 
impact on economic activity in addition to overall morbidity and mortality.  
One of the biggest driverʼs of the tuberculosis epidemic in the modern era has been the 
emergence of HIV/AIDS. As HIV has spread across many populations, it has fueled the re-
emergence of tuberculosis. Tuberculosis is the leading cause of death of people infected with 
HIV. Co-infected individuals are 30 times more likely to develop active TB than those with single 
infections2. Each year there are over 1 million new cases of TB from HIV-positive individuals and 
75% of these cases are in Africa2. The World Health Organization (WHO) has set special policy 
guidelines to try to combat the synergism of these diseases.  Intensified case finding for TB 
cases, preventative isoniazid treatment, and infection control aim to ease the burden of TB 
disease on HIV-positive individuals4. 
 In addition to HIV-TB co-infection, the other major obstacle to combating tuberculosis is 
the rise of multi-drug resistant tuberculosis (MDR-TB), strains of bacteria resistant to the two most 
common first-line therapies, isoniazid and rifampin. With current drug regimens, treatment of 
tuberculosis requires 6-9 months of combination antibiotic drug therapy. These drugs can cause 
many painful side effects, leading to failures in treatment adherence and selection for mutants 
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resistant to antibiotics3. There are currently 450,000 new cases of MDR-TB each year as well as 
many case reports of extensively drug-resistant tuberculosis (XDR-TB), strains with drug 
resistance to additional second-line antibiotics2. The rise of MDR-TB and XDR-TB has put 
pressure on the public health community to push forward research of new antibiotic candidates. 
There is additional anxiety derived from the fact that the antibiotics used to treat tuberculosis were 
almost entirely developed in the 1950s and 1960s5. The recent breakthrough in the development 
of Bedaquiline in 2012 has added one more drug to the arsenal5. 
The World Health Organization (WHO) has made fighting the global TB epidemic a 
priority. The Stop TB WHO Strategy along with DOTS (directed observed treatment, short-course) 
have saved 22 million lives and decreased the death rate by 45% from 1990 to 20122. Moving 
forward, the WHO estimates that the global cost of combating TB disease over the ten-year 
period from 2006-2015 will be $56 billion. While half of the funding is available, they estimate a 
$31 billion funding shortage6. WHO guidelines focus on both directly treating and preventing 
disease as well as improving basic health infrastructure, empowering communities, and investing 
in resources for health care providers. While these steps will go far towards addressing the basic 
needs of infected individuals and stemming the wave of transmission, there are still many basic 
scientific questions remaining that must be addressed by basic research to move forward in 
therapeutic discovery.  
 
History of tuberculosis 
DNA from Mycobacterium tuberculosis has been found in human remains that date as far 
back as 9000 years, in neolithic relics found along the Eastern Mediterranean1 and Egyptian 
mummies dating back to 2000 BC7. Around 460 BC, Hippocrates identified tuberculosis, then 
known by its Greek name “phthisis,” as the most widespread infectious disease of the age.  
It was not until March 24, 1882 that the causative agent of tuberculosis, the bacterium 
Mycobacterium tuberculosis, was identified by Robert Koch. He received the 1905 Nobel Prize for 
this discovery. In 1890, based on his discovery of tuberculosis, he went on to publish “Kochʼs 
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Postulates”, a list of fundamental principles for identifying disease-causing pathogens8. Many of 
these criteria are still used today in the practice of modern microbiology.  
Through the 19th and early 20th century, tuberculosis continued to be a major public 
health problem fueled by poor urban living conditions that led to high transmission of the disease 
within crowded city tenements. In the U.S., the rate of death from tuberculosis in 1900 was 194 
out of 100,000 people9 and tuberculosis was estimated to cause nearly one-quarter of all deaths 
in Europe (the most by any single cause) through the early 1900ʼs. Around the same time, a 
movement in the medical field emerged with doctors moving patients into rural sanatoria, 
believing that fresh air and rural surroundings would help to cure them.  
Despite the length of human history in which public health has battled tuberculosis, there 
has only been one vaccine, BCG, implemented by public health programs to prevent tuberculosis. 
BCG is named Bacillus Calmette–Guérin after two French doctors at the Pasteur Institute, Albert 
Calmette and Camille Guerin, who subcultured virulent strains of a related mycobacteria species, 
Mycobacterium bovis, until it lost much of its virulence. It was first used as a vaccine in 1921 and 
continues to be used today to provide protection for newborns, although its reported efficacy in 
adults (0-80%) is highly variable10. The failure of BCG to provide long-lived protection against Mtb 
in adults remains one of the greatest dilemmas in the vaccine development and TB immunity 
fields. After years of research, it is still not clear what crucial aspect of immunity is missing during  
BCG-induced immune responses. Many vaccines in the development pipeline seek to boost the 
BCG response in order to lengthen protection, while others aim to replace it completely. In order 
to eventually develop an improved vaccine against Mtb, much more must be learned about what 
constitutes an effective immune response. 
 
Immunity to TB 
Infection of Mycobacterium tuberculosis generally begins with inhalation of aerosolized 
droplets containing Mtb bacilli, coughed up from another infected individual (Figure 1-1)11. These 
droplets fall into distal lung alveoli. While 70% of TB cases are pulmonary, Mtb can disseminate 
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to other organs including lymph node, bones, and the brain12. Mtb primarily infects alveolar 
macrophages, but can also infect other cells situated in the lung including dendritic cells13, 
recruited monocyte-derived macrophages14, neutrophils15, and epithelial cells16. As an obligate 
intracellular bacterium, Mtb has evolved numerous pathways to be taken up by myeloid cells17, 18. 
Macrophages phagocytose Mtb through a number of different receptors including complement 
receptors19, scavenger receptors20, and mannose receptors21, many of which are upregulated 
following recognition of the bacteria through pattern recognition receptors.  
 
Innate Immune recognition of Mtb 
Macrophages utilize numerous cell surface and intracellular receptors to recognize Mtb 
pattern-associated molecular patterns (PAMPs). Surface Toll-like receptor (TLR) TLR2 
recognizes lipoproteins, phosphatidylinositol mannans, and lipomannan22,	   and	   TLR9 located in 
phagosomes and lysosomes recognizes Mtb DNA23. C-type lectin receptors like DC-SIGN and 
mannose receptor recognize mannose-capped lipoarabinomannan (ManLAM)24, while Dectin-1 
recognition of Mtb remains unknown. Mincle was recently shown to recognize trehalose 
dimycolate (TDM), previously known as mycobacterial cord factor25, 26. Cytosolic receptors like 
NOD2 and NLRP3 recognize the peptidoglycan subunit N-glycolyl muramyl dipeptide as well as 
ESX-1 secreted products27. 
Many of these receptors have redundant functions and single knock-out murine models 
generally have minimal phenotypes. However, the lack of certain receptors like NOD2 and the 
absence of downstream factors that multiple signaling pathways convene on including ASC, 
caspase-1 and CARD9 lead to diminished immune responses with lower production of pro-
inflammatory cytokines like IL-12p70, IL-23, IL-6, IL-1β and TNF, ultimately leading to decreased 
T cell activation, higher bacterial burdens, and decreased overall survival of the host23, 28, 29, 30, 31. 
Interestingly, although mice lacking the signaling factor MyD88 also have increased susceptibility,  
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Figure 1-1. Immune Response to Mycobacterium Tuberculosis 
Mtb infection occurs primarily via the aerosol route, where alveolar macrophages take up the 
bacteria. Pattern recognition receptors (PRR) detect Mtb and signaling leads to pro-inflammatory 
cytokine production. During the innate immune response, innate lymphocytes, myeloid cells, and 
granulocytes are recruited to the lung. After dendritic cell migration to the draining lymph node, 
the adaptive response is initiated and granulomas are formed. In 90% of infected individuals, the 
immune response controls the infection leading to bacterial containment. In 10% of individuals, 
necrosis and caseation leads to bacterial dissemination and further transmission. (Adapted from 
“In search of a new paradigm for protective immunity to TB” (2014)32). 
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this has been attributed to its role in IL-1β and IL-18 signaling rather than TLR signal 
transduction23, 30, 31, 33. 
 
Initiation of the adaptive immune response 
By day 7 to 10 post-infection, dendritic cells are thought to transport Mtb from the lung to 
the draining lymph node, where they present antigen to T cells and initiate the adaptive immune 
response34. Here, IL-12p70 production has been shown to be crucial to generate Th1 IFNγ 
response35. Antigen-specific T cells expand and differentiate into effector cells, which then 
migrate back to the lung with other recruited lymphocytes to control the infection (Figure 1-1). 
Knockout mice studies have confirmed the crucial role for CD4+ T cells and their production of 
IFNγ and TNF at this stage36, 37, 38, 39. IFNγ plays an important role in activating infected 
macrophages to kill intracellular bacteria through expression of inducible nitric oxide synthase 
(iNOS) leading to production of nitric oxide, IFNγ-inducible GTPases, phagosomal maturation and 
acidification, Vitamin D receptor signaling and autophagy40, 41, 42, 43, 44. In addition, human genetic 
studies have linked mutations in IL-12, IFNγ, and STAT1 to disseminated infections of BCG and 
non-tuberculous mycobacteria (a closely related species to Mtb that is commonly found in the 
environment)45.  The presence of T cells in the lung also leads to the formation of granulomas, 
organized collections of lymphocytes, macrophages, and fibroblasts as well as inflammatory 
induced cell types including multinucleated giant cells and foam cells designed to wall off and 
control the growth of bacteria (Figure 1-1)46. Loss of control of bacterial growth due to T cell 
exhaustion, immunopathology, and other undescribed conditions leads to recrudescence and 
reactivation of Mtb. A major focus in the TB field is to better understand the immunological factors 
that keep Mtb in check and how these may change over the course of chronic infections. 
 
Mtb intracellular survival strategies 
 Once internalized, Mtb utilizes a number of strategies for intracellular survival. First, Mtb 
uses a number of secreted virulence factors to inhibit phagosome maturation, preventing 
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lysosomal fusion and excluding phagosomal vATPase, leading to inhibition of vesicle acidification 
and cargo degradation normally employed by macrophages to degrade intracellular pathogens47, 
48, 49. Second, Mtb expresses an arsenal of enzymes and proteins to detoxify reactive oxygen 
species (ROS) and reactive nitrogen intermediates (RNI) produced by activated macrophages 
and to repair cellular damage from environmental stresses produced by an active immune 
response50. Third, Mtb induces production of certain lipid mediators like LXA4 and inhibits the 
production of others like PGE2 to alter the cell death modality and inflammatory environment of its 
host cell51, 52. While a range of cell death fates have been observed during infection, these cellular 
changes, along with secretion of Mtb virulence factors like nuoG are thought to tip the cell fate of 
the macrophage in favor of necrosis over apoptosis53. Necrosis leads to release of bacteria and 
dissemination into other target cells, while apoptosis leads to containment of the bacteria within 
apoptotic blebs. Efferocytosis, uptake of the apoptotic debris by other macrophages, is 
associated with ultimate control of bacterial growth54, 55, 56. An apoptotic cell fate has also been 
linked to more efficient priming of CD8+ T cells during the adaptive phase of the immune 
response57. Fourth, Mtb manipulates antigen presentation by downregulating MHC II surface 
expression, essentially “hiding out” from the CD4+ T cell response, once it is initiated58. 
 
Critical immune cytokines 
Given the many strategies Mtb employs to buffer the antimicrobial efforts of IFNγ-
activated macrophages, it is no surprise that other cytokines and cell types also play crucial roles 
in controlling infection59. While CD4+ T cell production of IFNγ is critical, research has also shown 
that it is not sufficient to induce protection. For example, increased risk of infection for HIV-
positive patients has reinforced the critical nature of the CD4+ T cell response. However, risk for 
active TB in these patients does not actually correlate with the timing of loss of their CD4+ T cells, 
suggesting that the relationship between CD4+ T cells and the immune protection against TB is 
more complicated60, 61. In addition, a recent vaccine trial using MVA85A, a booster to BCG 
vaccination that led to enhanced IFNγ and polyfunctional T cell responses in initial studies, failed 
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to protect 4-6 month infants in a 2-year follow-up study, again suggesting that IFNγ responses 
are not sufficient to mediate protection62. There are now several studies that have directly 
addressed IFNγ-independent mechanisms of CD4+ T cell control63, 64. 
There are many other cytokines identified that participate in the immune response against 
Mtb. IL-18 enhances the IFNγ response as well as plays a secondary antimicrobial role that has 
yet to be fully worked out65. Antimicrobial activity has also been shown for IL-1α/β31. TNF is 
another critical T cell effector cytokine during infection and TNF-/- mice have been shown to be 
quite susceptible to Mtb66, 67. TNF synergizes with IFNγ to induce iNOS production as well as 
helps to maintain granuloma formation and reduce immunopathology52, 68, 69. The numerous 
reported cases of reactivated TB upon treatment with anti-TNF blockade for rheumatoid arthritis 
patients reinforce the importance of TNF in human infection as well70. 
GM-CSF-/- mice are highly susceptible to Mtb and GM-CSF treatment of human 
macrophages restricts intracellular growth of Mtb and M. avium71, 72, 73, 74. GM-CSF is produced by 
a multitude of cells including leukocytes, epithelial cells and fibroblasts, and loss of this cytokine 
leads to abnormalities in surfactant recycling and the development of a lung disease that 
resembles human pulmonary alveolar proteinosis. Overexpressing GM-CSF in epithelial cells 
reverses these lung abnormalities but the susceptibility to Mtb remains, suggesting that GM-CSF 
production by other cells contributes to protection in mice. Additionally, the presence of anti-GM-
CSF autoantibodies that block GM-CSF function has been linked to both cryptococcal meningitis 
and pulmonary TB in otherwise healthy subjects indicating that GM-CSF plays an important role 
in host defense against infection in people75. (The role of GM-CSF during Mtb infection will be 
discussed and tested further in Chapter 3 and 4).  
While many pro-inflammatory cytokines have been shown to play positive roles during 
Mtb infection, murine knock-out studies have shown that mice lacking type I IFN signaling have 
improved outcomes suggesting that IFNα/β may play detrimental roles during infection, although 
there is evidence that they can stimulate the immune system and may also have more positive 
effects too76, 77. 
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Contribution of additional immune cell types 
 Murine studies demonstrate a critical role for cell types other than conventional CD4+ T 
cells. In addition, data from non-human primates as well as human studies emphasize how the 
immune response is most effective when the responses from multiple cell types are coordinated.  
 Mice and non-human primates lacking CD8+ T cells are more susceptible to infection than 
intact mice, although the phenotype does not appear until very late during infection78, 79. Apart 
from production of IFNγ, CD8+ T cells have been shown to recognize Mtb-antigens and inhibit 
bacterial growth in vivo via cytolytic activity using perforin and Fas/FasL pathways80. Mice that 
lack these cytolytic effectors are also susceptible and a role for granulysin-mediated killing was 
demonstrated in human CD8+ T cells81, 82, 83. A role for B cells during infection is still unknown84.  
Th17 CD4+ T cells contribute to granuloma formation and recruitment of both antigen-
specific Th1 cells and neutrophils to the lung85, 86. IL-23 was shown to be critical for establishing a 
Th17 response87. While a Th17 response contributes to antimicrobial activity early on, adoptive 
transfer of Th17 cells led to only moderate protection and a prolonged Th17 response has been 
shown to increase immunopathology63, 88.  
 Similarly, neutrophils have been shown to play an important antimicrobial role early on 
during infection by producing pro-inflammatory cytokines and antimicrobial peptides, but their 
ongoing presence in the lung also leads to excess immunopathology and inflammation that can 
make resolution of the infection difficult89, 90, 91, 92. A role for IFNγ in limiting neutrophil-mediated 
inflammation may be an additional underappreciated effect of IFNγ93. This is one of many 
immunoregulatory pathways during infection that limit immunopathology. Others include: 
suppression of IL-1β by NO94, PD-1 expression95, 96, and Foxp3+ regulatory T cells97, 98, 99. 
Although limiting immunopathology is important, the response must be fine-tuned because it 
comes at the expense of an efficient immune response. 
 While conventional CD4+ and CD8+ T cells have been the focus of most vaccine 
research, there is now renewed interest in reviewing the role of non-classically-restricted T cells 
during infection100.  
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 γδ T cells are not required for bacterial control in mice, yet they are the dominant source 
of IL-17 during infection36, 86. In a non-human primate model, activation of γδ T cells by IL-2 and 
phosphoantigens have been shown to decrease bacterial burden during Mtb infection101. γδ T 
cells are capable of forming a recall response after BCG vaccination and Mtb challenge and 
recently the small organic phosphate antigens and alkylamines recognized by γδ T cells were 
identified, opening the door for future investigation of this cell type during Mtb infection102, 103, 104. 
 Mucosal associated invariant T (MAIT) cells recognize microbial-derived riboflavin 
metabolites presented on MR1 antigen presenting molecules and, as their name suggests, are 
found primarily at mucosal tissues, including the lung105. As innate-like lymphocytes, they share 
some characteristics with CD1-restricted T cells and γδ T cells. MAIT cells recognize Mtb-
infected cells and have been found in the human lung and peripheral blood106. While an 
antimicrobial role has been demonstrated for MAIT cells during other infection models, their role 
in Mtb infection has yet to be determined107. 
 Group I CD1-restricted T cells recognize mycobacterial lipids presented on CD1a, b, or c. 
While not present in mice, they have been detected in human peripheral blood and Mtb-infected 
individuals108, 109, 110, 111. CD1a, CD1b and CD1c-restricted T cells specifically recognize 
mycobacterial lipids: CD1a-restricted T cells recognize dideoxymycobactin, CD1b-restricted T 
cells recognize glucose monomycolate, and CD1c-restricted T cells recognize C32-
phosphomycoketide112. Their function and activation state during infection still remains to be 
determined. 
While there are many cell types whose function during infection requires further 
investigation, the work of this thesis was initiated by an interest in the role of invariant natural 
killer T (iNKT) cells during Mtb infection. iNKT cells recognize lipid and glycolipid antigens 
(reviewed in depth in the following section). In human biomarker studies, patients with active TB 
have reduced iNKT cell numbers in peripheral blood compared to latently infected or healthy 
individuals113, 114, 115. Murine iNKT cells cultured with Mtb-infected macrophages restrict bacterial 
growth in vitro and adoptive transfer of iNKT cells limits bacterial growth in vivo116. In addition, 
	   12	  
stimulation of infected mice with αGalCer, a potent synthetic ligand and activator of iNKT cells, 
has been shown to improve disease outcome and synergize with antibiotics117, 118. αGalCer also 
stimulates human iNKT cells to lyse Mtb-infected macrophages through granulysin production 
and kill intracellular bacteria in vitro119. This activation has also been implemented as an adjuvant-
strategy in vaccine design, where αGalCer was conjugated to BCG to enhance its efficacy120. 
Despite their ability to control Mtb growth when activated, iNKT cells are dispensable for bacterial 
control in an intact mouse during infection. Whether this is due to a murine-specific reliance on 
the dominant CD4+ T cell pathway, an iNKT cell effector function that is redundant with other cell 
types, or inhibition of activation during infection will be discussed in this thesis.  
 
Biology of Invariant Natural Killer T (iNKT) cells  
NKT cells influence many different immunological conditions including microbial infection, 
autoimmunity, asthma and allergy, cancer, and graft-versus-host disease121. NKT cells are 
thymus-derived T cells that recognize lipid antigens with both CD4+ and CD4-CD8- double-
negative (DN) populations in the mouse and CD4+, CD8+ or DN populations in humans. They 
were first discovered in 1987 as TCRαβ+ DN cells that produced cytokines and later in 1990 as 
NK1.1+ TCRαβ+ DN cells that were MHC class II-independent122. Eventually, these cells were 
discovered to express a semi-invariant TCR123, 124 and to be restricted by CD1d125 126.  
The first CD1d-presented lipid antigen to be discovered was α-Galactosylceramide 
(αGalCer), a lipid derived from marine sponges. Recognition of αGalCer is now used to identify 
iNKT cell populations127.  
Group I NKT cells express a semi-invariant TCR with invariant alpha-chains (Vα14-Jα18 
in mice and Vα24-Jα18 in humans) paired to a limited set of TCR beta-chains (Vβ8.2, Vβ7, and 
Vβ2 in mice, and Vβ11 in humans) and are the subject of the research in this thesis, further 
known as invariant NKT (iNKT) cells. Group II NKT cells or diverse NKT (dNKT) cells also 
recognize lipid antigens but are less prevalent and less well studied due to the challenge of 
identifying them as a population with diverse TCRs128. (Appendix II includes one study examining 
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the recognition of live Mtb infection and isolated mycobacterial lipids by human dNKT cell 
clones129). 
While many parallels can be drawn between iNKT cell TCR binding to antigens presented 
on CD1d and conventional T cell TCR binding to peptide-MHC complexes, there are also striking 
differences. Crystallography studies have discovered that the binding alignment of the iNKT cell 
αβ-TCR with the antigenic groove of CD1d is rotated compared to classical TCR-MHC that binds 
in a more parallel position130. In this configuration, only the CDR3 loop of the TCR α-chain is in 
contact with the lipid head group, with the CDR3 loop of the TCR β-chain binding directly to 
CD1d, shedding light on the requirement for α- but not β-chain invariance. This is in contrast to 
classic TCR-MHC binding where the CDR3 loop of both the α- and β-chain bind the loaded 
peptide.  
 
CD1d: trafficking, lipid antigen uptake, and presentation  
CD1d is one of 5 active CD1 genes found in humans. CD1a, CD1b, and CD1c present 
antigen to Group I CD1-recognizing T cells131.  While CD1e is not expressed on the cell surface, it 
is brought directly to endosomal compartments where it may assist in the lipid processing and 
loading of other CD1 molecules132, 133. Mice have lost CD1a, CD1b, CD1c, and CD1e due to a 
chromosomal break and express duplicate copies of CD1d134, making mice a useful biological 
tool for studying CD1d and iNKT cells. CD1d has similar structural homology to Class I MHC, with 
3 α-domains non-covalently associated with β2m135. CD1d is constitutively expressed by many 
different cell types including professional antigen presenting cells such as macrophages, dendritic 
cells, as well as B cells, granulocytes, and epithelial cells136, 137.  
CD1d heavy chain is synthesized in the endoplasmic reticulum (ER) and associated with 
β2-microglobulin (β2m). CD1d is first loaded with ER-resident self-lipids with help from 
microsomal triglyceride transfer protein138, 139. CD1d then follows the secretory route out of the 
ER, through the Golgi apparatus to the plasma membrane. From the cell surface, CD1d is then 
endocytosed into endosome and lysosome compartments, where ER-lipids are exchanged for 
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self- or microbial-lipids with the help of accessory proteins like saposins, apolipoprotein E, and 
CD1e (in human cells only)133, 140, 141, 142. Interactions with the invariant chain and MHC class II 
molecules have also been shown to be required for the presentation of lysosomal proteins143 144, 
145.  
 
iNKT cell development 
iNKT cells develop from the same precursor population as other T lymphocytes, starting 
in the bone marrow and migrating to the thymus. iNKT cells continue to follow the same pathway 
of thymic development through the CD4+CD8+ double-positive stage. Once they express the 
invariant Vα14 α-chain and limited β-chains through stochastic rearrangement, iNKT cells are 
positively selected on double-positive cortical thymocytes126 through presentation of yet identified 
self antigens presented on CD1d. Strong TCR signals lead to expression of early growth 
response protein 1 (EGRP1) and EGRP2, which promote expression of promyelocytic leukemia 
zinc finger protein (PLZF) transcription factor146. PLZF is thought to be a master regulator of iNKT 
cells and its expression is sufficient to promote many of the functions of iNKT cells147, 148. The 
shared usage of PLZF between iNKT cells and other innate lymphocytes including human MR1-
restricted MAIT cells147 and γδ T cells149 suggests that PLZF may serve a crucial role in inducing 
the “innate” phenotype and function shared by these cell types.	  
 iNKT cells then undergo four distinct stages of development, marked by changes in the 
surface expression of CD24, NK1.1 and CD44: (stage 0) CD24+, CD44lo, NK1.1-, (1) CD24-, 
CD44lo, NK1.1-, (2) CD24-, CD44hi, NK1.1-, (3) CD24-, CD44hi, NK1.1+121. iNKT cells generally exit 
the thymus at stage 2, where they finish their development in the periphery.  
Once in the periphery, iNKT cells undergo final maturation through interactions with 
professional APCs. While development of iNKT cells does not require CD1d-encoded sorting 
motifs, the peripheral activation of these cells does, as shown in studies utilizing CD1d-enhanced 
yellow fluorescent fusion protein (CD1d-EYFP)150. It has also been recently published that 
commensal microbiota influence the peripheral development of iNKT cells151, 152. 
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In C57BL/6J mice, iNKT cells constitute about 0.2-0.5% of total lymphocytes in most 
organs including spleen, lung, lymph nodes, gastrointestinal tract, thymus, and bone marrow, 
while they make up between 20-30% of lymphocytes in the liver153, 154. In human peripheral blood, 
iNKT cells make up 0.1-0.5% of lymphocytes155. Similar frequencies are found in human spleen, 
bone marrow, and lymph nodes, and the highest frequencies are found in the liver (1%) and 
omentum (10%)156. 
 
iNKT cell activation by TCR-dependent signals  
There are just several microbial lipids for iNKT cells that have been identified thus far with 
reproducible antigenicity. iNKT cells recognize: α-linked glycosphingolipids from Sphingomonas 
capsulata157, 158, α-linked glucosyl or galactosyl diacyglycerol from Borrelia burgdorferi159, and 
Streptococcus pneumoniae (Figure 1-2A)160.  
However, it was noted that there are numerous conditions that stimulate iNKT cells, 
including viral infections, cancer, autoimmune diseases, as well as developmental requirements 
for activation that would not occur in the presence of microbial products. Therefore, there was 
early understanding that self-lipid antigens could play an important role in iNKT cell activation and 
many groups attempted to identify these antigens. One of the early self-lipids discovered was 
isoglobotrihexosylceramide (iGb3), although aspects of its antigenicity and role in development 
are now controversial161, 162. The self antigen lysophosphatidylcholine activates human but not 
murine iNKT cells163. β-glucosylceramide (βGlcCer) was recently shown to activate iNKT cells 
and accumulate in response to TLR stimulation164. A role for plasmalogen 
lysophosphatidylethanolamine (plasmalogen lysoPE) in iNKT cell thymic development was 
recently demonstrated165. In addition, a recent study showed that endogenous lipid expression 
may be regulated by danger signals, where TLR/MyD88 stimulation leads to a decrease in 
lysosomal α-galactosidase A activity, allowing for the accumulation of stimulatory endogenous 
lipids166.  
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The system is fine-tuned so that every aspect of the loaded lipids contributes to the 
quality of the response. Lipid acyl chain length alters antigen processing/presentation pathways, 
while the head group influences affinity and half-life of the interaction167. Different ligands can 
induce different response polarization. While initially it was thought that this difference was due to 
variations in ligand affinities, studies have shown that kinetics of lipid loading and presentation 
play a larger role than affinity168. It was recently determined that autoreactivity (recognition of 
endogenous ligands) could partly be explained by a particular CDR3 β-loop sequence that 
directly associates with CD1d molecules169. 
 
iNKT cell activation by TCR-independent signals  
  In contrast to microbial and endogenous lipid stimulation, iNKT cells can also be 
activated independently of TCR signals through high concentration of cytokines including: IL-12, 
IL-18, IL-23, and IL-25 (Figure 1-2B)170. IL-12 especially has been shown to play an important role 
in iNKT cell activation in response to TLR agonists like LPS170, CpG and viral infections171, 172. 
 
iNKT cell activation by a combination of TCR-dependent and -independent signals  
   
As studies on iNKT cell activation have progressed, there is more and more evidence that 
iNKT cells are likely to be most often activated in vivo by a combination of weak TCR-dependent 
and TCR-independent signals (Figure 1-2C).  This was first described for Salmonella typhimurium 
infection157, 173 and more recently for 11 different heat-killed bacteria strains including gram-
positive, gram-negative, and α-proteobacteria, which all required both CD1d APC expression and 
IL-12p40 for IFNγ production174. Activation by Aspergillus fumigatus requires both CD1d 
expression as well as IL-12 production by dendritic cells dependent on dectin-1 recognition of β-
glucans presented by the fungi175. 
While independent effects of both CD1d-presented lipids and pro-inflammatory cytokines 
have been demonstrated for iNKT cells, there are also additional links in signaling that have been 
defined between these pathways. There are numerous examples of cytokine signals inducing 
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Figure 1-2.  Activation pathways of iNKT cells 
 
iNKT cells are activated during infection by multiple pathways. (A) TCR-dependent pathway. iNKT 
cells are activated by CD1d-mediated presentation of microbial lipids through their TCR. (B) TCR-
independent pathway. iNKT cells are activated by strong pro-inflammatory cytokines like IL-12 
and IL-18. (C) Combination TCR-dependent and -independent pathway. iNKT cells are activated 
by a combination of weak self-lipid presentation and low pro-inflammatory cytokine production.    
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changes in CD1d expression on APCs. Type I IFN was reported to upregulate CD1d expression 
during Listeria monocytogenes infection176. IFNγ and TNF produced by mycobacterial products 
induces CD1d expression on macrophages during Mtb infection177. In addition, a panel of TLR 
agonists leads to changes in glycosphingolipid biosynthesis in dendritic cells and increases in 
IFNγ production by co-cultured iNKT cells178. 
 
iNKT cell effector functions 
iNKT cells have been coined “the Swiss-Army knife of the immune system”179 due to their 
diverse repertoire of effector functions (Figure 1-3). They are best known for their ability to rapidly 
produce cytokines. These include: IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17, IL-21, IFNγ, 
GM-CSF, TNF, TGF-β and chemokines RANTES, Eotaxin, LT, MIP-1α, and MIP-1β179, 180. iNKT 
cells also have demonstrated cytolytic ability. In several murine studies, in vitro and in vivo 
αGalCer stimulation induced cytotoxicity that was predominantly Fas/FasL dependent181, 182. 
αGalCer stimulation of human iNKT cell clones also induced granulysin-mediated cytolysis of 
Mtb-infected macrophages119.  
Given the many effector functions ascribed to iNKT cells, many studies have divided 
iNKT cell populations into various subsets based on their function. One study of human peripheral 
iNKT cells found that effector function could be grouped by CD4 expression155. CD4- iNKT cells 
predominantly produced Th1 cytokines IFNγ and TNF, while CD4+ iNKT cells produced both Th1 
cytokines as well as Th2 cytokines like IL-4, IL-5, and IL-13. Apart from “Th1” and “Th2” iNKT cell 
subsets, several other minor populations have been described. Th17 iNKT cells require RORγt 
for development in the thymus, produce IL-17A, respond to IL-23, and are involved in neutrophil 
recruitment in the lung in mice, although a resident population of human Th17 iNKT cells has not 
been verified yet183, 184. An IL-21 producing follicular helper (Tfh) iNKT cell subset and an in vitro 
derived Foxp3+ regulatory T cell (Treg) iNKT subset have also been described185, 186. 
Because iNKT cells respond so rapidly and to many different inflammatory signals, 
studies have recognized their enormous influence in altering other aspects of the immune system. 
	   19	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3. iNKT cell effector functions 
 
iNKT cells have multiple effector functions  including: production of Th1, Th2, and Th17 cytokines,  
secretion of factors for monocyte maturation, chemokine production for recruitment of 
inflammatory cells, costimulation, and cytolytic activity. 
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iNKT-mediated immunomodulation can have dramatic pro-inflammatory effects. Through many 
mechanisms, iNKT cells can influence the activation of dendritic cells.  Production of GM-CSF 
and IL-13 by iNKT cells leads to the differentiation of monocytes into dendritic cells187. Early iNKT 
cell IFNγ production as well as costimulation through CD40/CD40L lead to maturation of DCs and 
increased IL-12 production from DCs that subsequently enhances CD8+ T cell cross-priming188, 
189. iNKT cells can also activate macrophages in a similar manner190. iNKT cell IFNγ production 
can also lead to trans-activation of NK cells191. iNKT cells also provide cognate B cell help192. 
Tim-1 expression on iNKT cells leads to activation by dying cells expressing phosphatidylserine, 
and this recognition was shown to contribute to airway inflammation193. 
Under certain conditions, immunomodulation by iNKT cells can also lead to 
immunosuppression. A number of studies have identified iNKT cells as an intermediary in the 
downregulating effect of type I IFN on CD8+ T cell priming in adjuvant stimulation and multiple 
sclerosis therapy194, 195. A lung inflammation model of IL-33-induced inflammation showed that 
iNKT cells led to downregulation of pulmonary inflammation, where Jα18-/- mice had increased 
inflammation and neutrophil recruitment196. Similarly, an anti-inflammatory role has been 
attributed to iNKT cells in the lung and liver during the resolving stages of infection with BCG (M. 
bovis)197. A number of studies have found a role for iNKT cells during airway inflammation in 
response to environmental antigens198, airborne lipid antigens199, susceptibility to acute influenza 
A200, as well as human asthma and COPD studies201. 
 
 Role for iNKT cells during microbial infection 
 The majority of the research on iNKT cells and infection has focused on the activating 
signals of iNKT cells. As a result, the number of infectious agents that have been demonstrated to 
activate iNKT cells is greater than the number of diseases where iNKT cells have been shown to 
be required. In addition, the majority of the studies demonstrating that iNKT cells are essential for 
pathogen control used knock-out animals to establish the requirement for iNKT cells, while very 
few studies followed up to determine the specific effector function utilized by iNKT cells to achieve 
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control. This section aims to summarize the studies thus far that have established a role for iNKT 
cells during infection and emphasize known effector functions.  
 
αGalCer-induced iNKT cell antimicrobial activity 
 One of the easiest ways to assess the function of iNKT cells during infection is to treat 
infected animals with αGalCer, an agent known to selectively activate and expand iNKT cells. 
Using this strategy, improved disease outcome has been observed after αGalCer treatment in 
bacterial, viral, parasite, and fungal infection models (See Table 1-1 for a full list and citations). In 
almost all studies that measured changes in iNKT cell function after αGalCer treatment, IFNγ was 
the effector function that was measured and the effector function that was found to be required. 
The other main immunological change observed in these studies was an expansion of CD8+ T 
cells, although this could also be attributed to an increase in IFNγ. In very few studies was any 
other effector function measured, despite the fact that αGalCer treatment has been linked to 
production of many different cytokines180 as well as cytolytic activity181, 182. 
 
Use of murine knock-out models to assess requirement for iNKT cells during infection 
 Once murine knock-out models like CD1d-/- and Jα18-/- became available to study 
infection in the absence of iNKT cells, this strategy became the easiest way to assess the role of 
iNKT cells. Additionally, comparing the two knock-out models allowed the role of diverse NKT 
cells to also be determined. There are at least 10 bacterial infections, 5 parasite models, 6 viral 
infections, and 1 fungus infection model that have associated the presence of iNKT cells with 
improved disease outcome and just 3 bacterial infections that demonstrated a worse outcome in 
the presence of iNKT cells (see Tables 1-2, 1-3, 1-4 for study details and citations)202.  
 The three infections where iNKT cells were demonstrated to have a negative impact on 
disease outcome reveal important aspects of iNKT biology. iNKT cells worsened infection of one 
strain of Chlamydia, (C. muridarum, the murine model for C. trachomatis) but not another (C. 
pneumoniae)203, 204. In these studies, the different strains polarized the immune response to either 
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Table1-1. αGalCer-induced iNKT cell antimicrobial activity 
 
Pathogen 
strain 
αGalCer 
treatment 
Disease outcome iNKT cell 
effector 
function 
Function 
shown to 
control 
infection 
Citation 
Brucella suis αGalCer loaded 
macrophages in 
vitro 
Decreased CFU IFNγ, 
cytolysis 
IFNγ, 
Fas/FasL, 
perforin 
205 
Chlamydia 
pneumoniae 
ip injection Decreased CFU IFNγ, 
decreased 
IL-4 
 204 
Listeria 
monocytogenes 
ip injection Decreased CFU IFNγ, NO IFNγ 206 
Mycobacterium 
tuberculosis 
ip injection Decreased CFU   118 
 ip injection, with 
antibiotics 
Decreased CFU, 
synergistic with 
antibiotics 
IFNγ  117 
 vaccination, 
added to BCG 
Decreased CFU 
after challenge 
Increased 
CD8+ T cell 
response 
 120 
 αGalCer loaded 
macrophages in 
vitro 
Decreased CFU granulysin-
mediated 
cytolysis 
granulysin 119 
Pseudomonas 
aeruginosa 
ip injection Decreased CFU IFNγ  207 
 ip injection Decreased CFU IFNγ, TNF  208 
EMCV-D ip injection Decreased paralysis   209 
HBV iv injection Decreased viral load Increased 
IFNα, IFNβ, 
IFNγ 
IFNα, 
IFNβ, 
IFNγ (not 
shown to 
be direct) 
210 
Influenza ip injection Decreased viral 
load, increased 
survival 
  211 
RSV ip injection Delayed viral 
clearance, 
decreased 
immunopathology 
Enhanced 
CD8+ T cell 
response 
 212 
Cryptococcus 
neoformans 
ip injection Decreased CFU IFNγ IFNγ 213 
Plasmodium 
berghei 
ip injection Decreased parasite 
burden 
IFNγ IFNγ 214 
 Vaccine, added 
to irradiated 
sporozoites or 
recombinant 
virus  
Decreased parasite 
burden 
IFNγ IFNγ 215 
Trypanosoma 
cruzi 
ip injection Decreased parasite 
burden, increased 
survival 
  216 
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a Th1 IFNγ (C. pneumoniae) or Th2 IL-4 response (C. muridarum). This polarization was 
exacerbated by the presence of iNKT cells and further by the stimulation of iNKT cells with 
αGalCer. Here, the strain that induced iNKT cell Th2 polarization, but not Th1 polarization, led to 
a worsening of disease in the presence of these cells. This result suggests that iNKT cell 
polarization and the subsequent transactivation of other cell types may be a critical component of 
iNKT cell effector responses during infection.  
In the second infection, the presence of iNKT cells was critical for bacterial control with 
Sphingomonas capsulata, yet mice lacking iNKT cells were spared from fatal septic shock 
induced by high dose iv infection157. These results suggest that the rapid and strong response 
produced by iNKT cells is generally beneficial to the host, but under conditions of massive 
inflammation, iNKT cells can push the system over the edge.  
In the third infection model, mice infected with an α-proteobacteria strain commonly found 
in soil and water, Novosphingobium aromaticivorans, developed autoantibodies against a 
mitochondrial enzyme leading to liver damage similar to human primary biliary cirrhosis217. This 
autoimmune effect was mediated by iNKT cells and mixed bone marrow chimera data suggest 
iNKT cells may provide direct B cell help to induce autoantibody production through CD1d-
mediated recognition. Other data suggest that the biological link between mitochondrial Pyruvate 
Dehydrogenase Complex E2 (PDC-E2) and Novosphingobium aromaticivorans may be an 
example of molecular mimicry.  
 
Pathogen-induced iNKT cell antimicrobial activity 
 The majority of studies examining iNKT cell antimicrobial activity measured iNKT cell 
IFNγ production during infection. One study of Streptococcus pneumoniae infection found that 
Jα18-/- mice had increased susceptibility compared to WT mice218 and treatment with recombinant 
IFNγ reversed this phenotype. Adoptively transferring liver mononuclear cells, as a source of 
primary iNKT cells, from both WT and IFNγ-/- mice into Jα18-/- hosts, the authors demonstrated 
that IFNγ directly coming from iNKT cells was required for their effect. However, it was not clear 
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Table 1-2. iNKT cell effector function during bacterial infection. 
 
Pathogen 
strain 
KO model Disease outcome iNKT cell 
effector 
function 
Function 
shown to 
control 
infection 
Citation 
Borrelia 
burgdorferi 
Jα18-/- Increased CFU IFNγ  219 
 CD1d-/- Increased CFU IFNγ  220 
Chlamydia 
pneumoniae 
Jα18-/-, CD1d-/- Increased CFU, 
Increased 
immunopathoogy 
IFNγ, increase 
in T cell IFNγ 
 203 
Ehrlichia muris CD1d-/- Increased CFU IFNγ  157 
Listeria 
monocytogenes 
CD1d-/- Increased CFU IFNγ  221 
Mycobacterium 
bovis 
Jα18-/- Increased 
immunopathology 
anti-
inflammatory 
 197 
Mycobacterium 
tuberculosis 
Anti-CD1d Increased CFU 
(early) 
  222 
 In vitro 
infection, 
adoptive 
transfer 
Addition of iNKT 
cells decreased 
CFU in vitro and in 
vivo 
IFNγ  116 
Pseudomonas 
aeruginosa 
CD1d-/- Increased CFU PMN 
recruitment, 
MIP-2 
 207 
Sphingomonas 
capsulata 
Jα18-/-, CD1d-/- Increased CFU IFNγ  157 
Sphingomonas 
yanoikuyae 
CD1d-/- Increased CFU IFNγ, IL-4  158 
Streptococcus 
pneumoniae 
Jα18-/- Increased CFU, 
decreased survival 
IFNγ  174 
 Jα18-/- Increased CFU, 
decreased survival 
PMN 
recruitment 
 223 
 Jα18-/- Decreased survival IFNγ IFNγ 218 
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Table 1-3. iNKT cell effector function during viral infection. 
 
Pathogen 
strain 
KO model Disease outcome iNKT cell 
effector 
function 
Function 
shown to 
control 
infection 
Citation 
EMCV-D CD1d-/- Increased paralysis IFNγ  224 
 CD1d-/-, in vitro 
infection 
Increased viral titer 
in vivo and in vitro 
Enhanced T 
cell activation 
 225 
 CD1d-/- Increased paralysis   209 
HSV-1 Jα18-/-, CD1d-/- Increased viral load   226 
 Jα18-/-, CD1d-/- Increased viral 
load, decreased 
survival (CD1d-/- 
only) 
IFNγ  227 
HSV-2 CD1d-/- Decreased survival Early IFNγ  228 
Influenza A Jα18-/-, CD1d-/- Decreased survival CD40/CD40L; 
Inhibition of 
MDSCs and 
expansion of 
CD8+ T cells 
 229 
 
  Decrease in 
epithelial cell death 
IL-22  230 
 
 Jα18-/ Decreased survival, 
no change in viral 
load 
Inhibition of 
inflammatory 
monocytes 
 231 
 
 Jα18-/ Decreased survival, 
increased 
pathology, no 
change in viral load 
Expansion of 
antigen-
specific CD8+ 
T cells, 
increase in 
CD103 DC 
 200 
MCMV CD1d-/- Decreased survival IFNγ, increase 
in NK cell 
IFNγ 
 232 
RSV CD1d-/- Increased viral load Expansion of 
antigen-
specific CD8+ 
T cells 
 212 
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Table 1-4. iNKT cell effector function during parasitic and fungal infections. 
 
Pathogen 
strain 
KO model Disease outcome iNKT cell 
effector 
function 
Function 
shown to 
control 
infection 
Citation 
Aspergillus 
fumigatus 
CD1d-/- Increased CFU IFNγ  175 
Leishmania 
major 
Jα18-/- Increased parasite 
burden (iv, not sc) 
IFNγ, 
enhanced 
NK 
cytotoxicity 
 233 
Leishmania 
donvani 
CD1d-/- Increased parasite 
burden 
IFNγ  234 
Plasmodium 
berghei 
CD1d-/- Decreased survival 
(BALB/c, not B6) 
Th2 
polarization 
 235 
Trypanosoma 
cruzi 
Anti-CD1d Decreased survival   236 
 Jα18-/-, CD1d-/- Decreased survival 
(Jα18-/- only) 
Decreased 
cytokine 
production 
 237 
 Jα18-/-, CD1d-/- Increased parasite 
burden 
IFNγ, IL-4  238 
Toxoplasma 
gondii 
Jα18-/-, CD1d-/- Decreased survival, 
increased 
immunopathology, 
no change in 
parasite burden 
Decreased 
CD4+ T cell 
activation 
 239 
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whether in this model, the IFNγ had a direct antimicrobial effect or transactivated other immune 
cell types. 
 Another function attributed to iNKT cells during infection is the expansion of CD8+ T cell 
responses200, 212, 225, 229. De Santo et al found during Influenza A viral infection, in a CD40/CD40L-
dependent mechanism iNKT cells inhibited a population of myeloid derived suppressor cells 
(MDSC) which allowed the expansion of CD8+ T cells229. In another Influenza A model, iNKT cell-
mediated expansion of CD103+ dendritic cells increased CD8+ T cell responses200. 
Other attributed effector functions during infections include: neutrophil recruitment207, 223, 
IL-22 production230, anti-inflammatory effects197, 231, 240, transactivation of NK cells both for 
increased IFNγ production232,  as well as enhanced cytolytic activity233. 
 Recently, using spinning disk confocal intravital microscopy, Lee et al visualized hepatic 
iNKT cells responding to Borrelia burgdorferi infection220. The authors found that iNKT cells 
interacted with Kupffer cells, after responding to CXCR3 signals. The activated iNKT cells 
produced IFNγ and clustered in stable CD1d-dependent contacts with the Kupffer cells. These 
cell contact interactions were strong enough to lead to a dramatic arrest of iNKT cell movement in 
the liver.  
 While most studies have focused on the activation and function of iNKT cells during 
infection, there are also indications that after their rapid responses, iNKT cells can become 
hyporesponsive and undergo cell death and contraction before the infection has been resolved.241  
 While iNKT cells have been shown to have important roles in many different 
immunological conditions including infection, cancer, autoimmunity, and graft-versus-host 
disease, the full spectrum of their effector functions in each of these models has yet to be 
catalogued. Given the new tools available to iNKT cell researchers, including multicolor flow 
cytometry, microarray analysis, and multiplex immunoassays, multiple effector functions will now 
be able to be assayed at one time, allowing for a more nuanced and comprehensive view of iNKT 
cell function.  
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ABSTRACT 
Invariant natural killer T (iNKT) cells are activated during infection, but how they limit 
microbial growth is unknown in most cases. We investigated how iNKT cells suppress 
intracellular Mycobacterium tuberculosis (Mtb) replication. When co-cultured with infected 
macrophages, iNKT cell activation, as measured by CD25 upregulation and IFNγ production, was 
primarily driven by IL-12 and IL-18. In contrast, iNKT cell control of Mtb growth was CD1d-
dependent, and did not require IL-12, IL-18, or IFNγ. This demonstrated that conventional 
activation markers did not correlate with iNKT cell effector function during Mtb infection. iNKT cell 
control of Mtb replication was also independent of TNF and cell-mediated cytotoxicity. By 
dissociating cytokine-driven activation and CD1d-restricted effector function, we uncovered a 
novel mediator of iNKT cell antimicrobial activity: GM-CSF. iNKT cells produced GM-CSF in vitro 
and in vivo in a CD1d-dependent manner during Mtb infection, and GM-CSF was both necessary 
and sufficient to control Mtb growth. Here, we have identified GM-CSF production as a novel 
iNKT cell antimicrobial effector function and uncovered a potential role for GM-CSF in T cell 
immunity against Mtb. 
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INTRODUCTION 
CD1 restricted T cells were first proposed to have a role in antimicrobial immunity based 
on the observations that CD4-CD8- (DN) T cells restricted by group 1 CD1 (CD1a, CD1b, and 
CD1c) recognized unique and complex lipids from the Mtb cell wall1, 2. Similarly, invariant natural 
killer T (iNKT) cell antimicrobial function was originally based on the recognition of microbial lipid 
or glycolipid molecules presented by the MHC-like molecule CD1d. iNKT cells are now 
recognized to influence many different immunological conditions including autoimmune disease, 
asthma and allergy, anti-tumor response, graft-versus-host disease, and infection3. 
There are several pathways by which iNKT cells can be activated. Classically, high 
affinity antigens that are potent agonists, typified by the synthetic lipid α-galactosylceramide 
(αGalCer), trigger TCR activation in a CD1d-dependent manner. Several infectious agents 
produce microbial lipids that are presented on CD1d and recognized by iNKT cells including 
Borrelia burgdorferi and Sphingomonas capsulata4, 5, 6. Activation can also occur when iNKT cells 
recognize a weak lower affinity self or microbial ligand, insufficient by itself to induce activation, in 
the context of costimulatory signals. This mode of activation has been shown for pathogens, such 
as Salmonella typhimurium, viruses such as Influenza A, and fungi such as Aspergillus 
fumigatus7, 8, 9. There is strong evidence that a major driver of this type of iNKT cell activation is 
IL-12, which is produced when microbial danger signals stimulate pattern recognition receptors 
such as Toll-like receptors (TLRs) or dectin-17, 9, 10.  
One of the remaining unanswered questions in iNKT cell biology is what specific role 
these cells have during infection and whether their activation by different pathways leads to the 
expression of diverse functions. To address the role of iNKT cells during infection, many of these 
studies have used mouse models that lack iNKT cells (Jα18-/-, CD1d-/-) or administered αGalCer, 
a potent activator of iNKT cells. While this strategy has been useful for determining whether iNKT 
cells are required for host resistance, and for revealing potential antimicrobial effector functions 
induced after strong activation, much less is known about the physiological role of iNKT cells 
during infection. Tracking iNKT cell function in vivo has relied extensively on CD69 upregulation 
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and IFNγ production. Interestingly, in the absence of exogenous αGalCer treatment, there is little 
evidence that IFNγ production by iNKT cells is protective during infection 11. Given that iNKT cells 
are capable of producing a variety of different cytokines and chemokines including IL-4, IL-10, IL-
17, TNF, GM-CSF, MIP-1α, MIP-1β as well as having immunomodulatory effects via expression 
of CD40 and other costimulatory ligands12, it is surprising that it is still unknown for most 
infections whether iNKT cells have a direct antimicrobial role. Only in select cases have protective 
mechanisms been defined. For example, iNKT cells are important for neutrophil recruitment to the 
lung during Pseudomonas infection13 and IFNγ is required for protection by iNKT cells against 
Streptococcus pneumoniae, although this could represent a direct or indirect effect11.  
There are several lines of evidence that activated iNKT cells enhance host resistance to 
Mtb. Administration of αGalCer, which activates iNKT cells in vivo, significantly prolongs the 
survival of susceptible mouse strains following Mtb infection and this effect is synergistic with 
antibiotics14, 15. αGalCer activates human iNKT cells to lyse Mtb-infected macrophages and kill 
intracellular bacteria16. Even BCG vaccination is more effective when it is conjugated with 
αGalCer17. Although αGalCer is used as a pharmacological activator of iNKT cells in this context, 
it is not required. iNKT cells cultured with Mtb-infected primary macrophages stimulate 
antimicrobial activity that restricts bacterial growth and adoptive transfer of iNKT cells limits 
bacterial growth in vivo18. Finally, several clinical studies find that a decrease of iNKT cells in the 
periphery is a marker of active disease compared to latent infection or healthy controls19, 20, 21. 
Despite these findings of iNKT cell activation leading to enhanced control, iNKT cells are 
dispensable in the murine model of chronic tuberculosis infection22, 23, 24, 25.  
Our model, in which iNKT cells activate infected macrophages to control Mtb infection in 
the absence of exogenous stimulation (e.g., αGalCer), provided a unique opportunity to define the 
direct effector functions of iNKT cells. This model allowed us to study the interaction between 
iNKT cells and Mtb-infected macrophages and provided the opportunity to perturb specific 
signaling and effector pathways and then measure subsequent changes in bacterial control. 
Greater insight into the effector function of iNKT cells during Mtb infection could lead to novel 
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therapeutic approaches for augmenting their antimicrobial capacity and boosting the host immune 
response during infection14, 15. 
Here we report that iNKT cells upregulated activation markers and produced IFNγ during 
Mtb infection in vitro and these markers of activation were driven largely by IL-12 and IL-18.  
Blocking these cytokine signals almost completely inhibited IFNγ production, but surprisingly had 
little effect on the ability of iNKT cells to control Mtb growth. In contrast, the antimicrobial function 
of iNKT cells required CD1d signaling and was mediated by a soluble factor, GM-CSF. Blocking 
GM-CSF abrogated restriction of bacterial growth by iNKT cells and GM-CSF was sufficient to 
inhibit mycobacterial growth in vitro. We identified GM-CSF as an antimycobacterial effector 
molecule produced by iNKT cells with the ability to suppress Mtb infection. 
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RESULTS 
iNKT cells are activated by Mtb-infected macrophages 
CD69 and CD25, both classic T cell activation markers, as well as IFNγ production, were 
chosen to track the activation of iNKT cells by Mtb-infected macrophages. Primary mouse iNKT 
cell lines were co-cultured with thioglycollate-elicited peritoneal macrophages infected with 
increasing multiplicity of infection (MOI) of H37Rv, a virulent strain of Mtb. After 24 hours, iNKT 
cells cultured with Mtb-infected macrophages expressed higher levels of CD69 and CD25 and 
produced more IFNγ compared to iNKT cells cultured with uninfected macrophages (Figure 2-1). 
A similar activation pattern was observed when hepatic mononuclear cells (HMNC), a source of 
primary uncultured iNKT cells, were used (Figure 2-2A) or when iNKT cells were cultured with 
H37Rv-infected bone marrow derived macrophages (BMDM) (Figure 2-2B). These data indicate 
that iNKT cells become activated after stimulation with Mtb-infected APCs. 
 
iNKT cell activation by Mtb-infected macrophages requires a combination of cytokine and CD1d-
dependent signals 
Infection by various microbes including Salmonella, Aspergillus, and E. coli LPS, induce 
iNKT cell activation by a combination of IL-12, IL-18, and/or TCR stimulation through interaction 
with CD1d7, 9, 10, 26. To determine whether these signals were required for the activation of iNKT 
cells by Mtb-infected macrophages, we added neutralizing antibodies to cell co-cultures and 
measured iNKT cell activation after 24 hours. We found that CD25 and IFNγ were inhibited to 
varying degrees by blockade of the activating signals (Figures 2-3A and 2-3B). CD69 expression 
was more variable and blocking antibodies had little effect on its expression (data not shown). 
Blocking cytokine signals (IL-12p40, IL-18) had a greater inhibitory effect on the markers than 
blocking the TCR-CD1d interaction. For example, anti-IL-12p40 reduced CD25 surface 
expression by 45.7 ± 3.3%, and inhibited IFNγ production nearly completely (91.4 ± 4.4%) (mean 
± SEM, n=4 experiments) (Figures 2-3A and 2-3B). In contrast, anti-CD1d had no effect on CD25 
expression and only a modest effect on IFNγ production (37.5 ± 6.4% reduction) (mean ± SEM,  
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Figure 2-1. iNKT cells are activated by Mtb-infected mφ.  
 
(A) iNKT cells were cultured either alone, with uninfected thioglycollate-elicited peritoneal mφ, or 
H37Rv-infected mφ for 24 hours. Cells were stained for CD69 and CD25 and mφ were 
distinguished from iNKT cells by F4/80 staining. (B) Fold change in CD69 and CD25 MFI on iNKT 
cells cultured with uninfected or H37Rv-infected mφ compared to iNKT cells alone. Supernatant 
was harvested at 24 hours and IFNγ measured by ELISA. Error bars indicate mean ± SEM. *P < 
.05, **P < .01, ***P < .001. (One-way ANOVA with Dunnettʼs post-test, compared to iNKT cells 
alone). Data are representative of eight independent experiments. Mφ, macrophage; UI, 
uninfected; , MOI titration, 1.5:1, 3:1, 6:1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2. iNKT cell activation after Mtb infection is observed with primary iNKT cells and 
bone marrow derived-macrophages (BMDM).  
 
(A) HMNC were cultured either alone, with uninfected thioglycollate-elicited peritoneal mφ (TGL-
PM), or H37Rv-infected TGL-PM for 24 hours and gated on CD1d-tetramer+CD3+ population. (B) 
iNKT cells were cultured with uninfected or H37Rv-infected WT bone marrow derived 
macrophages (BMDM) for 24 hours. Fold change in CD69 MFI over HMNC (A) and iNKT cells (B) 
cultured alone. Supernatant was harvested at 24 hours and IFNγ measured by ELISA. Error bars 
indicate mean ± SEM. The data are from single experiments.  
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Figure 2-3. Production of IL-12 and IL-18 by Mtb-infected mφ induce traditional markers of 
iNKT cell activation.  
 
(A) iNKT cells were cultured either alone, with uninfected mφ,  H37Rv-infected mφ, or αGalCer-
loaded mφ for 24 hours in the presence of blocking antibodies against IL-12p40 (20 μg/ml), IL-18 
(10 μg/ml), CD1d (20 μg/ml), or respective isotype controls. Cells were stained for CD25 and mφ 
were distinguished from iNKT cells by F4/80 staining. Supernatant was harvested at 24 hours and 
IFNγ measured by ELISA. (B) % reduction calculated as 100*[(iNKTH37Rv-mφ - iNKTalone) - 
(iNKTAb+H37Rv-mφ - iNKTalone)] / (iNKTH37Rv-mφ - iNKTalone). Conditions with αGalCer stimulation 
calculated similarly. Supernatant was harvested at 24 hours and IFNγ and IL-12p40 measured by 
ELISA. Error bars indicate mean ± SEM. **P < 0.01 compared to isotype control. (One-way 
ANOVA with Dunnettʼs post-test). #P < 0.05, ##P < 0.01 compared to isotype control (data not 
shown) (unpaired Studentʼs t-test). Data are representative of, or compiled from three (anti-
CD1d), four (anti-IL-12), or two (anti-IL-18) independent experiments. 
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n=3-4 experiments). The failure of anti-CD1d to block iNKT cell activation was not due to a 
problem with the experimental conditions since anti-CD1d blocked induction of CD25 and 
abrogated IFNγ production after α-GalCer stimulation of iNKT cells (Figures 2-3A and 2-3B). To 
verify that cytokines were driving iNKT cell activation, iNKT cells were cultured with MyD88-/- 
macrophages, which do not produce IL-12 after H37Rv infection27 (Figure 2-4). When co-cultured 
with Mtb-infected MyD88-/- macrophages, iNKT cells did not upregulate CD25 or secrete IFNγ. 
These results indicated that IL-12 and IL-18 produced by macrophages during Mtb infection drove 
the activation of iNKT cells as measured by induction of CD25 surface expression and IFNγ 
production. Thus, these conventional markers of iNKT cell activation were not reliable indicators 
of CD1d-dependent TCR-mediated signaling during Mtb infection. 
 
Control of intracellular Mtb growth by iNKT cells requires CD1d but not IL-12 and IL-18 
 As shown previously, iNKT cells cultured with H37Rv-infected macrophages reduced 
intracellular bacterial growth over a 5 day infection18 (Figure 2-5A). We used this co-culture model 
to evaluate how the different activation signals affected iNKT cell antimicrobial activity. 
  We first tested the requirement for IL-12 and IL-18 signaling. The addition of anti-IL-
12p40 and/or anti-IL-18 blocking antibodies to co-cultures of iNKT cells and H37Rv-infected WT 
macrophages did not affect the ability of iNKT cells to inhibit bacterial growth (Figure 2-5A). We 
confirmed this result using MyD88-/- macrophages, which did not induce upregulation of CD25 or 
IFNγ by iNKT cells (Figure 2-4). iNKT cells were able to inhibit bacterial growth in H37Rv-infected 
MyD88-/- macrophages (Figure 2-5B). These findings were unexpected because they suggested 
that the traditional markers of activation did not correctly predict iNKT cell antimycobacterial 
function. 
We next addressed whether CD1d expression by the infected macrophages was 
required. iNKT cells were able to limit intracellular bacterial growth only if the infected 
macrophages expressed CD1d (Figure 2-6A). Normalizing the bacterial growth in each 
experiment allowed us to determine the requirement for CD1d across multiple experiments (see  
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Figure 2-4. iNKT cell activation is decreased by MyD88-/- Mtb-infected mφ.  
 
iNKT cells were cultured with uninfected or H37Rv-infected WT or MyD88-/- mφ for 24 hours. 
Cells were stained for CD25 and mφ were distinguished from iNKT cells by F4/80 staining. 
Supernatant was harvested at 24 hours and IFNγ and IL-12p40 measured by ELISA. Error bars 
indicate mean ± SEM. +P < 0.05, ++P < 0.01, +++P < 0.001 (unpaired Studentʼs t-test). Data are 
representative of two independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5. iNKT cell mediated control does not require IL-12 or IL-18.  
 
(A) Colony forming unit (CFU) assay measuring Mtb bacterial growth in H37Rv-infected WT mφ 
on d1 and d5 post-infection. iNKT cells, anti-IL-12p40, anti-IL-18 blocking or isotype control 
antibodies were added on d1 after infection. (B) CFU assay d1 and d5 post-infection for H37Rv-
infected MyD88-/- mφ with iNKT cells added on d1. Error bars indicate mean ± SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001  (One-way ANOVA with Dunnettʼs post-test, compared to d5 untreated 
mφ). Data are representative of two independent experiments with three or more replicates. 
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Figure 2-6. iNKT cell mediated control is CD1d-dependent.  
 
(A, C) CFU assay d1 and d5 post-infection for H37Rv-infected WT and CD1d-/- mφ with iNKT 
cells added on d1 at a ratio of 1:1 (A) or HMNC at a ratio of 3:1 (C). (B) Compiled data from 6 
independent experiments as described in (A). Error bars indicate mean ± SEM. *P < 0.05, **P < 
0.01, ***P < 0.001  (One-way ANOVA with Dunnettʼs post-test, compared to d5 untreated mφ). 
+++P < .001 (unpaired Studentʼs t-test). Data are representative of six (A, B) and one (C) 
independent experiment(s) with three or more replicates. 
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Experimental Procedures for details). When Mtb growth inhibition by iNKT cells in WT and CD1d-/- 
macrophages were compared in this manner, iNKT cells suppressed growth of Mtb in WT 
macrophages significantly more than in CD1d-/- macrophages (73.1 ± 4.7% CFU reduction vs. 
31.5 ± 9.3%) (mean ± SEM, n=6 experiments, p=0.0002) (Figure 2-6B). To confirm the 
dependence on CD1d for bacterial control by iNKT cells, and to show that the culture conditions 
of the primary cell lines had not significantly altered the effector functions of the iNKT cells, we 
repeated this experiment using HMNC as a source of primary uncultured iNKT cells.  We found 
that HMNCs also required CD1d signaling for inhibition of bacterial growth (Figure 2-6C).  
Since CD1d expression by macrophages was required to elicit optimal iNKT cell effector 
function, we considered whether Mtb infection altered the CD1d surface expression on 
macrophages. After 24 hours, H37Rv infection led to a modest increase in CD1d surface 
expression on macrophages (1.5 ± 0.1 fold change) (mean ± SEM, n=13 experiments, p<0.0001) 
(Figure 2-7). Co-culture with iNKT cells led to a slight increase in CD1d expression during H37Rv 
infection (1.9 ± 0.1 fold change) (mean ± SEM, n=22 experiments, p<0.0001) (Figure 2-7). These 
increases were averages for the bulk culture and may have underestimated the increase for 
individually infected macrophages, because not every macrophage was infected.  
These results indicated that the cytokines (IL-12, IL-18) that drive expression of CD25 
and IFNγ production were not required to stimulate iNKT cell antimycobacterial effector functions. 
In contrast, CD1d expression, which played only a small role in stimulating IFNγ production, was 
required for iNKT cell mediated control of intracellular Mtb growth. The dissociation between 
standard measurements of iNKT cell activation from iNKT cell effector function in response to Mtb 
infection was unexpected.  
 
iNKT cells exhibit an antimycobacterial function independent of IFNγ 
 Since IL-12 and IL-18 blockade largely inhibited IFNγ production but had little impact on 
CFU control, we considered whether iNKT cell antimicrobial effector function was independent of 
IFNγ. To test this, we derived an IFNγ-/- iNKT cell line. When IFNγ-/- iNKT cells were added to 
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Figure 2-7. Mφ CD1d expression increases with Mtb infection.  
 
H37Rv-infected mφ after 24 hours. CD1d MFI fold change over uninfected mφ either without or 
with iNKT cells. Error bars indicate mean ± SEM. +++P < .001 (unpaired Studentʼs t-test). Data 
are compiled from more than 12 independent experiments. 
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H37Rv-infected macrophages, they inhibited bacterial growth similar to WT iNKT cells (Figure 2-
8A). Over multiple experiments, WT and IFNγ-/- iNKT cells reduced bacteria growth similarly by 
d5 by 60.0 ± 4.7% versus 60.1 ± 4.0%, respectively (mean ± SEM, n=13 experiments, p=NS) 
(Figure 2-9). A similar result was found by d7 post-infection (Figure 2-9).  
IFNγ plays an important antimicrobial role during Mtb infection. To be certain that iNKT 
cells were controlling bacterial growth independently of IFNγ signaling, WT and IFNγ-/- iNKT cells 
were cultured with H37Rv-infected IFNγR-/- macrophages. The iNKT cells still limited bacterial 
growth by d5 in these cells (Figure 2-8B). We also examined whether iNKT cells controlled Mtb 
growth through nitric oxide, an important mediator of antimycobacterial immunity produced during 
infection by IFNγ stimulation of the enzyme inducible nitric oxide synthase (iNOS)28. Neither IFNγ 
nor nitrite, a stable breakdown product of nitric oxide, were detected after addition of IFNγ-/- iNKT 
cells, while both were detected when WT iNKT cells were present (Figure 2-8C). Furthermore, 
naïve splenocytes (as a source of iNKT cells18) inhibited bacterial replication similarly in WT, 
IFNγR-/-, and iNOS-/- macrophages (data not shown).  
We next tested whether the IFNγ-/- iNKT cells also required CD1d to mediate their 
antimicrobial effector function. Similar to WT iNKT cells, IFNγ-/- iNKT cells inhibited growth of Mtb 
in WT macrophages significantly more than in CD1d-/- macrophages by 73.3 ± 7.2% versus 34.4 
± 10.6% (mean ± SEM, n=5 experiments, p=0.0043) (Figure 2-8D). These data demonstrated that 
iNKT cells were capable of controlling Mtb growth independently of IFNγ and nitric oxide and that 
the IFNγ-independent effector function required CD1d-mediated activation. 
 
iNKT cell antimicrobial function is independent of cytolytic activity and TNF  
Human iNKT cells stimulated with αGalCer were shown to control Mtb infection in human 
monocyte-derived macrophages through granulysin-mediated cytolytic activity16. Based on this 
finding, we determined whether iNKT cells, in the absence of additional stimulation, inhibited Mtb 
growth through cytolytic activity. To block the major pathways of cytolysis, we added Perforin-/- 
(Pfn-/-) iNKT cells to H37Rv-infected WT macrophages (Figure 2-10A). In addition, we added 
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Figure 2-8. iNKT cell mediated control is independent of IFNγ.  
 
(A) CFU for H37Rv-infected WT mφ with WT and IFNγ-/- iNKT cells added on d1 post-infection. 
CFU were measured on d0 (mφ alone) and on d1, d3, d5 and d7 post-infection. (B) CFU assay 
d1 and d5 post-infection for H37Rv-infected IFNγR-/- mφ with WT and IFNγ-/- iNKT cells added on 
d1. (C) IFNγ and nitrite, a stable breakdown product of NO2, measured for H37Rv-infected WT 
mφ with WT and IFNγ-/- iNKT cells added on d1 post-infection. (D) Compiled data from 5 
independent experiments of the CFU assay d1 and d5 post-infection with H37Rv-infected WT and 
CD1d-/- mφ with IFNγ-/- iNKT cells added on d1. Error bars indicate mean ± SEM. *P < 0.05, **P < 
0.01, ***P < .001 (One-way ANOVA with Dunnettʼs post-test, compared to d3, d5, or d7 untreated 
mφ). ++P < .01 (Unpaired Studentʼs t-test). Data are representative of or cumulative from 13 (d5) 
and four (d7) (A), two (B) three (C), or four (D) independent experiments with three or more 
replicates.  
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Figure 2-9. WT and IFNγ-/- iNKT cells inhibit Mtb growth at comparable levels.  
 
Compiled data from CFU assays d5 and d7 post-infection for H37Rv-infected WT mφ with WT or 
IFNγ-/- iNKT cells added on d1. The CFU reduction for WT and IFNγ-/- iNKT cells on d5 was 60.0 
± 4.7%, and 60.1 ± 4.0%, respectively. On d7, the CFU reduction was 81.9 ± 5.4%, and 67.9 ± 
6.2%, respectively. Error bars indicate mean ± SEM. (Unpaired Studentʼs t-test, p = NS). The data 
are compiled from 13 (d5) and four (d7) independent experiments. 
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either WT or IFNγ-/- iNKT cells to Fas-/- macrophages (Figure 2-10B). Under these conditions, 
iNKT cells still significantly suppressed Mtb growth in macrophages. To eliminate the possibility of 
redundancy between cytolytic pathways, Pfn-/- iNKT cells were added to H37Rv-infected Fas-/- 
macrophages, and despite elimination of both of the dominant CTL pathways, iNKT cells were 
still able to significantly inhibit bacterial growth (data not shown). These data show that the major 
cytolytic pathways were not required for iNKT cell antimicrobial function in this system.  
We also took an alternative approach to inhibit cytolytic activity by blocking an important 
downstream effector of cytolytic activity, caspase-3. Using a specific peptide inhibitor to inhibit 
caspase-3 activity and apoptosis in target cells, we found that addition of caspase-3 inhibitor to 
co-cultures of IFNγ-/- iNKT cells and H37Rv-infected macrophages, at concentrations that block 
apoptosis of infected macrophages29, did not affect the ability of IFNγ-/- iNKT cells to inhibit 
bacterial growth (Figure 2-10C). 
TNF plays an important antimicrobial role during Mtb infection30 and we detected TNF, 
albeit at low levels, in our co-culture system (data not shown). Therefore, we used TNFR1/2-/- 
macrophages, which lack both TNF receptors, to test whether TNF signaling was required for 
iNKT cell control of Mtb. Both WT and IFNγ-/- iNKT cells inhibited bacterial growth when cultured 
with H37Rv-infected TNFR1/2-/- macrophages, indicating that TNF did not mediate the 
antimicrobial effector function of IFNγ-/- iNKT cells (Figure 2-10D).  Finally, based on the newly 
appreciated role of IL-1β in limiting growth of Mtb in macrophages31, 32, we determined whether 
IL-1β mediated iNKT cell control of bacterial growth. IFNγ-/- iNKT cells cultured with IL-1R-/- 
macrophages controlled Mtb growth, ruling out a role for IL-1β signaling (data not shown). 
These data showed that iNKT cells controlled Mtb growth independently of cytolytic 
activity and cytokines previously identified as antimycobacterial, TNF and IL-1β. They suggested 
that iNKT cells limit bacterial growth through a non-classical effector function.  
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Figure 2-10. IFNγ-independent antimicrobial effector function of iNKT cells is independent 
of cytolytic activity.  
 
(A-D) CFU assay d1, d5, and/or d7 post-infection with H37Rv-infected WT mφ (A, C), Fas-/- mφ 
(B), or TNFR1/2-/- mφ (D) with WT iNKT cells (A, B, D), IFNγ-/- iNKT cells (B-D), or Prf-/- iNKT cells 
(A) added on d1 post infection at a 1:1 ratio. (C) H37Rv-infected mφ were treated with 0.1-10 μM 
of caspase-3 inhibitor peptide (Z-DEVD-FMK) 2 hours prior to addition of iNKT cells. Error bars 
indicate mean ± SEM. *P < 0.05, **P < 0.01 (One-way ANOVA with Dunnettʼs post-test, 
compared to d5 or d7 untreated mφ.) Data are representative of three (A, C, D) or two (B) 
independent experiments with three or more replicates. 
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iNKT cells secrete a soluble factor with antimicrobial properties 
We next determined whether the antimicrobial activity was a soluble factor or cell contact 
dependent. Using a transwell system, we found that both WT and IFNγ-/- iNKT cells placed in 
trans from H37Rv-infected macrophages were able to suppress Mtb growth (Figure 2-11). 
Importantly, this effect was only observed if the iNKT cells were in contact with other 
macrophages in the transwell, but not when the iNKT cells were cultured alone. This was 
consistent with our observation that induction of the iNKT cell effector function required CD1d 
signaling via macrophage contact. The finding that contact between iNKT cells and uninfected 
macrophages was sufficient to induce the antimicrobial activity raised the possibility that a 
mediator secreted by infected macrophages (e.g., in trans) augmented iNKT cell activation, either 
by increasing macrophage CD1d expression or by costimulating iNKT cell activation. Most 
importantly, this experiment confirmed that iNKT cells required cell contact and CD1d expression 
for their activation, and indicated that their antimicrobial activity was mediated by a soluble factor.   
We also found that αGalCer stimulation of IFNγ-/- iNKT cells cultured in trans boosted 
their ability to control bacterial growth (data not shown). Furthermore, conditioned media 
produced from IFNγ-/- iNKT cells stimulated with αGalCer-loaded WT but not CD1d-/- 
macrophages stimulated bacterial control when added to macrophages (Figure 2-12B). We then 
used conditioned media samples derived from IFNγ-/- iNKT cells stimulated by unloaded or 
αGalCer-loaded WT or CD1d-/- macrophages for screening purposes. These samples were size 
fractionated at 10kDa and 50kDa MW cutoffs (Figure 2-12A). We identified several cytokines 
present at high levels only in the fractions that had antimicrobial activity: GM-CSF, TNF, and IL-4 
(Figure 2-12C). Since TNF had been previously eliminated and IL-4 is not known to enhance 
bacterial control33, we investigated whether iNKT cells produced GM-CSF after co-culture with 
Mtb-infected macrophages and whether it had antimycobacterial activity. 
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Figure 2-11. The antimicrobial effector function of iNKT cells is a soluble factor.  
 
Transwell CFU assay for H37Rv-infected WT mφ in a 24-well plate with either WT or IFNγ-/- iNKT 
cells added directly (cis) or 0.4 μm transwell inserts with WT or IFNγ-/- iNKT cells in the presence 
of uninfected WT mφ (trans) added on d1. Error bars indicate mean ± SEM. *P < 0.05, **P < 0.01 
(One-way ANOVA with Dunnettʼs post-test, compared to d5 untreated mφ.) Data are 
representative of two independent experiments with four replicates each. 
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Figure 2-12. Conditioned media fractions from α-GalCer-stimulated IFNγ-/- iNKT cells 
inhibit bacterial growth.  
 
(A) Size fractionation strategy for conditioned media samples using 50kDa and 10kDa Amicon 
Ultra-15 Centrifugal Filter Units. (B) CFU assay for H37Rv-infected WT mφ treated on d1 with 
whole and size fractionated conditioned media samples from IFNγ-/- iNKT cells stimulated for 24 
hours with untreated or αGalCer-loaded WT or CD1d-/- mφ at 1:50 dilution. (C) Cytokines 
measured in whole and size fractionated conditioned media samples from IFNγ-/- iNKT cells 
stimulated for 24 hours with untreated or αGalCer-loaded WT or CD1d-/- mφ. Cytokines were 
measured using Bioplex immunoassay. Error bars indicate mean ± SEM. *P < 0.05, **P < 0.01 
(One-way ANOVA with Dunnettʼs post-test, compared to d5 untreated mφ). The data are 
representative of two independent experiments. 
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iNKT cells produce GM-CSF during Mtb infection in a CD1d-dependent manner and it is critical 
for controlling Mtb growth 
We detected GM-CSF production 24 hours after co-culture of both WT and IFNγ-/- iNKT 
cells with H37Rv-infected macrophages (Figure 2-13A, Figure 2-14A). Because we had already 
established that the IFNγ-independent antimicrobial function was CD1d-dependent, we tested 
whether GM-CSF production by iNKT cells required CD1d expression. We found that IFNγ-/- iNKT 
cells produced significantly more GM-CSF when cultured with Mtb-infected WT macrophages 
than with Mtb-infected CD1d-/- macrophages; however, some GM-CSF was produced even in the 
absence of CD1d, especially at higher Mtb MOI (Figure 2-13B).  
To determine if GM-CSF was required for iNKT cell-mediated control in vitro, we added 
anti-GM-CSF blocking antibodies to the co-culture of IFNγ-/- iNKT cells and Mtb-infected 
macrophages. GM-CSF blockade impaired bacterial control by IFNγ-/- iNKT cells leading to a 
significant increase in CFU compared to both an isotype control and untreated conditions (Figure 
2-13C). This suggested that GM-CSF was required for iNKT cell mediated control of Mtb infection 
in this model. When we added anti-GM-CSF blocking antibodies to co-cultures of WT iNKT cells 
and Mtb-infected macrophages, we observed a modest decrease in bacterial inhibition by WT 
iNKT cells in the GM-CSF blockade condition compared to untreated or isotype control, although 
it was not significant (Figure 2-14B). These results suggest that either the antimicrobial functions 
of GM-CSF are less crucial in the presence of IFNγ or that there is redundancy in the 
antimicrobial mechanisms of these two cytokines. 
To determine if this iNKT cell effector pathway was also relevant for human cells, we 
tested the human iNKT cell clone J3N.5. The iNKT cells produced significantly more GM-CSF 
after co-culture with H37Rv-infected U937 cells, a human monocytic line, than with uninfected 
U937 cells and this was inhibited by addition of an anti-CD1d blocking antibody (Figure 2-15). 
J3N.5 also produced IFNγ in response to H37Rv-infected U937 cells, and this was similarly 
inhibited by an anti-CD1d blocking antibody (data not shown). Next, we determined whether iNKT 
cells produced GM-CSF during aerosol infection in vivo. We isolated cells from the lungs of mice  
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Figure 2-13. iNKT cells produce GM-CSF during Mtb infection in a CD1d-dependent 
manner and it is critical for controlling Mtb growth. 
 
(A, B) IFNγ-/- iNKT cells added to uninfected or H37Rv-infected WT (A, B) and CD1d-/- mφ (B). 
Murine GM-CSF measured in supernatant harvested after 24 hours. (C) % CFU reduction 
calculated from CFU assays for H37Rv-infected WT mφ with IFNγ-/- iNKT cells added on d1 in the 
presence of anti-GM-CSF blocking antibody (10-50 μg/ml) or isotype control. Error bars indicate 
mean ± SEM. ++P < .01 (unpaired Studentʼs t-test, WT versus CD1d-/- macrophages (B)). **P < 
0.01, ***p < 0.001 (One-way ANOVA with Tukey post-test (C), and Dunnettʼs post-test (A), 
compared to uninfected mφ). Data are representative of or compiled from four (A, C) and two (B) 
independent experiments with three or more replicates each , MOI titration approximately 0.5:1 
- 3:1 (A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-14. WT iNKT cells produce GM-CSF following Mtb infection and control is limited 
by anti-GM-CSF blocking antibody.  
 
(A) Murine GM-CSF measured in supernatants after 24-hr co-culture of WT iNKT cell line with 
uninfected and H37Rv-infected WT mφ. (B) WT iNKT cells were added to H37Rv-infected WT 
mφ on d1 without additives, or in the presence of anti-GM-CSF blocking antibody or nonspecific 
isotype control antibody (25 µg/ml). CFU were determined on d5. Error bars indicate mean +/- 
SEM. ***P < 0.001 (One-way ANOVA with Dunnettʼs post-test, compared to uninfected mφ). The 
data are representative (A) or compiled from (B) three independent experiments. Statistical 
analysis was performed using a one-way ANOVA and was not significant.  
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infected with virulent Mtb at serial time points after infection. Pulmonary iNKT cells were identified 
by TCRβ and CD1d-tetramer staining and their production of GM-CSF and IFNγ was assessed 
by intracellular cytokine staining (ICS) directly ex vivo without further stimulation. The frequency 
of iNKT cells in the lung did not change greatly over the course of infection, although the total 
number of iNKT cells increased in parallel with the overall increase in T cell recruitment to the 
lung (Figure 2-16A and 2-16B). Similar to our in vitro observations, CD69 expression increased 
on iNKT cells in the lung over the course of infection (Figure 2-16C). A small percentage of iNKT 
cells in the lungs of naive mice secreted GM-CSF. By two weeks post-infection, there was an 
increase in both the percentage and absolute number of iNKT cells producing GM-CSF; this was 
not the case for IFNγ (Figure 2-17A and 2-17B). At all time points examined post-infection, a 
significantly greater percentage of iNKT cells in the lung produced GM-CSF than IFNγ. For 
example, at week 2, 11.0 ± 1.3% iNKT cells were GM-CSF+ compared to 1.0 ± 0.3% IFNγ+ iNKT 
cells (mean ± SEM, p < 0.0001). These data demonstrated that iNKT cells are an early source of 
GM-CSF in the lung during Mtb infection and underscored our in vitro observation that GM-CSF 
and IFNγ production by iNKT cells are regulated differently during Mtb infection.  
In order to evaluate the role of CD1d signaling in the production of GM-CSF by iNKT cells 
in vivo, we used an adoptive transfer model, in which fluorescently-labeled iNKT cells were 
injected iv into Mtb-infected WT or CD1d-/- recipients. Downregulation of the iNKT cell TCR 
usually limits the ability to detect iNKT cells in vivo. This transfer model allowed monitoring of 
iNKT cells in vivo without the need for CD1d tetramer staining. We detected significantly less GM-
CSF and IFNγ production by iNKT cells transferred into Mtb-infected CD1d-/- hosts compared to 
WT hosts, while CD69 expression was induced on iNKT cells transferred into both WT and CD1d-
/- recipients (Figure 2-17C). Interestingly, we observed a strong CD1d-dependent IFNγ response 
by the transferred iNKT cells, which we did not detect in the intact mice (Figure 2-17A and 2-
17B). The transferred iNKT cells were likely to have a stronger response and a lower threshold 
for activation due to their prior stimulation in vitro. There is recent data, discussed below, that  
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Figure 2-15. Human iNKT cell clones produce GM-CSF in response to Mtb infection.  
 
J3N.5 human iNKT cell clone added to uninfected or H37Rv-infected U937 cells in the presence 
of anti-human-CD1d blocking antibody or isotype control. Human GM-CSF measured in 
supernatant harvested after 24 hours. Error bars indicate mean ± SEM. **P < 0.01 (One-way 
ANOVA with Dunnettʼs post-test (D) compared to uninfected mφ). Data are representative of 
three independent experiments with three or more replicates each , MOI titration approximately 
2:1 – 10:1. 
 
 
 
 
Figure 2-16. iNKT cells are found in the lung after aerosol Mtb infection.  
 
Lung mononuclear cells from WT Mtb-infected mice were stained and fixed. iNKT cells were 
identified as TCRβ+ and CD1d-tetramer+. Number (A) and percentage (B) of iNKT cells in the lung 
were measured. (C) CD69 MFI measured on iNKT cell subset. The data are representative of two 
independent experiments with 5 mice each. 
 
 
 
 
 	   71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-17. iNKT cells produce GM-CSF in the lungs of Mtb-infected mice in a CD1d-
dependent manner  
 
(A, B) Lung mononuclear cells from WT Mtb-infected mice were incubated with brefeldin A for 
four hours at 37°C and then stained. iNKT cells were identified as TCRβ+ and CD1d-tetramer+. 
Percentage (A) and number (B) of iNKT cells producing GM-CSF and IFNγ. (C) % GM-CSF+, % 
IFNγ+, and CD69 MFI for iNKT cells transferred iv into WT or CD1d-/- Mtb-infected hosts and iNKT 
cells cultured for 20 hours in basic media. Lung mononuclear cells were treated and stained as in 
(A, B). Transferred iNKT cells were distinguished from host cells by eFluor 450 staining. Error 
bars indicate mean ± SEM.  +P < .05, ++P < .01, +++P < .001 (unpaired Studentʼs t-test, GM-
CSF+ versus IFNγ+ for respective time points (A, B), WT versus CD1d-/- hosts (C)). Data are 
representative of two independent experiments with 5 mice each (A, B) or three independent 
experiments with three or more replicates each (C). 
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epigenetic modifications at the IFNG locus of iNKT cells may explain why IFNγ is only detected 
after priming by a strong stimulus34. The observation that the in vivo IFNγ response was almost 
entirely CD1d-dependent suggests that our in vitro infection model may be over-estimating the 
effect of cytokine-driven stimulation. This experiment also confirmed our in vitro results that 
activation marker expression and effector functions could be elicited by distinct activating 
pathways in iNKT cells.  
These data showed that both murine and human iNKT cells produced GM-CSF upon 
recognition of Mtb infection in a CD1d-dependent manner and GM-CSF was a critical component 
of iNKT cell antimycobacterial function in vitro.  
 
GM-CSF is sufficient to inhibit Mtb growth  
We next determined whether GM-CSF alone was sufficient to mediate control of Mtb 
growth. In a dose-dependent manner, recombinant GM-CSF added to infected macrophages was 
sufficient to inhibit Mtb growth (Figure 2-18). Recombinant GM-CSF has also previously been 
reported to inhibit the growth of mycobacterium in human monocyte-derived macrophages 
(MDM)35, 36, 37. The data showed that GM-CSF was sufficient to inhibit bacterial growth in murine 
macrophages. 
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Figure 2-18. GM-CSF is sufficient to inhibit Mtb growth in mφ.  
 
CFU assay for H37Rv-infected murine WT mφ treated with recombinant GM-CSF from 0.001-10 
ng/ml concentration on d1. Error bars indicate mean ± SEM. *P < .05, **P < 0.01 (One way 
ANOVA with Dunnettʼs post-test, compared to d5 untreated mφ). Data are representative of four 
independent experiments. 
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DISCUSSION 
We find that iNKT cells cultured with Mtb-infected macrophages inhibit intracellular 
bacterial growth18. This is the only model of which we are aware that allows investigation of the 
direct antimicrobial effector function of iNKT cells. In the presence of Mtb-infected macrophages, 
iNKT cells became activated and upregulated the activation markers, CD69 and CD25, and 
produced IFNγ.  While IL-12 and IL-18 produced by infected macrophages induced CD25 and 
IFNγ expression by iNKT cells, these cytokine signals were not required for iNKT cell control of 
Mtb. In addition, macrophage expression of CD1d was dispensable for the upregulation of CD25 
and only a minor factor in promoting IFNγ production, yet was essential to elicit iNKT cell 
antimycobacterial activity.  
The ability to dissociate iNKT cell activation and IFNγ production from iNKT cell 
antimicrobial function uncovered a novel antibacterial function of iNKT cells: GM-CSF production. 
We showed that CD1d-mediated activation was crucial for the production of GM-CSF in response 
to Mtb infection by both murine and human iNKT cells in vitro, and by murine iNKT cells in vivo. In 
the absence of IFNγ, GM-CSF was essential for iNKT cell mediated inhibition of Mtb growth, and 
GM-CSF alone was sufficient for bacterial control in vitro. Interestingly, under conditions where 
either CD1d signaling or GM-CSF was blocked during iNKT cell co-culture there was still on 
average a 30% reduction in CFU. In the case of antibody blocking, inefficient inhibition during the 
five day assay may be a technical confounder. In addition, these data point to two alternative 
biological explanations. First, signals apart from TCR activation may contribute to the production 
of GM-CSF by iNKT cells (Figure 2-13B). Cytokines such as IL-12 plus IL-18 stimulate iNKT cells 
to produce GM-CSF (data not shown). Second, there may be molecules other than GM-CSF and 
IFNγ that are produced by iNKT cells and activate infected macrophages to inhibit bacterial 
growth. While GM-CSF is unlikely to be the only iNKT cell effector function that inhibits Mtb 
replication, our experiments demonstrate that it is a dominant antimicrobial pathway during Mtb 
infection. 
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 Although signaling by IFNγ is crucial for control of Mtb, clinical data show that IFNγ 
present at the site of ongoing infection is inadequate to clear bacteria and IFNγ levels produced 
by CD4+ T cells do not correlate with disease progression or protection provided by BCG 
vaccination38, 39, 40. An implication of these studies is that alternative pathways exist that control 
Mtb. A number of studies have demonstrated IFNγ-independent mechanisms of control by CD4+ 
and CD8+ T cells41, 42, 43. Using iNKT cells as a model, we evaluated IFNγ-independent pathways 
of control in the innate immune compartment.  
Two previous studies find GM-CSF to be required for host resistance in vivo based on the 
greater susceptibility of GM-CSF-/- mice compared to WT mice44, 45. Although alveolar 
macrophages and type II epithelial cells were presumed to be the dominant source of GM-CSF in 
the lung, ectopic expression of GM-CSF driven by the surfactant C promoter did not fully rescue 
the susceptibility of GM-CSF-/- mice, suggesting that GM-CSF from other sources might be 
important for immunity. T cells are an important source of GM-CSF, and in addition to iNKT cells, 
other innate-like T cells produce GM-CSF during Mtb infection (Chapter 3). We have also found 
that conventional CD4+ T cells in the lungs of Mtb infected mice produce GM-CSF and may 
replace innate lymphocytes as a source of GM-CSF as the immune response to Mtb evolves. 
This may be one explanation for why iNKT cells are redundant during Mtb infection. Although 
GM-CSF restricts bacterial replication in human macrophages, its role as an effector molecule 
during clinical infection is harder to discern. Importantly, recent clinical data indicates that the 
development of anti-GM-CSF neutralizing antibodies are a form of acquired immunodeficiency 
associated with cryptococcal meningitis and pulmonary tuberculosis in otherwise normal 
individuals46. This suggests that inhibition of GM-CSF signaling may increase clinical 
susceptibility to Mtb and other pulmonary pathogens. 
To put our in vitro experiments in context, cytokines induced by Mtb-infected 
macrophages, which include IL-12 and IL-18, are drivers of IFNγ and other cytokine production by 
iNKT cells, independent of TCR activation (e.g., in an antigen-independent manner). An important 
question is whether this mechanism is relevant in vivo. In vitro, our assays use numerous 
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macrophages that are uniformly infected, with the consequence that the effective cytokine 
concentration that the iNKT cells are exposed to could be higher than is relevant in vivo. 
Furthermore, the iNKT cell lines are primed to produce IFNγ because they have been repeatedly 
stimulated in vitro with αGalCer (see below). Interestingly, the iNKT cell lines produced both IFNγ 
and GM-CSF after short-term adoptive transfer into Mtb-infected mice, but only in a CD1d-
dependent manner. Cytokine production was only observed when the iNKT cells were transferred 
into Mtb-infected WT mice but not when transferred into infected CD1d-/- mice. Thus, although 
CD1d-independent GM-CSF and IFNγ was observed in vitro, TCR signaling is crucial in vivo 
during infection to stimulate iNKT cells to produce cytokines. 
After a strong stimulus such as αGalCer, human iNKT cell clones produce both GM-CSF 
and IFNγ; in contrast, GM-CSF dominates after a weak or autoreactive stimulus47. GM-CSF 
production by iNKT cells plays an important role in the maturation of DC, which has been linked to 
effective T cell priming47, 48. Wang et al found that in resting human iNKT cells the CSF2 (GM-
CSF) locus already had high histone H4 acetylation, indicative of chromatin availability, while the 
IFNG (IFNγ) locus had low histone H4 acetylation, which was increased only after strong 
stimulation34. In contrast to the iNKT cell lines, we observed that endogenous polyclonal iNKT 
cells in the lungs of Mtb-infected mice more frequently produced GM-CSF than IFNγ, consistent 
with the idea that iNKT cells are poised to produce GM-CSF more readily than IFNγ, particularly 
when exposed to weak TCR agonists. This study further confirms that different iNKT cell effector 
functions may require different stimuli and that epigenetic modifications may explain at least part 
of this phenomenon.  
It is clear that there is great heterogeneity in iNKT cell responses and that part of this 
variability comes from the diversity in activating stimuli iNKT cells encounter. We observed two 
distinct modes of activation that initiated different effector functions: (1) the IL-12/IL-18 pathway 
activated iNKT cells to produce IFNγ, and (2) a TCR-dependent pathway elicited 
antimycobacterial activity. Interestingly, in the context of Mtb infection, the conventional markers 
of iNKT cell activation did not correlate with effector function and our data indicate that GM-CSF 
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production may be a better marker of TCR-dependent iNKT cell effector function than IFNγ. Using 
transcriptional profiling, Cohen et al elegantly showed that iNKT cells share features of both NK 
cells and T cells49. Here we show that during the host response to infection, different stimuli may 
trigger different iNKT cell effector programs characteristic of NK cells (e.g. activation by IL-12 and 
IL-18) or T cells (e.g. TCR activation). Future insight into iNKT cell immunity will require better 
understanding of how different activation stimuli can dictate subsequent effector functions and 
may facilitate the discovery of other novel antimicrobial roles for iNKT cells.  
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MATERIALS AND METHODS 
 
Ethics Statement 
All mice were bred and maintained using standard humane animal husbandry protocols. All 
animal experiments were performed in accordance with relevant guidelines for the care and 
handling of laboratory animals and were approved by the Dana Farber Cancer Institute Animal 
Care and Use Committee (Animal Welfare Assurance number A3023-01) under Public Health 
Service assurance of the Office of Laboratory Animal Welfare guidelines. Human blood collected 
from healthy donors was purchased from Research Blood Components (Boston, MA), and its use 
was approved by the Institutional Review Board of Brigham and Womenʼs Hospital (Human 
Subjects Assurance FWA00000484). Written informed consent was obtained for each donor by 
Research Blood Components. 
 
Mice  
C57Bl/6 WT, IFNγ-/-, IFNγR-/-, TNFR1/2-/-, Perforin-/-, and Fas-/- mice were obtained from Jackson 
Laboratories. Vα14-Jα281 transgenic mice were provided by Dr. Albert Bendelac50. CD1d-/- mice 
were provided by Dr. Mark Exley 51. MyD88-/- mice were provided by Dr. Koichi Kobayashi52.  
  
Macrophage isolation and culture 
Thioglycollate (TGL)-elicited peritoneal macrophages were lavaged 4–5 days after 3% 
intraperitoneal TGL injection and then isolated by positive selection with CD11b microbeads and 
magnetic columns (Miltenyi Biotec). Purified cells were over 95% F4/80+ CD11b+, as determined 
by flow cytometry. Bone marrow-derived macrophages (BMDM) were differentiated from bone 
marrow after 7 days in RPMI supplemented with 20% L929 cell supernatant. U937 cell line was 
grown in complete media. Macrophages were seeded at 5x105 cells/well in 24-well culture plates 
or 1x105 in 96-well culture plates in complete RPMI 1640 medium (Invitrogen Life Technologies) 
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supplemented with 10% fetal calf serum (HyClone). For transwell assays, macrophages were 
seeded at 2x105 in 0.4 μm cell culture inserts for 24-well plates (BD Bioscience). 
 
iNKT cells and HMNC  
iNKT cell lines were derived as previously reported 53. T cells were selected from splenocytes 
using the Pan T Isolation Kit (Miltenyi Biotec) and then cultured overnight at 37°C. The next day, 
T cells were labeled with PE-conjugated CD1d tetramer loaded with PBS-57 lipid antigen 
(National Institutes of Health Tetramer Core Facility) and sorted using anti-PE beads (Miltenyi 
Biotec). The purity of iNKT cells was higher than 95%. iNKT cells were then cultured with 
irradiated αGalCer-pulsed BMDCs in 24-well plates in complete RPMI medium with 10% FBS. 
Three to four days later, 1 ng/ml IL-2 (R&D Systems) and 10 ng/ml IL-7 (PeproTech) were added. 
iNKT cells were rested for at least 18 days before use. Human iNKT cell clones were derived and 
cultured as previously described 7. Hepatic mononuclear cells (HMNCs) were isolated from 
mouse liver perfused with PBS and homogenized through 70 υm cell strainer to single cell 
suspension. After centrifugation, the cells were resuspended in 30% Percoll and overlayed onto 
80% Percoll layer (Sigma). The interface containing the lymphocytes was collected and washed 
before use.  
 
Mtb in vitro culture and infection  
H37Rv was grown and prepared as previously described 18. Bacteria was counted and added to 
macrophages at an effective multiplicity of infection (MOI) of 0.2 for CFU experiments (or higher 
for ELISA and FACS assays) for two hours. Cultures were washed three times to remove 
extracellular bacteria. Infected macrophages were cultured overnight and iNKT cells or other 
conditions were added on d1. For CFU measurement, cells were lysed with 1% Triton X-100/PBS 
and lysate from quadruplicate conditions were plated in serial dilutions on Middlebrook 7H10 agar 
plates (ThermoFisher Scientific), and cultured at 37oC for 21 days. Infected macrophages were 
treated with the following reagents: caspase-3 inhibitor and caspase inhibitor negative control 
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(Calbiochem), anti-mouse-IL-12p40 (C17.8; Biolegend), anti-mouse-IL-18 (93-10C; MBL), anti-
mouse-CD1d (19G112.2) 54, anti-human-CD1d (CD1d42; BD Pharmingen), anti-mouse-GM-CSF 
(MP1-22E9; Biolegend), recombinant murine GM-CSF (Peprotech), and IFNγ (murine, Peprotech; 
human, Biolegend). αGalCer was kindly provided by Gurdyal S. Besra. 
 
% CFU reduction 
To compare inhibition of bacterial growth across multiple experiments, % CFU reduction was 
calculated. 100% CFU reduction on d5 indicates complete inhibition of bacterial growth to d1 
levels while 0% CFU reduction indicates no change in bacterial growth from untreated 
macrophages. % CFU reduction = 100 x [CFU(untreated mf-d5) - CFU(treated mf-d5)] / [(CFU(untreated mf-d5) - 
CFU(untreated mf-d1)] 
 
In vivo aerosol infections 
In vivo infections were performed using virulent Mtb (Erdman strain). Mice infected with Mtb were 
housed under BSL3 conditions. For each infection, a bacterial aliquot was thawed, sonicated 
twice for 10 s, and then diluted in 0.9% NaCl/0.02% Tween 80. A 15-ml suspension of M. 
tuberculosis was loaded into a nebulizer (MiniHEART nebulizer; Vortran Medical Technology) and 
mice were infected via the aerosol route with a nose-only exposure unit (Intox Products) and 
received ~50–100 CFU/mouse. Mice were euthanized by CO2 inhalation and lungs were 
aseptically removed after perfusion of 10 ml of sterile RPMI into the right ventricle of the heart. 
Lung mononuclear cells were obtained by mechanical disruption using a gentleMACS dissociator 
(Miltenyi Biotec) followed by incubation in collagenase (Sigma-Aldrich) for 30 mins at 37°C. Cells 
were isolated by forcing suspensions through a 70 μM cell strainer and then enumerated in 4% 
trypan blue with a hemacytometer. Samples used for ICS were incubated for 4 hours at 37°C with 
IL-2 and Brefeldin A (GolgiPlug, BD Biosciences). 
 
Adoptive transfer of iNKT cell lines 
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3-5x106 iNKT cells were stained with Cell Proliferation Dye eFluor® 450 (eBioscience) following 
the manufacturerʼs protocol and then iv injected via tail vein into Mtb-infected WT or CD1d-/- mice. 
Twenty hours later, mice were euthanized and lungs were removed and digested. Lung 
mononuclear cells were stained by surface and ICS protocols and paraformaldehyde fixed. 
Untransferred iNKT cells cultured in standard media were similarly treated to ascertain baseline 
activation. Flow cytometry gating strategies allowed for separation of endogenous versus 
transferred iNKT cells independent of tetramer staining by the presence of fluorescent dye. 
 
Flow cytometry and ICS 
Cells were first incubated with CD16/CD32 (FcBlock; BD Biosciences). Surface staining for in 
vitro experiments included antibodies for mouse CD69 (H1.2F3), CD25 (PC61), F4/80 (BM8), 
CD1d (1B1), and isotype controls (all from Biolegend). Surface staining of lung mononuclear cells 
included antibodies for mouse TCRβ (H57-597), CD69, CD3 (17A2), CD19 (6D5) and isotype 
controls (all from Biolegend). PBS-57-loaded and control PE- and APC-conjugated CD1d 
tetramers were provided by the National Institute of Allergy and Infectious Diseases Tetramer 
Facility (Emory University Vaccine Center). After tetramer staining, ICS with antibodies specific 
for mouse GM-CSF (MP1-22E9; eBioscience) and IFNγ (XMG1.2; Biolegend) was performed 
following fixation with 4% paraformaldehyde and permeabilization with Perm/Wash buffer (BD 
Biosciences). Data were collected using FACSCanto (BD Biosciences) and analyzed with FlowJo 
(Tree Star, Inc.).  
 
ELISA, Nitric Oxide, and Bioplex Immunoassays 
Culture supernatants were filtered through 0.2 µm filter to remove any bacteria. IFNγ, IL-12p40, 
and GM-CSF ELISAs were done in accordance with the manufacturerʼs instructions (Biolegend), 
and absorbance was recorded at 450 nm on SoftMax Pro ELISA analysis software (Molecular 
Devices). Nitric oxide (NO) production was measured using the Griess reaction to detect nitrite, a 
stable breakdown product of NO, as described previously18. For size fractionation, Amicon Ultra-
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15 Centrifugal Filter Units with 10kDa and 50kDa cutoff were used (EMD Millipore). Bioplex 
immunoassay was done in accordance with the manufacturerʼs instructions (BioRad). 
 
Statistical analysis 
Data was analyzed by one-way ANOVA (95% confidence interval) with Dunnettʼs post-test (for 
comparison against a single control) or Tukey post-test (for comparison between all conditions) or 
unpaired Studentʼs t-test. Analysis was performed using GraphPad Prism software.  
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ABSTRACT  
 
There are several key T cell effector cytokines that have been shown to be critical for 
control of Mycobacterium tuberculosis (Mtb). These include IFNγ and TNF. To gain a more 
comprehensive understanding of what constitutes effective immunity, other protective T cell 
factors must be tested as well. We have identified GM-CSF as a protective cytokine produced by 
iNKT cells in response to Mtb infection. Here we test the contribution of T cell-derived GM-CSF to 
the Mtb immune response. We demonstrate that GM-CSF is produced in the lung during Mtb 
infection and both innate and adaptive T cell subsets in the lung produce GM-CSF over the 
course of infection. Preliminary adoptive transfer experiments reveal that T cell-derived GM-CSF 
contributes to antimicrobial control in vivo, despite having no direct effect on myeloid recruitment 
or global T cell function. In vitro experiments also demonstrate that the direct antimicrobial effect 
of GM-CSF on Mtb-infected macrophages enhances the direct effects of IFNγ at low cytokine 
concentrations. Together, these data establish GM-CSF as a protective T cell effector function 
during Mtb infection.  
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INTRODUCTION 
 
In order for the host immune response to effectively control infection of Mycobacterium 
tuberculosis (Mtb), a strong T cell response is required1. IFNγ has been identified as a key 
immune factor that can lead to inhibition and killing of Mtb through induction of nitric oxide2, 
phagolysosomal fusion3, autophagy4, and Vitamin D receptor expression5. Although many studies 
have measured T cell production of IFNγ and many TB diagnostic tools rely on IFNγ from T cells 
for their readout, formal analysis has only recently been performed to show that IFNγ from CD4+ 
T cells is critical for bacterial control6. However, there is also evidence that T cells can control Mtb 
growth in vivo independently of IFNγ7, 8. It is likely that both IFNγ-dependent and independent 
pathways are important for complete immune control. 
Apart from IFNγ, there are several other T cell effector functions that have been 
described to contribute to an antimicrobial response. TNF production plays an important role in 
controlling bacterial growth9. IL-17 has been shown to be effective early on in controlling Mtb and 
for effective granuloma formation, but also can have detrimental effect increasing 
immunopathology later during infection7, 10, 11. In addition, CD8+ T cells have been shown to 
control infection through cytolytic activity12, 13. Identifying additional T cell effector functions could 
help improve vaccine efforts and offer new immunotherapy targets.  
GM-CSF is a T cell effector function that has been shown to be a factor in initiating 
autoimmune conditions like experimental autoimmune encephalomyelitis (EAE)14, 15. GM-CSF has 
also been identified as a key protective cytokine during Mtb infection. GM-CSF treatment of 
human macrophages inhibits intracellular growth of Mtb and M. avium16, 17, 18. We demonstrated in 
Chapter 2 that iNKT cell production of GM-CSF contributes to their ability to restrict bacterial 
growth in vitro and that GM-CSF treatment of macrophages restricts Mtb growth in murine cells.  
GM-CSF-/- mice are highly susceptible to Mtb, with increased bacterial burden and 
decreased survival after virulent aerosol infection compared to WT mice19, 20. GM-CSF is 
produced by many different cell types including leukocytes, epithelial cells and fibroblasts and is 
critical for the development and maturation of pulmonary macrophages. Interestingly, the absence 
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of this cytokine leads most dramatically to defects in lung function, while the effect on other 
organs is minimal21. Lack of GM-CSF leads to abnormalities in surfactant recycling and a 
pulmonary inflammatory disease resembling human pulmonary alveolar proteinosis (PAP). 
Overexpressing GM-CSF in epithelial cells reverses these lung abnormalities22 but the 
susceptibility to Mtb is not fully rescued, suggesting that GM-CSF production by other cells, 
perhaps T cells, may contribute to protection in mice19, 20. Additionally, the presence of anti-GM-
CSF autoantibodies that block GM-CSF function has been linked to susceptibility to both 
cryptococcal meningitis and pulmonary TB in otherwise healthy subjects indicating that GM-CSF 
may also participate in host defense against infection in people. 
Here we demonstrate that GM-CSF is produced in the lung during Mtb infection and that 
both innate and adaptive T cell subsets produce GM-CSF at the site of infection. Through 
preliminary adoptive transfer experiments we demonstrate that T cell-derived GM-CSF 
contributes to antimicrobial control in vivo. Lastly, we show that the antimicrobial effect of GM-
CSF on Mtb-infected macrophages is additive in combination with the direct effects of IFNγ. 
Together, these data reveal that GM-CSF is a protective T cell effector function during Mtb 
infection.  
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RESULTS 
GM-CSF is produced during the normal immune response to Mtb 
To determine the overall production of GM-CSF in the lung during Mtb infection, we 
measured GM-CSF protein in lung homogenate by Bioplex. We found an increase in total GM-
CSF protein over the course of infection (Figure 3-1A) with a fold change of 1.97 ± 0.28 (mean ± 
SEM) at 4 weeks, 5.02 ± 0.22 at 12 weeks, and 5.11 ± 0.11 at 24 weeks compared to naïve lungs 
(Figure 3-1B). This data shows that GM-CSF production accumulates over the course of infection 
and increases in the lung in a manner consistent with an adaptive immune response. 
 
GM-CSF is produced by multiple T cell subsets during infection 
Early work studying the pulmonary effects of GM-CSF showed that pulmonary epithelial 
cells could produce GM-CSF in culture23. In addition, insertion of a GM-CSF transgene on a 
promoter expressed by type II lung epithelial cells (surfactant C) rescued the GM-CSF-/- PAP 
phenotype22. Therefore, it has been assumed that epithelial cells were one of the main producers 
of GM-CSF in the lung. However, these studies did not address the dynamics of an immune 
response. Our previous work provided evidence that at least one T cell subset, iNKT cells, 
produced GM-CSF in the lung during infection (Chapter 2). 
Therefore, we undertook a more comprehensive analysis of GM-CSF production by T cell 
subsets in the lungs of naïve and infected mice. We performed intracellular cytokine staining 
(ICS) analysis of lung samples at multiple time points post-infection in the presence of IL-2 and 
Brefeldin A without further stimulation. Separate staining panels were set up to assess 4 major T 
cell subsets, gated following doublet and auto-fluorescence exclusion: iNKT cells (TCRβ+ CD1d-
tetramer+), γδ T cells (CD3+ TCRβ- TCRγδ+), CD4+ T cells (TCRβ+ CD4+ CD8-), and CD8+ T cells 
(TCRβ+ CD4- CD8+). We found that all 4 cell types produced GM-CSF at some point during 
infection. A small but detectable number of iNKT cells and γδ T cells produced GM-CSF early 
during infection. CD4+ T cells dominated the GM-CSF response by week 4, while CD8+ T cells did 
not start producing GM-CSF reliably until week 8 post-infection (Figure 3-2A). We then compared  
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Figure 3-1. GM-CSF production in the lung increases over the course of Mtb infection.  
 
GM-CSF measured by Bioplex immunoassay in lung homogenate at multiple weeks post aerosol 
infection with Erdman strain in WT C57Bl/6J mice. (A) GM-CSF protein normalized per lung. (B) 
Fold increase in GM-CSF protein at infection timepoints compared to naïve lung (0 weeks post 
infection). Data is from a single experiment at multiple timepoints with 5 mice per group.  
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this pattern of GM-CSF production to that of IFNγ production, where the response was dominated 
by CD4+ and CD8+ T cells starting at week 4 post-infection (Figure 3-2B). Interestingly, while there 
were very few double positive (GM-CSF+IFNγ+) iNKT cells or γδ T cells especially early during 
infection, there were many double positive CD4+ and CD8+ T cells by weeks 4 and up (Figure 3-
2C).  
The relative proportion of each T cell subset producing both GM-CSF and IFNγ over the 
course of infection was also analyzed (Figure 3-3). While the IFNγ response was clearly 
dominated by CD4+ T cells throughout the entire infection, GM-CSF production was more evenly 
split among the four T cell subsets analyzed. Both iNKT cells and γδ T cells dominated the 
production of GM-CSF early during infection through week 3. CD4+ T cells made up the greatest 
proportion of GM-CSF+ T cells at week 4 and week 8 and CD8+ T cells made up the greatest 
proportion of GM-CSF+ T cells at late time points. 
This data shows that both innate and adaptive T cell subsets produce GM-CSF as part of 
an immune response to Mtb infection. In addition, it demonstrates that GM-CSF and IFNγ 
production are regulated by different signals during infection. While the GM-CSF response has 
clear differences in kinetics compared to the IFNγ response, it is interesting to note that later 
during infection there are significant numbers of T cells producing both cytokines. 
 
GM-CSF production by T cells is critical for control 
Given that both innate and adaptive T cell subsets were found to produce GM-CSF during 
infection, we next determined whether GM-CSF production by T cells contributed to control of 
bacterial growth in vivo. We performed adoptive transfer experiments, transferring naïve T cells 
from either WT or GM-CSF-/- mice that were isolated from spleen and lymph nodes, separated by 
magnetic bead selection, and then transferred into Rag-/- hosts. These mice were then infected 
with Erdman strain of Mtb by low dose aerosol infection within 24 hours. After 4 weeks, lung and 
spleen were removed and analyzed for bacterial burden, pathology, and T cell cytokine 
production.  
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Figure 3-2. Multiple T cell subsets produce GM-CSF in the lung during Mtb infection.  
 
Number of GM-CSF (A), IFNγ (B), and double producing (C) T cells isolated from the lung of WT 
C57Bl/6J after aerosol infection with Erdman strain and stained by ICS with no further stimulation 
and 4 hours of Brefeldin A incubation. iNKT cells (TCRβ+ CD1d-tetramer+), γδ T cells (CD3+ 
TCRβ- TCRγδ+), CD4+ (TCRβ+ CD4+ CD8-), CD8+ (TCRβ+ CD4- CD8+). Data is compiled from 6 
independent infections with at least 2 independent infections per time point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. Relative proportion of cytokine production by T cell subsets over the course of 
infection. 
 
Relative frequency of GM-CSF and IFNγ producing T cells from 4 major T cell subsets at each 
time point. Cells were isolated from the lung of WT C57Bl/6J after aerosol infection with Erdman 
strain and stained by ICS with no further stimulation and 4 hours of Brefeldin A incubation. iNKT 
cells (TCRβ+ CD1d-tetramer+), γδ T cells (CD3+ TCRβ- TCRγδ+), CD4+ (TCRβ+ CD4+ CD8-), CD8+ 
(TCRβ+ CD4- CD8+). Data is compiled from 6 independent infections with at least 2 independent 
infections per time point. 
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We found that mice that received WT T cells had lower bacterial burden than mice that received 
GM-CSF-/- T cells, evident by both CFU enumeration as well as histology samples (Figure 3-4A 
and 3-4B). This data suggests that GM-CSF production by T cells contributes to control of Mtb 
during in vivo infection.  
 
The absence of T cell-derived GM-CSF does not significantly alter other features of the 
pulmonary immune response  
 Because we observed a difference in bacterial burden between mice that received the 
WT versus GM-CSF-/- T cell transfer, we next determined whether this was due to differences in 
recruitment or differentiation of immune cell populations. We specifically focused on myeloid cell 
populations, because previous reports suggest that GM-CSF plays a critical role in the maturation 
and development of myeloid cells, especially dendritic cells. By flow cytometry, we analyzed the 
following myeloid cell populations in the lung using surface markers: polymorphonuclear 
leukocytes (PMN) (CD3- Ly6G+ CD11b+), iNOS-expressing macrophages24 (CD3- CD11c+ 
CD11b+), dendritic cells (DC) (CD3- CD11c+ CD11b-), and a smaller CD8α+ DC population (CD3- 
CD8α+ CD11c+) (Figure 3-5A). Although there were small differences in the percentages of the 
myeloid populations between the two groups, these trends were not reproducible over multiple 
experiments. Percentages of CD4+ T cells (TCRβ+ CD4+ CD8-), CD8+ T cells (TCRβ+ CD4- CD8+), 
iNKT cells (TCRβ+ CD1d-tetramer+) and γδ T cells (CD3+ TCRβ+ TCRγδ+) were also analyzed 
and there were also no major differences between groups (data not shown). This data suggests 
that the lack of T cell-derived GM-CSF does not significantly alter the recruitment or differentiation 
of inflammatory cell populations in the lung.  
 By ICS, GM-CSF and IFNγ production by CD4+ and CD8+ T cells in response to both 
peptide and anti-CD3/anti-CD28 stimulation were measured (Figure 3-5B). As expected, GM-
CSF-/- T cells did not produce any GM-CSF.  This also served as a control for our antibody 
staining. However, we did not observe any differences in IFNγ production for either CD4+ or CD8+ 
T cells between the two groups. This indicates that any difference in bacterial growth produced by  
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Figure 3-4. T cell derived GM-CSF is critical for control of Mtb growth.  
 
WT and GM-CSF-/- naïve T cells isolated from spleen and lymph nodes were transferred on d0 
into Rag-/- hosts, followed by low-dose aerosol infection with Erdman strain. (A) CFU measured in 
lung and spleen on d30 post-infection. (B) Representative histology samples from lung tissue 
fixed in formalin, paraffin-embedded and then stained with hematoxylin and eosin (H&E) and 
AFB. Studentʼs unpaired t-test. *p<.05, **p < .01. Data representative of two independent 
experiments. 
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Figure 3-5. GM-CSF-/- T cells still produce IFNγ.  
 
30 days after transfer of WT and GM-CSF-/- naïve T cells into Rag-/- hosts and low-dose aerosol 
infection with Erdman strain, T cells were isolated from the lungs of infected mice. (A) By flow 
cytometry, the percentage of myeloid cell populations in the total lung were analyzed based on 
the following surface markers: PMN (CD3- Ly6G+ CD11b+), Mφ (CD3- CD11c+ CD11b+) cells, DC 
(CD3- CD11c+ CD11b-), CD8α+ DC population (CD3- CD8α+ CD11c+). (B) Cells were stimulated 
for 5 hours with peptides ESAT6 and TB10.4 and anti-CD3/anti-CD28 with Brefeldin A and IL-2. 
Intracellular cytokine staining for GM-CSF and IFNγ was performed. Error bars indicate mean ± 
SEM. Data representative of two independent experiments. 
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T cell-derived GM-CSF is unlikely to be the result of major changes in immune cell recruitment, 
overall T cell function, or IFNγ production more specifically.  
 
GM-CSF and IFNγ have an additive antimicrobial effect 
 In vivo data suggested that the absence of T cell-derived GM-CSF led to an increase in 
overall bacterial burden, despite intact immune cell recruitment and an adaptive IFNγ response. 
ICS data in intact mice also demonstrated that during the adaptive response there were a 
significant proportion of CD4+ and CD8+ T cells that were GM-CSF+ IFNγ+ double positive cells. 
We hypothesized that GM-CSF and IFNγ could be working together to directly limit bacterial 
growth. Utilizing our in vitro macrophage infection model, we tested whether the antimicrobial 
effects of GM-CSF and IFNγ could be augmented when combined (Figure 3-6). Both GM-CSF 
and IFNγ were individually able to inhibit Mtb growth at higher cytokine concentrations (such as 
10 ng/ml). However, at lower concentrations of 0.1 ng/ml, the combination of GM-CSF and IFNγ 
led to a statistically significant decrease in CFU from the single cytokine treatment conditions. 
This indicates that especially at lower cytokine concentrations that are likely more representative 
of concentrations perceived by infected cells in the lung, GM-CSF and IFNγ appear to have an 
additive effect. Although the results do not reveal a clear synergistic effect between these 
cytokines, further investigation into the antimicrobial mechanism of GM-CSF may reveal 
mechanistic connections with IFNγ that will compel follow-up studies. 
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Figure 3-6. GM-CSF and IFNγ have an additive antimicrobial effect.  
 
CFU assay for H37Rv-infected WT mφ with recombinant GM-CSF and/or IFNγ added on d1 post-
infection. CFU were measured on d1 (mφ alone) and on d5 post-infection. Error bars indicate 
mean ± SEM. **P < 0.01 (One way ANOVA with Dunnettʼs post-test, comparing combination 
treatment with individual cytokine treatment at each concentration.) Data are representative of 
two independent experiments with three replicates per condition.  
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DISCUSSION 
 
Here we have shown that GM-CSF protein increases in the lung over the course of 
infection and can be produced by both innate (iNKT, γδ T cells) and adaptive (TCRαβ+ CD4+ and 
CD8+ T cells) T cell subsets in the lung in response to Mtb infection. Using an adoptive transfer 
model, we now have preliminary evidence that T cell-produced GM-CSF contributes to control of 
bacterial growth in vivo. Mice lacking GM-CSF-producing T cells have about a half of a log 
increase in CFU at four weeks post infection compared to mice with WT T cells. In vitro 
experiments demonstrated that GM-CSF can have a direct antimicrobial effect on Mtb-infected 
macrophages (see also Chaper 2) and here we show that this direct effect of GM-CSF can work 
in concert with IFNγ, especially at low cytokine concentrations. This suggests that GM-CSF and 
IFNγ may work together in the lung to control Mtb growth during the adaptive immune response, 
when T cells are producing both cytokines concurrently (Figure 3-2C).  
There are at least two previous examples in the literature that describe GM-CSF 
production by human T cells in response to mycobacterial infection. The first study examined 
CD4+ CD1-restricted T cell lines derived from the lesions of leprosy patients that produced IFNγ 
and GM-CSF in response to sonicated Mycobacterium leprae25. The second study analyzed T 
cells from the peripheral blood of children with either active or latent TB and found that CD4+ T 
cells produced GM-CSF in response to both Mtb and Mtb-antigens, but this population was not 
increased in active versus latent patients26. 
Establishing GM-CSF as a novel T cell effector function during Mtb infection identifies 
another component of the anti-mycobacterial T cell arsenal, which potentially could be utilized for 
host-directed therapeutics. This is critical because our current understanding of what immune 
factors need to be elicited for an effective vaccine response remains limited and is likely 
incomplete. While the current TB vaccine, bacilli Calmette-Guerin (BCG), is used to elicit immune 
protection in pediatric patients, its efficacy in adults has been limited. Therefore, many new 
vaccine candidates are now being tested that could induce sufficient protective and long-lasting 
immunity in adults. Several recent vaccines tested in clinical trials have had disappointing results, 
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including the prime-boost model using MVA85A, made up of a modified and replication defective 
vaccinia ankara virus expressing the Mtb antigen 85A, to boost initial BCG vaccination. While 
MVA85A was shown to induce strong IFNγ responses27, the latest pediatric clinical trial did not 
show efficacy among infants, aged 4-6 months, when given as a booster to BCG vaccination28. 
Although it did induce IFNγ, TNF, and IL-2 producing antigen-specific T cells, this did not 
correlate with protection over the two-year follow-up28. Studies such as this one suggest that we 
still do not have a complete picture of effective T cell-induced Mtb immunity. Therefore, it is 
critical to identify new factors such as GM-CSF that may potentially be more informative 
measures of protection. A better understanding of how GM-CSF cooperates with other cytokines 
produced in the lung, including IFNγ and TNF, could further improve our understanding of 
immune dynamics during TB infection.  
The therapeutic effect of GM-CSF has already been tested in several recombinant 
therapy studies. In a study of pulmonary Streptococcus pneumonia infection in mice, orotracheal 
instillation of adenoviral vectors encoding GM-CSF led to an increase in host survival and a 
decrease in bacterial burden29, a proof-of-principle study demonstrating that increased expression 
of GM-CSF in the lung can alter bacterial infection outcomes. More recently, using an i.t. Mtb 
infection model, a single dose of adenoviral-encoded GM-CSF prior to infection was shown to 
decrease the CFU of BALB/c mice by 2 weeks post-infection through the end of the experiment at 
15 weeks30. In a third study of i.v. Mtb infection, mice received intramuscular treatment of 
recombinant IL-2 and/or GM-CSF with and without standard isoniazid/rifampin immunotherapy. 
While treatment with recombinant GM-CSF alone had only a minor effect on bacterial burden in 
the H37Rv infection, a more dramatic effect (a 1.5 log reduction at 6 weeks) was observed when 
rGM-CSF was given in combination with rIL-2 and antibiotics for treatment of an MDR-TB OB35 
strain infection where treatment with standard antibiotics alone failed31. 
Interestingly, a human Phase II safety trial was conducted in Brazil for recombinant GM-
CSF treatment of tuberculosis over a decade ago. Recombinant GM-CSF was injected 
subcutaneously twice a week as an addition to standard drug therapy (isoniazid/rifampin plus two 
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months of pyrazinamide). After four weeks of treatment with very low side-effects, clinical 
outcomes were equal between GM-CSF treatment and placebo, although the authors found a 
small but non-statistical trend towards faster time to negative culture in the treated patients32. 
Taken together, these studies suggest that under the right treatment conditions, GM-CSF 
has potential as an immunotherapy for tuberculosis, including MDR-TB. Finding the most effective 
dosing, timing, and treatment routes are all critical studies that still need to be performed before 
any human trials should be attempted. 
In the end, the short half-life of GM-CSF may restrict the efficacy of a recombinant GM-
CSF therapeutic approach33. However, this study suggests that there are various T cell subsets 
that could be stimulated to increase endogenous GM-CSF production in the lung. While IFNγ 
production is dominated by conventional CD4+ T cells, GM-CSF production was detected in all 4 
subsets tested (iNKT cells, γδ T cells, CD4+ T cells, and CD8+ T cells). Research on non-
conventional T cells has found that these cell types can be strongly stimulated by non-Mtb 
antigens that still lead to increased survival and decreased bacterial burden in Mtb-infected 
animals. For iNKT cells, treatment with αGalCer was shown to increase survival in susceptible 
mouse strains34 and synergized with standard antibiotic treatment35. For γδ T cells, stimulation 
with IL-2 and phosphoantigen led to significant expansion and trafficking of γδ T cells into the 
lung and increased resistance to Mtb infection of non-human primates36. While GM-CSF 
production was not measured, IL-2 and phosphoantigen treatment led to increases in both IFNγ 
production as well as perforin and granulysin expression. These studies hint at potential 
strategies to induce GM-CSF production early on in the lung. 
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MATERIALS AND METHODS 
 
Ethics Statement 
All mice were bred and maintained using standard humane animal husbandry protocols. All 
animal experiments were performed in accordance with relevant guidelines for the care and 
handling of laboratory animals and were approved by the Dana Farber Cancer Institute Animal 
Care and Use Committee (Animal Welfare Assurance number A3023-01) or by the Department of 
Animal Medicine of the University of Massachusetts Animal Care and Use Committee (Animal 
Welfare Assurance number A2420-13) under Public Health Service assurance of the Office of 
Laboratory Animal Welfare guidelines. Mice infected with M. tuberculosis were housed in a 
biosafety level 3 facility under specific pathogen-free conditions in Animal Biohazard Containment 
Suites (Dana Farber Cancer Institute, Boston, MA and University of Massachusetts, Worcester, 
MA). 
 
Mice  
C57BL/6J (WT) and B6.129S7-Rag1/J (Rag-/-) mice were obtained from Jackson Laboratories. 
C57BL/6J GM-CSF-/- mice were provided by Dr. Glenn Dranoff37.  
 
In vivo aerosol infections 
In vivo infections were performed using virulent Mtb (Erdman strain). For each infection, a 
bacterial aliquot was thawed, sonicated twice for 10 s, and then diluted in 0.9% NaCl/0.02% 
Tween 80. A 15-ml suspension of M. tuberculosis was loaded into a nebulizer (MiniHEART 
nebulizer; Vortran Medical Technology) and mice were infected via the aerosol route with a nose-
only exposure unit (Intox Products) and received ~50–100 CFU/mouse. Mice were euthanized by 
CO2 inhalation and lungs were aseptically removed after perfusion of 10 ml of sterile RPMI into 
the right ventricle of the heart. Lung mononuclear cells were obtained by mechanical disruption 
using a gentleMACS dissociator (Miltenyi Biotec) followed by incubation in collagenase (Sigma-
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Aldrich) for 30 mins at 37°C. Cells were isolated by forcing suspensions through a 70 μM cell 
strainer and then enumerated in 4% trypan blue with a hemacytometer. For ICS stimulations, 
cells were plated in a 96-well plate and incubated for 4-5 hours at 37°C with IL-2 either in the 
absence of stimuli or in the presence of TB10.44-11 peptide (10 μM; New England Peptide), 
ESAT61-20 peptide (10 μM; New England Peptide), or αCD3/αCD28 (1 ug/mL; BioLegend). 
Brefeldin A (GolgiPlug, BD Biosciences) was added to the cultures 1 hour after the addition of 
exogenous stimuli.  
 
Adoptive T cell transfer 
Naïve T cells were isolated from the spleen and lymph nodes of WT and GM-CSF-/- mice and 
then separated using the Pan T cell Isolation kit (Miltenyi Biotec) following manufacturerʼs 
protocol. Magnetic separation was performed using LS columns (Miltenyi Biotec). 5x106 T cells 
were then iv injected via tail vein into each Rag-/- mouse. All mice were infected with Mtb via the 
aerosol route within 24 h of cell transfer. 
 
Flow cytometry and ICS 
Cells were first incubated with CD16/CD32 (FcBlock; BD Biosciences). Surface staining included 
antibodies for murine TCRβ (H57-597), TCRγδ (UC7-13D5), CD3 (17A2), CD19 (6D5), CD4 
(RM4-5), CD8(53-6.7), CD25 (PC61), CD69 (H1.2F3), CD11b (M1/70), CD11c (N418) Ly6C 
(HK1.4), Ly6G (1A8) and isotype controls (all from Biolegend). Except for iNKT cell staining, ICS 
with antibodies specific for mouse GM-CSF (MP1-22E9; eBioscience) and IFNγ (XMG1.2; 
Biolegend) was performed in Perm/Wash buffer (BD Biosciences) following fixation and 
permeabilization with Fix/Perm buffer (BD Biosciences). PBS-57-loaded and control PE- and 
APC-conjugated CD1d tetramers were provided by the National Institute of Allergy and Infectious 
Diseases Tetramer Facility (Emory University Vaccine Center). For iNKT cells, after tetramer 
staining, ICS with antibodies specific for mouse GM-CSF and IFNγ (see above) was performed 
following fixation with 4% paraformaldehyde and permeabilization with Perm/Wash buffer (BD 
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Biosciences). Data were collected using FACSCanto (BD Biosciences) or MACSQuant (Miltenyi 
Biotec) and analyzed with FlowJo (Tree Star, Inc.).  
 
Macrophage isolation and culture 
Thioglycollate (TGL)-elicited peritoneal macrophages were lavaged 4–5 days after 3% 
intraperitoneal TGL injection and then isolated by positive selection with CD11b microbeads and 
LS magnetic columns (Miltenyi Biotec). Purified cells were over 95% F4/80+ CD11b+, as 
determined by flow cytometry. Macrophages were seeded at 1x105 in 96-well culture plates in 
complete RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 10% fetal calf 
serum (HyClone).  
 
Mtb in vitro culture and infection  
H37Rv was grown and prepared as previously described38. Bacteria was counted and added to 
macrophages at an effective multiplicity of infection (MOI) of 0.2 for CFU experiments for two 
hours. Cultures were washed three times to remove extracellular bacteria. Infected macrophages 
were cultured overnight and iNKT cells or other conditions were added on d1. For CFU 
measurement, cells were lysed with 1% Triton X-100/PBS and lysate from quadruplicate 
conditions were plated in serial dilutions on Middlebrook 7H10 agar plates (ThermoFisher 
Scientific), and cultured at 37oC for 21 days. Infected macrophages were treated with the 
following reagents: recombinant murine GM-CSF (Peprotech), and recombinant IFNγ (murine, 
Peprotech). 
 
ELISA and Bioplex Immunoassays 
Protein from lung homogenate was extracted using the Bio-Plex Cell Lysis Kit (Bio-Rad) and 
filtered through 0.2 µm filter to remove any bacteria. The concentration of GM-CSF was 
measured using a mouse Bio-Plex cytokine assay in accordance with the manufacturerʼs 
instructions (Bio-Rad).  
	   107	  
 
Statistical analysis 
All data are represented as mean +/- SEM. Data was analyzed by one-way ANOVA (95% 
confidence interval) with Dunnettʼs post-test (for comparison against a single control) or unpaired 
Studentʼs t-test. Analysis was performed using GraphPad Prism software.  
 
Acknowledgements 
 We thank the NIH Tetramer Core Facility for mouse CD1d tetramers. 
 
 
 
  
	   108	  
REFERENCES 
 
1. Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ. The relative importance of T 
cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis 
infection in mice. J Exp Med 2001, 193(3): 271-280. 
 
2. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis 
by reactive nitrogen intermediates produced by activated murine macrophages. J Exp 
Med 1992, 175(4): 1111-1122. 
 
3. Macmicking J, Taylor G, Mckinney J. Immune Control of Tuberculosis by IFN-{gamma}-
Inducible LRG-47. Science 2003, 302(5645): 654-659. 
 
4. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a 
defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected 
macrophages. Cell 2004, 119(6): 753-766. 
 
5. Fabri M, Stenger S, Shin D-M, Yuk J-M, Liu PT, Realegeno S, et al. Vitamin D Is 
Required for IFN- -Mediated Antimicrobial Activity of Human Macrophages. Science 
Translational Medicine 2011, 3(104): 104ra102. 
 
6. Green AM, Difazio R, Flynn JL. IFN-  from CD4 T Cells Is Essential for Host Survival and 
Enhances CD8 T Cell Function during Mycobacterium tuberculosis Infection. J Immunol 
2013, 190(1): 270-277. 
 
7. Gallegos AM, Van Heijst JWJ, Samstein M, Su X, Pamer EG, Glickman MS. A Gamma 
Interferon Independent Mechanism of CD4 T Cell Mediated Control of M. tuberculosis 
Infection in vivo. PLoS Pathog 2011, 7(5): e1002052. 
 
8. Cowley SC, Elkins KL. CD4+ T cells mediate IFN-gamma-independent control of 
Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol 2003, 171(9): 
4689-4699. 
 
9. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor 
necrosis factor-alpha is required in the protective immune response against 
Mycobacterium tuberculosis in mice. Immunity 1995, 2(6): 561-572. 
 
10. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al. IL-23 and 
IL-17 in the establishment of protective pulmonary CD4+ T cell responses after 
vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8(4): 
369-377. 
 
11. Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, Kishihara K, et al. 
Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma 
in the lung. J Immunol 2010, 184(8): 4414-4422. 
 
12. Woodworth J, Wu Y, Behar S. Mycobacterium tuberculosis-Specific CD8+ T Cells 
Require Perforin to Kill Target Cells and Provide Protection In Vivo. J Immunol 2008, 
181(12): 8595. 
 
13. Turner J, D'Souza CD, Pearl JE, Marietta P, Noel M, Frank AA, et al. CD8- and 
CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary 
tuberculosis. Am J Respir Cell Mol Biol 2001, 24(2): 203-209. 
	   109	  
 
14. Codarri L, Gyülvészi G, Tosevski V, Hesske L, Fontana A, Magnenat L, et al. RORγt 
drives production of the cytokine GM-CSF in helper T cells, which is essential for the 
effector phase of autoimmune neuroinflammation. Nat Immunol 2011, 12(6): 560-567. 
 
15. El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, et al. The encephalitogenicity of 
TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. 
Nat Immunol 2011, 12(6): 568-575. 
 
16. Bermudez LE, Young LS. Recombinant granulocyte-macrophage colony-stimulating 
factor activates human macrophages to inhibit growth or kill Mycobacterium avium 
complex. J Leukoc Biol 1990, 48(1): 67-73. 
 
17. Denis M, Ghadirian E. Granulocyte-macrophage colony-stimulating factor restricts growth 
of tubercle bacilli in human macrophages. Immunology Letters 1990, 24(3): 203-206. 
 
18. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor 
stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to 
kill avirulent M. avium: killing effector mechanism depends on the generation of reactive 
nitrogen intermediates. J Leukoc Biol 1991, 49(4): 380-387. 
 
19. Gonzalez-Juarrero M, Hattle JM, Izzo A, Junqueira-Kipnis AP, Shim TS, Trapnell BC, et 
al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs 
severely affects the ability of mice to control Mycobacterium tuberculosis infection. J 
Leukoc Biol 2005, 77(6): 914-922. 
 
20. Szeliga J, Daniel DS, Yang C-H, Sever-Chroneos Z, Jagannath C, Chroneos ZC. 
Granulocyte-macrophage colony stimulating factor-mediated innate responses in 
tuberculosis. Tuberculosis (Edinb) 2008, 88(1): 7-20. 
 
21. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. 
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major 
perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc 
Natl Acad Sci U S A 1994, 91(12): 5592-5596. 
 
22. Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA. Pulmonary epithelial cell 
expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin 
Invest 1996, 97(3): 649-655. 
 
23. Churchill L, Friedman B, Schleimer RP, Proud D. Production of granulocyte-macrophage 
colony-stimulating factor by cultured human tracheal epithelial cells. Immunology 1992, 
75(1): 189-195. 
 
24. Sköld M, Behar SM. Tuberculosis triggers a tissue-dependent program of differentiation 
and acquisition of effector functions by circulating monocytes. J Immunol 2008, 181(9): 
6349-6360. 
 
25. Sieling PA, Ochoa MT, Jullien D, Leslie DS, Sabet S, Rosat JP, et al. Evidence for human 
CD4+ T cells in the CD1-restricted repertoire: derivation of mycobacteria-reactive T cells 
from leprosy lesions. J Immunol 2000, 164(9): 4790-4796. 
 
	   110	  
26. Mueller H, Detjen AK, Schuck SD, Gutschmidt A, Wahn U, Magdorf K, et al. 
Mycobacterium tuberculosis-specific CD4+, IFNgamma+, and TNFalpha+ multifunctional 
memory T cells coexpress GM-CSF. Cytokine 2008, 43(2): 143-148. 
 
27. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. 
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed 
and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10(11): 
1240-1244. 
 
28. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety 
and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated 
with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381(9871): 
1021-1028. 
 
29. Steinwede K, Tempelhof O, Bolte K, Maus R, Bohling J, Ueberberg B, et al. Local 
delivery of GM-CSF protects mice from lethal pneumococcal pneumonia. J Immunol 
2011, 187(10): 5346-5356. 
 
30. Francisco-Cruz A, Mata-Espinosa D, Estrada-Parra S, Xing Z, Hernández-Pando R. 
Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage 
colony-stimulating factor in experimental pulmonary tuberculosis. Clin Exp Immunol 2013, 
171(3): 283-297. 
 
31. Zhang Y, Liu J, Wang Y, Xian Q, Shao L, Yang Z, et al. Immunotherapy using IL-2 and 
GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci 
China Life Sci 2012, 55(9): 800-806. 
 
32. Pedral-Sampaio DB, Netto EM, Brites C, Bandeira AC, Guerra C, Barberin MG, et al. Use 
of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. 
Braz J Infect Dis 2003, 7(4): 245-252. 
 
33. Marini G, Forno G, R K, M E. Recombinant human granulocyte-macrophage colony-
stimulating factor: effect of glycosylation on pharmacokinetic parameters. Electron J 
Biotechnol 2007, 10(2). 
 
34. Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from 
tuberculosis. Infect Immun 2002, 70(11): 6302-6309. 
 
35. Sada-Ovalle I, Sköld M, Tian T, Besra GS, Behar SM. Alpha-galactosylceramide as a 
therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am J Respir Crit 
Care Med 2010, 182(6): 841-847. 
 
36. Chen CY, Yao S, Huang D, Wei H, Sicard H, Zeng G, et al. Phosphoantigen/IL2 
expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in 
nonhuman primates. PLoS Pathog 2013, 9(8): e1003501. 
 
37. Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, Bronson RT, et al. Involvement 
of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 
1994, 264(5159): 713-716. 
 
38. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant NKT cells 
recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-
gamma, and kill intracellular bacteria. PLoS Pathog 2008, 4(12): e1000239. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Antimicrobial mechanism of GM-CSF 
 
 
 
This work is part of an unpublished and untitled manuscript with assistance from the following 
people: Girija Goyal and Glenn Dranoff (Dana-Farber Cancer Institute, Boston, MA), Sarah 
Kinicki, Karin Green, Scott Schaffer, Kadamba Papavinasasundaram, and Chris Sassetti 
(University of Massachusetts Medical School). 
	  	   112	  
ABSTRACT  
GM-CSF-/- mice are highly susceptible to Mtb infection compared to WT mice, yet the 
direct antimicrobial function of GM-CSF has not yet been eluciated. We have now identified that 
GM-CSF is produced during Mtb infection by different T cell subsets. Here we characterize the 
direct antimicrobial effect of GM-CSF on Mtb-infected macrophages. We show that GM-CSF 
antimicrobial activity requires macrophage PPARγ signaling. GM-CSF leads to an increase in 
neutral lipid content within macrophages and preliminary data reveal quantitative changes in lipid 
species. Utilizing an Mtb mutant that lacks cholesterol import machinery, we show that GM-CSF-
mediated growth inhibition requires cholesterol uptake by the bacteria. Furthermore, perturbing 
Mtb lipid metabolism using chemical inhibitors and metabolic cofactors, preliminary data shows 
that GM-CSF may induce a cellular environment of metabolic stress for the bacteria. To better 
understand how lipid accumulation alters macrophage activity, infected macrophages were 
treated with oxLDL, inducing a “foamy macrophage” state, which also led to inhibition in Mtb 
growth. Overall, these results indicate that GM-CSF plays a role in regulating lipid metabolism 
that may contribute to limiting intracellular Mtb growth. Here we have identified a pathway by 
which pro-inflammatory cytokine signaling impacts cellular metabolism, altering an intracellular 
niche for pathogens to restrict rather than promote bacterial growth.  
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INTRODUCTION 
 GM-CSF-/- mice are highly susceptible to Mtb infection1, 2. Although GM-CSF is often 
regarded as a myeloid growth factor, GM-CSF-/- mice have relatively normal steady-state 
myelopoiesis3. Instead, some of the susceptibility of GM-CSF-/- mice is derived from dysfunction 
of pulmonary alveolar macrophages due to the build-up of surfactants and subsequent 
inflammation in the lung4, 5. In the absence of GM-CSF signaling during fetal development, 
alveolar macrophages do not mature properly from fetal monocytes6. Rescuing the pulmonary 
alveolar proteinosis (PAP)-like phenotype with overexpression of GM-CSF by surfactant protein 
C-expressing epithelial cells reduces the susceptibility to Mtb aerosol infection but does not 
eliminate it1, 2. This disparity in susceptibility points to a second role for GM-CSF independent of 
alveolar macrophage homeostasis.  
In addition to animal model experiments, clinical data has shown that development of 
anti-GM-CSF neutralizing antibodies is associated with both cryptococcal meningitis and 
pulmonary tuberculosis7. Because these neutralizing antibodies develop over time, these patients 
likely experienced normal alveolar macrophage development early in life, again suggesting that 
Mtb susceptibility from the absence of GM-CSF may include a more direct pathway than just early 
lung development.  
 Several studies have examined the direct antimicrobial effect of GM-CSF during in vitro 
mycobacterial infections. Recombinant GM-CSF was found to restrict growth of Mycobacterium 
avium infection in human monocyte-derived macrophages (hMDM)8, 9 and Mtb infection in 
hMDM10. It was also shown to synergize with recombinant TNF8, 9. While reactive oxygen species 
were detected after GM-CSF treatment of Mtb-infected hMDM8, none of the studies defined a 
mechanism of control.  
 GM-CSF is associated with inducing numerous macrophage functions including: 
production of reactive nitrogen intermediates (RNI) and reactive oxygen species (ROS), 
increased FcR-dependent and independent phagocytosis, increased PGE2 production, enhanced 
priming for IFNγ/LPS-induced TNF production, and cell survival11, 12, 13. GM-CSF was also 
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recently shown to induce zinc sequestration, leading to enhanced control of intracellular 
Histoplasma capsulatum infection in macrophages14. 
 Due to the association of GM-CSF-/- mice with dysregulated surfactant recycling, another 
macrophage function that has been linked to GM-CSF is regulation of lipid metabolism5. 
Interestingly, research on Mtb has also zeroed in on bacterial lipid metabolism as one cellular 
process where Mtb may be vulnerable to host perturbations by demonstrating that Mtb has many 
strategies in place to maintain a balance between nutrient availability and toxicity15. 
Transcriptional analysis of Mtb found significant changes in fatty acid and cholesterol metabolism 
genes regulated over the course of infection in macrophages, suggesting that Mtb may sense 
changes in nutrient availability and respond at the transcriptional level16. For example, Mtb is 
sensitive to the type of carbon sources it imports and utilizes host fatty acids to alleviate 
metabolic stress caused by the accumulation of toxic cholesterol and propionyl-CoA metabolic 
products as well as upregulates cholesterol degradation enzymes in response to increased 
cholesterol exposure17, 18. 
Because Mtb can utilize both host fatty acids and cholesterol17, 19, lipid-laden “foamy” 
macrophages have been thought to be havens for bacterial growth. They are often found within 
Mtb lesions and granuloma structures and their formation in vitro can be induced by 
mycobacterial lipids and TLR stimulation20, 21. In vitro induction of foamy macrophages leads to an 
increase in expression of Mtb genes associated with dormancy and stress responses as well as 
growth arrest of M. avium species19, 22, 23. This suggests that Mtb responds to changes in lipid 
availability in its environment. Whether these changes are beneficial to the pathogen by providing 
additional nutrients or are beneficial to the host by creating a stressful metabolic environment is 
still not fully understood.  
Here we address the antimicrobial function of GM-CSF and examine a role for GM-CSF 
in regulating host lipid metabolism. We show that GM-CSF antimicrobial activity requires PPARγ 
signaling and that GM-CSF alters total neutral lipid content within the macrophage as well as the 
identity of the specific lipid species. Using a bacterial mutant that lacks cholesterol import 
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machinery, we demonstrate that the Mtb growth restriction induced by GM-CSF treatment is 
blocked when Mtb cannot take up cholesterol. Lastly, using oxLDL-induction of a foamy 
macrophage-like phenotype, we validate that increased neutral lipid content leads to inhibition of 
bacterial growth in our model.  
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RESULTS 
Recombinant GM-CSF restricts growth of Mtb 
As demonstrated in Chapter 2, stimulation of thioglycollate-elicited peritoneal 
macrophages with recombinant GM-CSF leads to restriction in Mtb growth in a dose dependent 
manner (Figure 2-18). In order to investigate the antimicrobial mechanism of GM-CSF, a 
comprehensive analysis of multiple dose-titration experiments was conducted. The % CFU 
reduction was calculated for 10 independent experiments with GM-CSF doses between 0.01-10 
ng/ml (Figure 4-1A). A striking dose-dependent effect was found with the % CFU reduction 
calculated as 25.8 ± 3.5% for 0.01 ng/ml, 43.8 ± 5.8% for 0.1 ng/ml, 63.8 ± 5.0% for 1 ng/ml and 
70.3 ± 5.3% for 10 ng/ml (mean ± SEM).  
Recombinant GM-CSF has previously been reported to inhibit the growth of 
mycobacterium in hMDM8, 9, 10. We confirmed these results by infecting primary monocyte-derived 
macrophages, from 4 independent healthy donors (Figure 4-1B). Although we observed variability 
among the different donors, GM-CSF inhibited bacterial growth to some degree in all cases, 
confirming that the antimycobacterial effect of GM-CSF pertained to both murine and human 
macrophages. 
 
GM-CSF antimicrobial activity requires PPARγ signaling in macrophages 
GM-CSF is reported to have many different effects on macrophages including inducing 
phagocytosis, nitric oxide production, reactive oxygen species, and cell survival and proliferation. 
We examined many of these functions after GM-CSF stimulation and did not find evidence for 
GM-CSF altering these outcomes, apart from an increase in cell survival. This data is compiled in 
Appendix I.  
To identify the antimicrobial mechanism of GM-CSF, we narrowed down our investigation 
by examining transcription factors that might be required for GM-CSF mediated control of Mtb 
growth within macrophages. While PPARγ is not essential for macrophage development, it plays 
an important role in lipid recycling and surfactant catabolism, especially in alveolar  
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Figure 4-1. Recombinant GM-CSF restricts growth of Mtb.  
 
(A) % CFU reduction calculated from CFU assays for H37Rv-infected WT murine mφ with 
recombinant GM-CSF (0.01-10 ng/ml). (B) CFU assay for H37Rv-infected human monocyte-
derived macrophages (hMDM) with human recombinant GM-CSF (0.1-10 ng/ml).  Error bars 
indicate mean ± SEM. *P < .05, **P < 0.01, ***P < .001  (One-way ANOVA with Dunnettʼs post-
test, compared to d5 untreated mφ). Data are compiled from 10 independent experiments (A) or 
from four independent experiments (B). 
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 macrophages24, 25, 26, 27. PPARγ has specifically been linked to GM-CSF function through the 
rescue of the pulmonary alveolar proteinosis (PAP)-like phenotype in GM-CSF-/- animals with 
lentiviral-directed overexpression of PPARγ, leading to net cholesterol efflux and reduction of lipid 
accumulation in alveolar macrophages28.   
H37Rv-infected WT and PPARγ-/- (PPARγfl/fl; LysM-cre) macrophages were treated with 
recombinant GM-CSF. While GM-CSF led to inhibition in bacterial growth in WT macrophages, no 
inhibition was observed for PPARγ-/- macrophages (Figure 4-2A). However, IFNγ/TNF treatment, 
used here as a positive control for growth restriction, led to inhibition in both macrophages types. 
When % CFU reduction was calculated for 4 independent experiments, there was a statistically 
significant difference for the CFU reduction between WT and PPARγ-/- macrophages for all GM-
CSF doses between 0.01-10 ng/ml (Figure 4-2B). Similar results were found for comparisons 
between PPARγ-/- (PPARγfl/fl; LysM-cre) and PPARγfl/fl control (PPARγfl/fl; no cre expression) 
macrophages (data not shown). This data suggests that PPARγ signaling is involved in the 
antimicrobial effector pathway stimulated by GM-CSF in Mtb-infected macrophages. 
 
GM-CSF alters gene expression of PPARγ and downstream target genes 
 Given that GM-CSF appears to require PPARγ expression in macrophages to restrict Mtb 
growth, we next determined whether GM-CSF was altering the gene expression of PPARγ as well 
as several other downstream gene targets of PPARγ. Previous research examining PPARγ 
signaling in alveolar macrophages has identified that PPARγ regulates expression of LXRα and 
LXRβ expression that in turn regulates cholesterol efflux transporters including ABCA1, ABCG1, 
and ApoE26, expression of receptors for modified LDL like CD36 and SR-β1, and negatively 
regulates pro-inflammatory NF-κB signaling29, 30. 
 Preliminary quantitative RT-PCR analysis was performed on GM-CSF treated uninfected 
and H37Rv-infected macrophages. Surprisingly, GM-CSF treatment led to a modest reduction in 
gene expression of Pparg, Lxra, Lxrb, and Apoe, with an increase in iNOS expression that is 
consistent with an overall reduction in the PPARγ signaling pathway (Figure 4-3). Although an  
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Figure 4-2. GM-CSF antimicrobial activity requires PPARγ signaling in macrophages.  
 
CFU assay on d1 and d5 post-infection (A) and % CFU reduction calculated from CFU assays (B) 
for H37Rv-infected WT and PPARγfl/fl; LysM-cre mφ with recombinant GM-CSF (0.01-10 ng/ml). 
Recombinant IFNγ (10 U/ml) and TNF (10 ng/ml) used for positive control. Error bars indicate 
mean ± SEM. **P < 0.01, ***P < .001 (One-way ANOVA with Dunnettʼs post-test, compared to d5 
untreated mφ  (A) and multiple Studentʼs t-tests (B)). Data are representative of or compiled from 
4 independent experiments. 
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Figure 4-3. GM-CSF alters gene expression of PPARγ and downstream target genes.  
 
Quantitative RT-PCR analysis of Pparg, Lxra, Lxrb, Apoe, and iNOS mRNA in WT uninfected or 
H37Rv-infected mφ treated with or without GM-CSF (10 ng/ml) for 24 hours (except for iNOS, 
measured at 48 hours). Results were calculated by the comparative Ct method relative to HPRT 
(internal control gene for hypoxanthine-guanine phosphoribosyltransferase) and relative to RNA 
levels in uninfected, untreated mφ. Error bars indicate mean ± SEM. Data are representative of 3 
independent experiments.  
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increase in iNOS gene expression was observed, no increase in nitric oxide was detected in 
response to GM-CSF stimulation (see Appendix I, Supplemental Figure 1). This trend was 
independent of Mtb infection, observed for both uninfected and infected macrophages. Despite 
several reports that PPARγ expression is induced during Mtb infection31, 32, 33, this was not 
observed in this system. We also found two genes (Abcg1, Abca1) that are downstream of 
PPARγ signaling that either had very little change in expression after GM-CSF treatment or 
inconsistent changes between experiments that did not seem to fit the overall signaling pattern 
observed for the other genes (data not shown). Overall, this data demonstrates that GM-CSF 
does not upregulate PPARγ gene expression and may in fact be downregulating PPARγ 
signaling, leading to a decrease in cholesterol efflux.  
 
GM-CSF increases neutral lipid content in a PPARγ-independent manner 
Due to the changes in cholesterol efflux receptor gene expression by GM-CSF stimulation 
and the requirement for PPARγ signaling for inhibition in Mtb growth by GM-CSF, we next 
determined whether GM-CSF changed the neutral lipid content of macrophages and whether this 
change was PPARγ-dependent. 
 To evaluate changes in total lipid content in the cell after GM-CSF treatment, 
macrophages were incubated with a commonly used neutral lipid dye: 4,4-Difluoro-1,3,5,7,8-
Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene (BODIPY 493/503). By flow cytometry, GM-CSF 
treatment of either uninfected or H37Rv-infected macrophages led to an increase in neutral lipid 
content, as measured by BODIPY fluorescence (FITC MFI) (Figure 4-4A). A similar result was 
found using a second neutral lipid dye, Oil Red O (data not shown).  Neutral lipid staining was 
also verified by widefield microscopy to ensure that BODIPY was marking small puncta within the 
macrophages, as expected (Figure 4-4B). This increase in neutral lipid content did not appear to 
be PPARγ-dependent, as this trend was observed for both the PPARγ-floxed control (PPARγfl/fl) 
and PPARγ-/- (PPARγfl/fl; LysM-cre) macrophages (Figure 4-4C). 
	  	   122	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4. GM-CSF increases neutral lipid content in a PPARγ-independent manner.  
 
Recombinant GM-CSF (10 ng/ml) was added to uninfected or H37Rv-infected WT (A, B) and 
PPARγfl/fl control and PPARγfl/fl; LysM-cre mφ (C) 1 day post-infection. After 4 days, cells were 
stained with BODIPY 493/503 for 20 minutes at 37°C and then fixed. (A, C) FITC MFI was 
determined by flow cytometry. (B) Representative images from widefield microscopy with 
BODIPY (green), DAPI nuclear (blue), and Phalloidin/F-actin (red) staining in fixed macrophages. 
Error bars indicate mean ± SEM. **P < .01 (Unpaired studentʼs t-test) (A). No difference in 
BODIPY MFI between two macrophage strains for any condition. (Multiple studentʼs t-test) (C). 
Data are representative of 2 independent experiments.  
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Both the flow cytometry and microscopy data suggest that GM-CSF induces an overall 
increase in neutral lipids in macrophages, yet this effect is not specifically regulated by the 
PPARγ signaling pathway. 
 
GM-CSF induces qualitative and quantitative changes in macrophage neutral lipid content 
 Next, we further evaluated the changes in the types of neutral lipids found within GM-CSF 
treated macrophages by utilizing liquid chromatography-mass spectrometry analysis. Neutral 
lipids extracted from cell lysates from uninfected WT, PPARγfl/fl; LysM-cre, and PPARγfl/fl control 
macrophages untreated or stimulated with GM-CSF were analyzed using positive ion electrospray 
mass spectrometry. Total amounts for each lipid family were calculated by comparing peak 
intensities of the samples to lipid standards spiked into each sample (see Materials and 
Methods). Although total neutral lipid extract weights were not measured due to low sample 
amounts, 10x106 macrophages were plated for each sample and the same percentage of each 
sample was analyzed so that the samples could be compared. In addition, we found the summed 
peak intensities (extracted ion chromatogram, XIC) for all samples were very similar (Figure 4-
5A).  
The data showed that total triacylglycerides increased and total ceramides decreased in 
response to GM-CSF (Figure 4-5B). In addition, GM-CSF induced changes in total free 
cholesterol and cholesterol esters. These preliminary results showed that changes in cholesterol 
content might be PPARγ-dependent, although further repeat experiments will need to be 
performed to verify these trends. Overall, these data suggest that GM-CSF induces both 
qualitative and quantitative changes in the neutral lipid content of macrophages. 
 
GM-CSF antimicrobial activity requires cholesterol uptake by Mtb 
 Measuring changes in total neutral lipid content (Figure 4-4) and qualitative changes in 
the lipid species (Figure 4-5) in GM-CSF-stimulated macrophages helps to reveal GM-CSF-
induced host metabolic changes. However, in addition to evaluating the effect of GM-CSF on host  
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Figure 4-5. GM-CSF induces qualitative and quantitative changes in macrophage neutral 
lipid content.  
 
Uninfected WT, PPARγfl/fl; LysM-cre (KO), and PPARγfl/fl control (CTR) mφ were untreated or 
stimulated for 4 days with 10 ng/ml GM-CSF, washed, scraped, and flash frozen. Neutral lipid 
extraction was performed on the cell extracts and samples were run through LC-MS. (A) Total 
extracted ion chromatogram of each sample. (B) Using lipid standards spiked into the samples, 
ng amounts of total triacylglycerides, ceramides, free cholesterol, and cholesterol esters were 
calculated for each sample. Data are representative of a single experiment, with technical 
triplicates. 
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pathways, we decided to survey the host-pathogen interface using Mtb mutants that lack genes 
for particular nutrient uptake or metabolism. Mtb relies upon a balance of carbon sources within a  
macrophage and alterations in this balance can affect bacterial growth17, 34. Given the data above 
that GM-CSF increases the amount of neutral lipids in the macrophage and induces changes in 
cholesterol ester and free cholesterol species, we hypothesized that GM-CSF might induce 
cholesterol toxicity in Mtb and this might explain the reduction in bacterial growth that we observe 
after GM-CSF.  
We utilized an Mtb mutant strain, Δmce4, that lacks cholesterol import machinery35 to test 
whether alterations in cholesterol metabolism play a role in the antimicrobial effect of GM-CSF. 
Interestingly, this strain has been tested both for in vitro macrophages infections and in vivo 
murine infections35, 36. The Δmce4 strain does not have a growth defect in WT macrophage 
infections or during acute infection in vivo, yet its growth is severely diminished in IFNγ-activated 
macrophages and chronic infection at late timepoints in vivo compared to WT Mtb. These results 
suggest that while Mtb does not require cholesterol utilization under all conditions, dynamics 
during host infection changes Mtbʼs requirement for cholesterol uptake. This is additional 
evidence that the host may have the ability to alter nutrient availability to Mtb over the course of 
infection.   
When macrophages infected with WT H37Rv were treated with recombinant GM-CSF, it 
led to a reduction in Mtb growth, as observed previously (Figure 4-6). However, when 
macrophages infected with Δmce4 H37Rv were treated with recombinant GM-CSF, no inhibition 
in Mtb growth was measured, despite adequate growth restriction by the positive control, 
IFNγ/TNF. This result suggests that cholesterol import is required for the antimycobacterial action 
of GM-CSF. 
 
GM-CSF inhibits the ability of Mtb to overcome 3-NP-mediated propionyl-CoA toxicity 
 The results from the Δmce4 H37Rv strain reveal that GM-CSF may be forcing the 
bacteria to import cholesterol. Mycobacterial cholesterol metabolism has been studied by several  
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Figure 4-6. GM-CSF antimicrobial activity requires cholesterol uptake by Mtb.  
 
CFU assay d1 and d5 post-infection for WT H37Rv (left) and Δmce4 H37Rv-infected (right) WT 
mφ with recombinant GM-CSF (0.1-10 ng/ml). Recombinant IFNγ (10 U/ml) and TNF (10 ng/ml) 
used for positive control. Error bars indicate mean ± SEM. **P < 0.01, ***P < .001 (One-way 
ANOVA with Dunnettʼs post-test, compared to d5 untreated mφ). Data are representative of 2 
independent experiments. 
  
 
 
 
 
 
 
 
  
Figure 4-7. GM-CSF inhibits the ability of Mtb to overcome 3-NP-mediated propionyl-CoA 
toxicity.  
 
CFU assay d1 and d5 post-infection with H37Rv-infected WT mφ treated on d1 with 3-
nitropropionate (3-NP) (0.25 mM) to inhibit Mtb growth through cholesterol toxicity, rescued with 
co-treatment with Vitamin B12 (10, 50, 100 μM). Recombinant GM-CSF (10 ng/ml) added in 
addition. Error bars indicate mean ± SEM. *P < .05, **P < 0.01, ***P < .001 (One-way ANOVA 
with Dunnettʼs post-test, compared to d5 untreated mφ). Data is representative of two 
independent experiments. 
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groups and many of the metabolic intermediates and the regulating enzymes have been worked 
out15, 37. One consequence of cholesterol metabolism that has been observed in mycobacteria is 
the resulting toxicity from propionyl-CoA pools. Multiple pathways of propionyl-CoA catabolism 
have been identified in Mtb that relieve this metabolic stress17, 34.  
 Previously, 3-nitropropionate has been used as a chemical inhibitor of the 
methylisocitrate lyase and isocitrate lyase (MCL/ICL) pathways. An enzyme encoded by the Mtb 
gene icl1 regulates these pathways. A Mtb Δicl1 mutant strain has been shown to have growth 
defects when cultured in cholesterol-containing media, even the presence of other carbon 
sources38. Similarly, Mtb growth in the presence of 3-NP is severely diminished. Growth can be 
rescued with the addition of Vitamin B12, which activates the methylmalonyl pathway (MMP) 
converting propionyl-CoA into succinyl-CoA, relieving propionyl-CoA toxicity34. Mtb cannot 
synthesize Vitamin B12 on its own, which is why exogenous Vitamin B12 supplementation 
activates this pathway.  
 As previously reported, when macrophages were infected with WT H37Rv and treated 
with 3-NP, growth of Mtb was dramatically inhibited (Figure 4-7). This growth defect was rescued 
in a dose-dependent manner with the addition of Vitamin B12. However, in the presence of 
recombinant GM-CSF, rescue by Vitamin B12 was inhibited. It is possible that cholesterol 
metabolism-independent effects of GM-CSF could explain this result. However, in combination 
with the other data collected, this result is consistent with the model that GM-CSF generates an 
excess of propionyl-CoA toxicity that the doses of Vitamin B12 used in this experiment were not 
enough to relieve the metabolic stress. Further follow-up studies are necessary to validate this 
interaction. This result suggests that GM-CSF induces mycobacterial metabolic stress through 
alterations in host metabolism. 
 
oxLDL treatment leading to a foamy macrophage phenotype inhibits Mtb growth  
 The fate of Mtb after increased lipid content within host macrophages has been 
contemplated ever since it was observed that foamy macrophages, filled with lipid droplets, 
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accumulate within granulomas during chronic infection of tuberculosis21. The increase in 
cholesterol content within the infected macrophage by GM-CSF appeared to produce a similar 
host environment. While foamy macrophages have long been associated with disease severity 
and increased bacterial burden, there is little evidence that foamy macrophages themselves are 
directly beneficial or harmful to the host response19, 39.   
To directly address whether a “foamy” macrophage phenotype alters Mtb growth within 
macrphages, we fed macrophages oxidized low-density-lipoprotein (oxLDL)40 after initial infection 
with H37Rv. Macrophages treated with oxLDL had significantly decreased bacterial burden 
compared to untreated macrophages by d5 and d7 post-infection (Figure 4-8A). This effect was 
also observed with resident peritoneal macrophages (Figure 4-8B). Measured by BODIPY 
staining, oxLDL treatment led to an increase in neutral lipid content, regardless of infection status 
of the macrophage (Figure 4-8C).  
Given that oxLDL treatment leads to an increase in cholesterol, cholesterol esters, and 
triacylglyceride species, we next tested whether oxLDL treatment would lead to an inhibition in 
bacterial growth in the absence of Mtb cholesterol import. Similar to the results with rGM-CSF, 
oxLDL treatment did not inhibit growth of Mtb when the Mtb strain (Δmce4) lacked the ability to 
take up cholesterol (Figure 4-8D).  
These results showed that an increase in neutral lipid content by a GM-CSF-independent 
mechanism also led to restriction of bacterial growth. This is additional evidence that alterations in 
host cellular metabolism can impact growth of intracellular Mtb and that this may be the 
antimicrobial mechanism of GM-CSF. Given the complexity of these metabolic pathways, further 
experiments will need to be performed to verify these findings.  
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Figure 4-8. oxLDL treatment leading to a foamy macrophage phenotype inhibits Mtb 
growth.  
 
(A) CFU assay d1, d5 and d7 post-infection with H37Rv-infected WT mφ treated on d1 with 
oxLDL (50 μg/ml). (B) CFU assay d1 and d5 post-infection with WT H37Rv-infected WT resident 
peritoneal mφ treated on d1 with oxLDL (50 μg/ml). (C) oxLDL (50 μg/ml) was added to 
uninfected or H37Rv-infected WT mφ 1 day post-infection. After 4 days, cells were stained with 
BODIPY 493/503 for 20 minutes at 37°C and then fixed. FITC MFI was determined by flow 
cytometry. (D) CFU assay d1 and d5 post-infection with WT H37Rv and Δmce4 H37Rv-infected 
WT TGL-elicited peritoneal mφ treated on d1 with oxLDL (50 μg/ml). Recombinant IFNγ (10 U/ml) 
and TNF (10 ng/ml) used for positive control. Error bars indicate mean ± SEM. *P < .05, **P < 
0.01, ***P < .001. (One-way ANOVA with Dunnettʼs post-test, compared to d5 or d7 untreated mφ 
(A, B, D) and unpaired studentʼs t-test (C)). Data is representative of two independent 
experiments (A, C) or are from single experiments (B, D). 
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DISCUSSION 
 Here we have shown that recombinant GM-CSF restricts Mtb growth in both murine 
thioglyollate-elicited peritoneal macrophages and hMDM. GM-CSF-induced growth inhibition 
requires PPARγ signaling in host macrophages. By quantitative mRNA analysis, PPARγ gene 
expression and several of its downstream target genes decrease modestly in response to GM-
CSF stimulation. GM-CSF leads to increases in neutral lipid content as measured by BODIPY 
493/503 staining and by mass spectrometry analysis. These increases are accompanied by 
qualitative changes in the lipid species. Utilizing an Mtb mutant that is unable to take up 
cholesterol as well as a chemical inhibitor of one of the enzymes required for propionyl-CoA 
break-down, we have preliminary data that GM-CSF interferes with baseline Mtb lipid metabolism, 
inducing intracellular stress and slowing Mtb growth. Lastly, using an independent pathway to 
increase lipid content in the macrophage, we demonstrate that oxLDL treatment of infected 
macrophages also leads to a decrease in Mtb growth.  
 While GM-CSF has been associated with many different macrophage functions that can 
contribute to an antimicrobial response, reports of its role in lipid metabolism so far have been 
restricted to pulmonary development. The initial observation that the antimicrobial effect of GM-
CSF required PPARγ expression in macrophages led us to consider whether regulation of lipid 
metabolism could function as an effector function against this intracellular pathogen.  
The concept of “nutritional immunity” as a mechanism of the immune system to limit 
growth of intracellular pathogens by either sequestering or overloading particular nutrients has 
gained recent attention. Lipid droplets, more specifically, have also become increasingly 
appreciated as important sites of host-pathogen interactions and immune pathways41, 42 and a 
source of cell membrane components for structures like autophagosomes43.  
 In addition, two recent articles have linked PPAR signaling to host metabolic changes that 
affect the outcome of intracellular bacterial infections. PPARδ was shown to play a detrimental 
role in Salmonella typhimurium infection where its signaling was associated with increased 
intracellular glucose availability and increased bacterial growth and persistence44. Additionally, an 
	  	   131	  
increase in PPARγ expression that caused a subsequent increases in intracellular glucose 
accounted for the increase in susceptibility of alternatively-activated macrophages to intracellular 
Brucella abortus infection45. 
 Previous research in pulmonary development found that GM-CSF stimulates PPARγ 
expression. Therefore, it was surprising to find that in our system GM-CSF led a modest decrease 
in PPARγ gene expression. However, both thioglyollate-elicted peritoneal macrophages and 
mature alveolar macrophages are both known for their high PPARγ expression at baseline, and 
so perhaps GM-CSF has alternative effects under these conditions.  
The concept of decreased PPARγ expression as a host-derived mechanism for 
mycobacterial control specifically has support from several previous studies that have 
demonstrated that Mtb induces PPARγ signaling during infection and inhibiting PPARγ 
expression (through RNAi or antagonists) leads to a decrease in bacterial growth. One study 
found that BCG induced PPARγ gene expression in both murine and hMDM in a TLR2-dependent 
manner32. The increase in PPARγ expression was associated with an increase in lipid bodies and 
PGE2 production and these phenotypes were reproduced with PPARγ agonists. In a second 
study, the Mtb lipid mannose-capped lipoarabinomannan (ManLam) was shown to induce PPARγ 
expression through mannose receptor binding in hMDM leading to p38-MAPK signaling and IL-8 
production33. siRNA PPARγ knockdown led to a decrease in H37Rv growth within the first 24 
hours of macrophage infection. The third study validated that Mtb lipids upregulated PPARγ 
expression and blocking expression through RNAi led to a decrease in H37Rv CFU and an 
increase in iNOS and pro-inflammatory cytokine expression31. 
Despite the evidence for the PPARγ signaling pathway promoting Mtb virulence, there is 
also evidence that LXRα and LXRβ, two downstream targets of PPARγ, are critical for host 
immunity. LXRα-/- and LXRα-/-LXRβ -/- mice have been shown to be highly susceptible to Mtb 
infection and both prophylactic and therapeutic LXR agonist treatment lead to improved disease 
outcome46. The absence of LXR signaling was associated with increased foamy macrophage 
formation and increased neutrophilic inflammation. The discrepancy between these published 
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results points to how complicated and multifaced these host pathways are. Therefore, 
interpretation of these various results must be made cautiously.   
It is still unclear exactly how host cholesterol status affects immunity. While a cholesterol-
rich diet was shown to decrease the time to negative culture in pulmonary tuberculosis47, it has 
also been shown that ApoE-/- mice on a high-fat diet with severe hypercholesterolemia have 
higher susceptibility to Mtb infection due to a delayed adaptive response and a decreased pro-
inflammatory response48. 
These studies clearly show that changes in host lipid metabolism may have a wide range 
of influences during infection, at the level of the macrophage, the priming of the adaptive immune 
response, as well as more systemic inflammation and cellular recruitment. Much more research 
will need to be done to tease these different effects apart.  It is also likely that for host lipid 
metabolism to be effective at altering the growth of pathogens, the host must hit upon a perfect 
equilibrium, where modest amounts of cholesterol contribute to bacterial control but too much 
leads to an inflammatory environment and immunopathology. Perhaps an endogenous signal like 
GM-CSF could achieve these types of modest and effective metabolic changes.  
For chronic infections, it is an appealing model that the immune system could alter the 
pathogenʼs environmental niche to slow its growth and allow other microbicidal mechanisms time 
to act. Specifically for tuberculosis, these types of host-directed therapy targets could be 
incredibly useful, especially in the context of drug resistance.  
Ultimately, understanding the metabolic vulnerability of Mtb in the context of a host 
macrophage could reveal novel therapeutic targets that would not be seen in the absence of the 
host response. An example of how this strategy could be effective was recently performed by 
testing for growth of mycobacterial mutants in the presence and absence of a CD4+ T cell immune 
response through a transposon library screen (TraSH) (see Appendix II). This screen identified an 
Mtb tryptophan production pathway that was only required in the presence of CD4+ T cells and 
was shown to synergize with IFNγ-mediated IDO production that depleted host tryptophan 
availability49. This study is one example of how the immune response alters the environmental 
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niche for Mtb, resulting in new nutritional vulnerabilities for the pathogen that can be taken 
advantage of therapeutically.  
Overall, this study demonstrated that the antimicrobial mechanism of GM-CSF requires 
host PPARγ-signaling and GM-CSF likely generates metabolic stress for the intracellular bacteria 
by altering host cellular metabolism. These results help to both characterize the antimicrobial 
function of GM-CSF as well as elucidate new mycobacterial pathways to target during Mtb 
infection.  
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MATERIALS AND METHODS 
 
Ethics Statement 
All mice were bred and maintained using standard humane animal husbandry protocols. All 
animal experiments were performed in accordance with relevant guidelines for the care and 
handling of laboratory animals and were approved by the Dana Farber Cancer Institute Animal 
Care and Use Committee (Animal Welfare Assurance number A3023-01) or by the Department of 
Animal Medicine of the University of Massachusetts Animal Care and Use Committee (Animal 
Welfare Assurance number A2420-13) under Public Health Service assurance of the Office of 
Laboratory Animal Welfare guidelines.  
 
Mice  
C57BL/6J (WT) mice were obtained from Jackson Laboratories. C57BL/6J PPARγfl/fl;LysMcre+/+ 
(PPARγ-/-) and PPARγfl/fl; LysMcre-/- (PPARγfl/fl control) were provided by Dr. Glenn Dranoff.  
 
Macrophage isolation and culture 
Thioglycollate (TGL)-elicited peritoneal macrophages were lavaged 4–5 days after 3% 
intraperitoneal TGL injection and then isolated by positive selection with CD11b microbeads and 
LS magnetic columns (Miltenyi Biotec). Purified cells were over 95% F4/80+ CD11b+, as 
determined by flow cytometry. Bone marrow-derived macrophages (BMDM) were differentiated 
from bone marrow after 7 days in RPMI supplemented with 20% L929 cell supernatant. Primary 
human peripheral blood (Research Blood Components, Boston, MA) monocyte-derived 
macrophages (MDM) were generated from adherent bead-selected CD14+ cells after 7 days in 
culture with human serum (Gemini Bioproducts). Macrophages were seeded at 1x105 in 96-well 
culture plates in complete RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 
10% fetal calf serum (HyClone).  
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Mtb in vitro culture and infection  
H37Rv was grown and prepared as previously described50. Bacteria was counted and added to 
macrophages at an effective multiplicity of infection (MOI) of 0.2 for CFU experiments for two 
hours. Cultures were washed three times to remove extracellular bacteria. Infected macrophages 
were cultured overnight and iNKT cells or other conditions were added on d1. For CFU 
measurement, cells were lysed with 1% Triton X-100/PBS and lysate from quadruplicate 
conditions were plated in serial dilutions on Middlebrook 7H10 agar plates (ThermoFisher 
Scientific), and cultured at 37oC for 21 days. Infected macrophages were treated with the 
following reagents: recombinant GM-CSF (murine, Peprotech; human, Biolegend), recombinant 
IFNγ (murine, Peprotech), 3-nitropropionate (Sigma-Aldrich), vitamin B12 (Sigma-Aldrich), and 
oxLDL (Biomedical Technologies). The Δmce4 H37Rv mutant strain was provided by Dr. Chris 
Sassetti35. 
 
Quantitative RT-PCR 
RNA was isolated from macrophages with Trizol and Purelink RNA Mini Kit (Invitrogen) according 
to the manufacturerʼs instructions. cDNA was prepared using the SuperScript RNA amplification 
system (Invitrogen) according to the manufacturerʼs instructions. Quantitative PCR assays were 
performed using Power SYBR Green and Fast SYBR Green (Invitrogen) systems on a ViiA 7 
QPCR machine (Applied Bioscience). Hypoxanthine guanine phosphoribosyl transferase (HPRT) 
was used as reference gene. Specific oligonucleotides were used for Hprt (sense, 5ʼ-GCT GGT 
GAA AAG GAC CTC T-3ʼ, antisense, 5ʼ-CAC AGG ACT AGA ACA CCT GC-3ʼ). Primers for 
Pparg, Lxra, Lxrb, Apoe, and iNOS were used as published by Korf et al46. For the Fast SYBR 
Green assays (60°C melting temperature only), the cDNA was denatured for 1 min at 95°C, 
followed by 40 cycles of 95 ̊C for 3 sec, annealing and extending at 60°C for 30 sec. For the 
Power SYBR Green assays (all other melting temperatures), the cDNA was denatured for 10 min 
at 95°C, followed by 40 cycles of 95 C̊ for 15 sec, incubation at the optimized melting temperature 
for 30 sec, and 72°C for 30 sec. Optimized melting temperatures were 60°C for Hprt, Lxrb, 55°C 
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for Pparg, iNOS, and 53°C for Apoe, Lxra. The expression level of each gene was determined 
using the ΔΔCt method. Data are represented as the ratio of the expression level of the gene for 
each stimulation condition over the mean expression level of the gene in uninfected untreated 
macrophages. 
 
BODIPY Neutral Lipid Staining 
Adherent macrophages were washed once with incomplete RPMI and then incubated for 20 
minutes with 10 μM BODIPY in complete RPMI at 37°C. Macrophages were then washed once in 
FACS buffer (1% FBS and 0.01% sodium azide in PBS) and then fixed with PFA (1% for flow 
cytometry and 3.7% for microscopy) for 45 minutes. For flow cytometry, macrophages were then 
washed in FACS buffer and scraped off the plate and analyzed with the MacsQuant flow 
cytometer (Miltenyi). For microscopy, macrophages were stained with Alexa Fluor® 568 
Phalloidin (Invitrogen) staining F-actin, before affixing to microscopy slides with Prolong Gold plus 
DAPI (Invitrogen). Images were taken with a Leica DM IRE2 Fluorescence and Phase Contrast 
Microscope at 63X. 
 
Liquid Chromatography-Mass Spectrometry 
Macrophages were seeded at 1x106 per well in 24-well plates and untreated or stimulated for 4 
days with GM-CSF (10 ng/ml). They were then washed with PBS, scraped, and pelleted. After the 
remaining liquid was removed, the pellets were flash frozen in dry ice and stored at -80°C. The 
Folch extraction method51 in combination with NH2 Bond Elute SPE 50mg cartridge (Agilent) was 
used to extract neutral lipids from the cell pellets. Neutral lipid standards were obtained from 
Avanti Lipids (Alabaster, Alabama), 1-heptadecanoyl-rac-glycerol (17:0 MG), 1,2-dilauroyl-sn-
glycerol (12:0/12:0 DG), 1,3(d5)-ditetradecanoyl-2-(9Z-hexadecenoyl)-glycerol (14:0/16:1/14:0 
TG-D5), cholest-5-en-3ß-yl pentadecanoate (15:0 cholesterol ester), 1-oleoyl-N-heptadecanoyl-D-
erythro-sphingosine (17:0/d18:1 ceremide). Cholesterol-D7 was obtained from Cambridge Isotope 
Labs. The neutral lipid standards were dissolved in methanol at a concentration of 1mg/mL to 
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keep as stock solution. They were then mixed to 0.2 ng/μl of TG/MG/cholesteryl Ester, 0.1ng/μl of 
DG, 2ng/μl of ceremide, and 20ng/μl of cholesterol.  
 
The neutral lipid fraction was resuspended in 100μl of mobile phase A and mixed with 100μl of 
the neutral lipid standard mix. 20μl of each sample was injected on to a Kinetex 2.6u C18 100A 
150 x 2.1 mm column (Phenomenex) using an Accela (Thermo Fisher Scientific) auto sampler 
and Accela 1250 LC-pump and analyzed in triplicate. Elution of the C18 column was carried out 
with (A) 95% Methanol, 5% 100 mM Ammonium Formate, pH 4.75 and (B) 95% Isopropanol, 5% 
100 mM ammonium formate, pH 4.75. The flow rate was at 150 μl/min and the gradient was as 
follows: 0 min 50% B, 5 min 50% B, 20 min 100% B, 30 min 100% B, 30.1 min 100% B with a 15 
min re-equilibration time at the end of the run. Full scan MS spectra were obtained using positive 
ion electrospray MS using a LTQ Orbitrap Velos (Thermo Scientific) at 60000 resolution with data 
dependent MS2 scans of the top 5 most intense ions in the MS spectra. 
 
% CFU reduction 
To compare inhibition of bacterial growth across multiple experiments, % CFU reduction was 
calculated. 100% CFU reduction on d5 indicates complete inhibition of bacterial growth to d1 
levels while 0% CFU reduction indicates no change in bacterial growth from untreated 
macrophages. % CFU reduction = 100 x [CFU(untreated mf-d5) - CFU(treated mf-d5)] / [(CFU(untreated mf-d5) - 
CFU(untreated mf-d1)] 
 
Statistical analysis 
All data are represented as mean ± SEM. Data was analyzed by One-Way ANOVA (95% 
confidence interval) with Dunnettʼs post-test (for comparison against a single control) or unpaired 
(multiple) Studentʼs t-test. Analysis was performed using GraphPad Prism software.  
 
  
	  	   138	  
REFERENCES 
 
1. Gonzalez-Juarrero M, Hattle JM, Izzo A, Junqueira-Kipnis AP, Shim TS, Trapnell BC, et 
al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs 
severely affects the ability of mice to control Mycobacterium tuberculosis infection. J 
Leukoc Biol 2005, 77(6): 914-922. 
 
2. Szeliga J, Daniel DS, Yang C-H, Sever-Chroneos Z, Jagannath C, Chroneos ZC. 
Granulocyte-macrophage colony stimulating factor-mediated innate responses in 
tuberculosis. Tuberculosis (Edinb) 2008, 88(1): 7-20. 
 
3. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. 
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major 
perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc 
Natl Acad Sci U S A 1994, 91(12): 5592-5596. 
 
4. Golde DW, Territo M, Finley TN, Cline MJ. Defective lung macrophages in pulmonary 
alveolar proteinosis. Ann Intern Med 1976, 85(3): 304-309. 
 
5. Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA. Pulmonary epithelial cell 
expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin 
Invest 1996, 97(3): 649-655. 
 
6. Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, et al. Alveolar 
macrophages develop from fetal monocytes that differentiate into long-lived cells in the 
first week of life via GM-CSF. J Exp Med 2013, 210(10): 1977-1992. 
 
7. Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, et al. 
Anti-GM-CSF Autoantibodies in Patients with Cryptococcal Meningitis. J Immunol 2013, 
190(8): 3959-3966. 
 
8. Bermudez LE, Young LS. Recombinant granulocyte-macrophage colony-stimulating 
factor activates human macrophages to inhibit growth or kill Mycobacterium avium 
complex. J Leukoc Biol 1990, 48(1): 67-73. 
 
9. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor 
stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to 
kill avirulent M. avium: killing effector mechanism depends on the generation of reactive 
nitrogen intermediates. J Leukoc Biol 1991, 49(4): 380-387. 
 
10. Denis M, Ghadirian E. Granulocyte-macrophage colony-stimulating factor restricts growth 
of tubercle bacilli in human macrophages. Immunology Letters 1990, 24(3): 203-206. 
 
11. Coleman DL, Chodakewitz JA, Bartiss AH, Mellors JW. Granulocyte-macrophage colony-
stimulating factor enhances selective effector functions of tissue-derived macrophages. 
Blood 1988, 72(2): 573-578. 
 
12. Heidenreich S, Gong JH, Schmidt A, Nain M, Gemsa D. Macrophage activation by 
granulocyte/macrophage colony-stimulating factor. Priming for enhanced release of tumor 
necrosis factor-alpha and prostaglandin E2. J Immunol 1989, 143(4): 1198-1205. 
 
	  	   139	  
13. Steinwede K, Tempelhof O, Bolte K, Maus R, Bohling J, Ueberberg B, et al. Local 
delivery of GM-CSF protects mice from lethal pneumococcal pneumonia. J Immunol 
2011, 187(10): 5346-5356. 
 
14. Subramanian Vignesh K, Landero Figueroa Julio A, Porollo A, Caruso Joseph A, Jr 
George SD. Granulocyte Macrophage-Colony Stimulating Factor Induced Zn 
Sequestration Enhances Macrophage Superoxide and Limits Intracellular Pathogen 
Survival. Immunity 2014, 39(4): 697-710. 
 
15. Russell DG, VanderVen BC, Lee W, Abramovitch RB, Kim MJ, Homolka S, et al. 
Mycobacterium tuberculosis wears what it eats. Cell Host Microbe 2010, 8(1): 68-76. 
 
16. Rohde KH, Veiga DF, Caldwell S, Balazsi G, Russell DG. Linking the transcriptional 
profiles and the physiological states of Mycobacterium tuberculosis during an extended 
intracellular infection. PLoS Pathog 2012, 8(6): e1002769. 
 
17. Lee W, Vanderven BC, Fahey RJ, Russell DG. Intracellular Mycobacterium tuberculosis 
Exploits Host-derived Fatty Acids to Limit Metabolic Stress. J Biol Chem 2013, 288(10): 
6788-6800. 
 
18. Wipperman MF, Yang M, Thomas ST, Sampson NS. Shrinking the FadE Proteome of 
Mycobacterium tuberculosis: Insights into Cholesterol Metabolism through Identification 
of an  2 2 Heterotetrameric Acyl Coenzyme A Dehydrogenase Family. J Bacteriology 
2013, 195(19): 4331-4341. 
 
19. Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. Mycobacterium tuberculosis 
uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like 
phenotype in lipid-loaded macrophages. PLoS Pathog 2011, 7(6): e1002093. 
 
20. O'garra A, Redford PS, Mcnab FW, Bloom CI, Wilkinson RJ, Berry MPR. The Immune 
Response in Tuberculosis. Annu Rev Immunol 2013, 31(1): 475-527. 
 
21. Russell DG, Cardona P-J, Kim M-J, Allain S, Altare F. Foamy macrophages and the 
progression of the human tuberculosis granuloma. Nat Immunol 2009, 10(9): 943-948. 
 
22. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, et al. Foamy 
Macrophages from Tuberculous Patients' Granulomas Constitute a Nutrient-Rich 
Reservoir for M. tuberculosis Persistence. PLoS Pathog 2008, 4(11): e1000204. 
 
23. Caire-Brandli I, Papadopoulos A, Malaga W, Marais D, Canaan S, Thilo L, et al. 
Reversible lipid accumulation and associated division arrest of Mycobacterium avium in 
lipoprotein (VLDL)-induced foamy macrophages may resemble key events during latency 
and reactivation of tuberculosis. Infect Immun 2013: 1-55. 
 
24. Baker AD, Malur A, Barna BP, Ghosh S, Kavuru MS, Malur AG, et al. Targeted PPAR  
deficiency in alveolar macrophages disrupts surfactant catabolism. J Lipid Res 2010, 
51(6): 1325-1331. 
 
25. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent 
and independent effects on macrophage-gene expression in lipid metabolism and 
inflammation. Nat Med 2001, 7(1): 48-52. 
 
	  	   140	  
26. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-
LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. 
Mol Cell 2001, 7(1): 161-171. 
 
27. Nagy L, Szanto A, Szatmari I, Széles L. Nuclear hormone receptors enable macrophages 
and dendritic cells to sense their lipid environment and shape their immune response. 
Physiol Rev 2012, 92(2): 739-789. 
 
28. Malur A, Baker AD, Mccoy AJ, Wells G, Barna BP, Kavuru MS, et al. Restoration of 
PPAR  reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice. 
AJP: Lung Cellular and Molecular Physiology 2011, 300(1): L73-L80. 
 
29. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma and PPARdelta 
negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes 
in macrophages. Proc Natl Acad Sci USA 2003, 100(11): 6712-6717. 
 
30. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, et al. Molecular 
determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 
122(5): 707-721. 
 
31. Mahajan S, Dkhar HK, Chandra V, Dave S, Nanduri R, Janmeja AK, et al. Mycobacterium 
tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARγ and TR4 for 
survival. J Immunol 2012, 188(11): 5593-5603. 
 
32. Almeida PE, Silva AR, Maya-Monteiro CM, Torocsik D, D'avila H, Dezso B, et al. 
Mycobacterium bovis Bacillus Calmette-Guerin Infection Induces TLR2-Dependent 
Peroxisome Proliferator-Activated Receptor   Expression and Activation: Functions in 
Inflammation, Lipid Metabolism, and Pathogenesis. J Immunol 2009, 183(2): 1337-1345. 
 
33. Rajaram MVS, Brooks MN, Morris JD, Torrelles JB, Azad AK, Schlesinger LS. 
Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-
activated receptor gamma linking mannose receptor recognition to regulation of immune 
responses. J Immunol 2010, 185(2): 929-942. 
 
34. Griffin Jennifer E, Pandey Amit K, Gilmore Sarah A, Mizrahi V, Mckinney John D, 
Bertozzi Carolyn R, et al. Cholesterol Catabolism by Mycobacterium tuberculosis 
Requires Transcriptional and Metabolic Adaptations. Chemistry & Biology 2012, 19(2): 
218-227. 
 
35. Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host 
cholesterol. Proc Natl Acad Sci U S A 2008, 105(11): 4376-4380. 
 
36. Sassetti CM, Rubin EJ. Genetic requirements for mycobacterial survival during infection. 
Proc Natl Acad Sci U S A 2003, 100(22): 12989-12994. 
 
37. Miner MD, Chang JC, Pandey AK, Sassetti CM, Sherman DR. Role of cholesterol in 
Mycobacterium tuberculosis infection. Indian J Exp Biol 2009, 47(6): 407-411. 
 
38. Gould TA, van de Langemheen H, Munoz-Elias EJ, McKinney JD, Sacchettini JC. Dual 
role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium 
tuberculosis. Mol Microbiol 2006, 61(4): 940-947. 
 
	  	   141	  
39. Singh V, Jamwal S, Jain R, Verma P, Gokhale R, Rao Kanury VS. Mycobacterium 
tuberculosis-Driven Targeted Recalibration of Macrophage Lipid Homeostasis Promotes 
the Foamy Phenotype. Cell Host and Microbe 2012, 12(5): 669-681. 
 
40. Xu S, Huang Y, Xie Y, Lan T, Le K, Chen J, et al. Evaluation of foam cell formation in 
cultured macrophages: an improved method with Oil Red O staining and DiI-oxLDL 
uptake. Cytotechnology 2010, 62(5): 473-481. 
 
41. Saka HA, Valdivia R. Emerging Roles for Lipid Droplets in Immunity and Host-Pathogen 
Interactions. Annu Rev Cell Dev Biol 2012, 28(1): 411-437. 
 
42. Melo RCN, Dvorak AM. Lipid Body–Phagosome Interaction in Macrophages during 
Infectious Diseases: Host Defense or Pathogen Survival Strategy? PLoS Pathog 2012, 
8(7): e1002729. 
 
43. Singh R, Cuervo AM. Lipophagy: Connecting Autophagy and Lipid Metabolism. Int J Cell 
Biol 2012, 2012(5): 1-12. 
 
44. Eisele Nicholas A, Ruby T, Jacobson A, Manzanillo Paolo S, Cox Jeffery S, Lam L, et al. 
Salmonella Require the Fatty Acid Regulator PPARdelta for the Establishment of a 
Metabolic Environment Essential for Long-Term Persistence. Cell Host and Microbe 
2013, 14(2): 171-182. 
 
45. Xavier Mariana N, Winter Maria G, Spees Alanna M, Den Hartigh Andreas B, Nguyen K, 
Roux Christelle M, et al. PPARgamma Mediated Increase in Glucose Availability Sustains 
Chronic Brucella abortus Infection in Alternatively Activated Macrophages. Cell Host and 
Microbe 2013, 14(2): 159-170. 
 
46. Korf H, Vander Beken S, Romano M, Steffensen KR, Stijlemans B, Gustafsson J-Υ, et al. 
Liver X receptors contribute to the protective immune response against Mycobacterium 
tuberculosis in mice. J Clin Invest 2009, 119(6): 1626-1637. 
 
47. Perez-Guzman C, Vargas MH, Quinonez F, Bazavilvazo N, Aguilar A. A cholesterol-rich 
diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest 2005, 127(2): 
643-651. 
 
48. Martens GW, Arikan MC, Lee J, Ren F, Vallerskog T, Kornfeld H. Hypercholesterolemia 
impairs immunity to tuberculosis. Infect Immun 2008, 76(8): 3464-3472. 
 
49. Zhang Yanjia J, Reddy Manchi C, Ioerger Thomas R, Rothchild Alissa C, Dartois V, 
Schuster Brian M, et al. Tryptophan Biosynthesis Protects Mycobacteria from CD4 T-Cell-
Mediated Killing. Cell 2013, 155(6): 1296-1308. 
 
50. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant NKT cells 
recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-
gamma, and kill intracellular bacteria. PLoS Pathog 2008, 4(12): e1000239. 
 
51. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of 
total lipides from animal tissues. J Biol Chem 1957, 226(1): 497-509. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Discussion 
 
 
	   143	  
Despite improved access to effective antibiotics and increased investment in medical 
infrastructure, the TB epidemic continues to be a global health crisis. The emergence of multi-
drug resistant and extensively-drug resistant strains necessitates the continual search for novel 
therapeutic targets and pathways.  
The last two decades of research have identified many immune pathways involved in 
protection against Mtb infection. Although basic research has characterized a variety of 
mechanisms, vaccine work has primarily focused on increasing the number and frequency of 
antigen-specific CD4+ T cells and their production of IFNγ. The absence of these factors 
dramatically increases the susceptibility of mice as well as people to Mtb infection1, 2, 3, 4. 
However, an increase in these measurements has not been associated with immune protection. 
In fact, it is often correlated with progression to active disease and bacterial burden5, 6, 7, 8. In light 
of the recent failure of the MVA85A vaccine Phase IIb clinical trial, where MVA85A did not show 
increased protection over standard BCG treatment despite generating enhanced CD4+ T cell 
IFNγ and TNF responses, it is critical to reassess this model9, 10. 
The work in this thesis focused on characterizing new antimicrobial roles for previously 
known immune components: iNKT cells and GM-CSF. These studies tried to ignore assumptions 
about known pathways (i.e. IFNγ production by iNKT cells) and test the requirement for these 
different effector functions in an in vitro macrophage infection model. This research revealed a 
novel iNKT cell effector function and new roles for GM-CSF in restriction of bacterial growth 
during Mtb infection. In addition, the study of these pathways produced mechanistic insight into 
the host-pathogen interface during Mtb infection.  
 
SUMMARY OF FINDINGS 
 The research in this thesis focused on antimicrobial effector functions during Mtb 
infection. Chapter 2 focused on iNKT cell activation and effector function during Mtb infection. 
The impetus for this work came from two previous observations about iNKT cells and Mtb. The 
first observation was an in vivo study that treatment of both C3H/HeJ and BALB/c mice with 
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αGalCer led to increased survival and decreased bacterial burden after aerosol infection in a 
CD1d-dependent manner11. The second was an in vitro study that addition of naïve iNKT cells to 
H37Rv-infected macrophages led to a restriction in bacterial growth12.  
The aim of this study was to understand how iNKT cells were protective during infection 
and which activation pathways were required. Here, we showed that iNKT cells became activated 
following co-culture with Mtb-infected macrophages. IL-12 and IL-18 cytokine signaling induced 
expression of activation markers and IFNγ production by iNKT cells. However, these signals did 
not contribute to iNKT cell antimicrobial activity. In contrast, CD1d-driven activation was critical for 
the ability of iNKT cells to inhibit Mtb growth but had little effect on other markers of activation. 
Using IFNγ-/- iNKT cells and IFNγR-/- macrophages, we were able to show that iNKT cells control 
Mtb independently of IFNγ. We next looked for an IFNγ-independent effector function that was 
stimulated after CD1d signaling.  We identified GM-CSF as a cytokine produced by iNKT cells in 
response to Mtb-infected macrophages in a CD1d-dependent manner. Blocking GM-CSF 
inhibited the antimicrobial effect of iNKT cells and recombinant GM-CSF was sufficient to restrict 
Mtb growth. We could detect GM-CSF-producing iNKT cells in the lungs of Mtb-infected mice 
early during infection and this production also appeared to be CD1d-dependent.  
In Chapter 3, we examined a role for T cell-derived GM-CSF during Mtb infection. By 
Bioplex immunoassay, we could detect an increase in GM-CSF protein in the lung over the 
course of infection. By ICS analysis, GM-CSF production was detected for 4 different T cell 
subsets: iNKT cells, γδ T cells, CD4+ and CD8+ T cells. Each T cell subset displayed different 
kinetics of GM-CSF production over the course of 8-12 weeks of infection. The dynamics of GM-
CSF production differed from the patterns of expression of IFNγ production, suggesting that the 
regulation of these two cytokines were independent. Next, using an adoptive transfer model, we 
tested the contribution of T cell-derived GM-CSF to control of Mtb. Preliminary evidence showed 
that Rag-/- mice that received GM-CSF-/- T cells had approximately a half log increase in bacterial 
burden by week 4 compared to Rag-/- mice that received WT T cells. This data suggested that 
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even in the presence of other cytokine and effector functions, GM-CSF has a non-redundant role 
in reducing bacterial growth during Mtb aerosol infection. 
Chapter 4 followed up on these results by investigating the direct antimicrobial 
mechanism of GM-CSF on infected macrophages. We found that the effect of GM-CSF required 
host macrophage PPARγ-signaling and led to a modest decrease in PPARγ gene expression. 
GM-CSF increased the total neutral lipid content of macrophages, as measured by BODIPY 
493/503 staining and this was independent of PPARγ-signaling.  Next, we examined the identity 
of the neutral lipid species within the treated macrophages and found significant changes in 
response to GM-CSF stimulation including increases in TAG, decreases in ceramides, and 
changes in cholesterol esters and free cholesterol species that may potentially be regulated by 
PPARγ. To assess how these host metabolic changes may alter the host-pathogen interface, we 
utilized an Mtb mutant strain, Δmce4 that lacks cholesterol import machinery. GM-CSF was 
unable to inhibit growth of the Δmce4 strain, suggesting that cholesterol uptake is required for the 
effect of GM-CSF. In addition, we used a chemical inhibitor that blocks one of the enzymes 
involved in cholesterol breakdown to provide additional evidence that GM-CSF may be inducing 
host metabolic changes that triggers bacterial metabolic stress, which in turn impedes bacterial 
growth. To address whether an increase in host lipids by another means would also impede Mtb 
growth, we treated macrophages with oxLDL and again measured inhibition of growth. These 
data support a model in which GM-CSF increases macrophage lipid content in a PPARγ-
dependent manner to disrupt the metabolic equilibrium of the host phagosomes and inhibit Mtb 
growth.  
 
IMPLICATIONS 
iNKT cell effector functions 
 iNKT cells have a unique role in the immune system as T cells that have acquired early 
innate function and the ability to rapidly respond following primary stimulation. With expression of 
a semi-invariant TCR, iNKT cells are found at a fairly high frequency in most organs, when 
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considered as a clonal population rather than an entire T cell subset. As described in detail in 
Chapter 1 in Tables 1-2, 1-3, and 1-4, a role for iNKT cells has been found in numerous bacterial, 
viral, and fungal infections.  However, the effector functions they utilize to achieve this are 
untested in many cases. iNKT cells have been coined the “Swiss army knife” of the immune 
system13 because of the multitude of effector functions they are capable of performing (see Figure 
1-3), so it is surprising that so few of these functions have been tested in the context of infection. 
The finding that iNKT cell production of GM-CSF controls Mtb infection is likely just one example 
among many of iNKT cell effector functions that are independent of IFNγ. The key to identifying 
these functions is the ability to isolate the conditions under which iNKT cells are tested. The 
difficulty with using whole mouse studies to address mechanism is that in vivo iNKT cells 
probably have multiple functions and transactivate many cell types, which could be hard to 
dissociate at the whole organism level. While in vitro studies suffer from synthetic conditions, they 
can offer the perfect opportunity to isolate specific iNKT cell functions and test them under 
rigorous conditions. 
In addition, our studies highlighted the strong influence of initial activation signals on 
subsequent effector functions. While both cytokine and CD1d-signaling activated iNKT cells in the 
context of Mtb infection, they induced very distinct effector programs. This finding predicts that 
different stimuli from different pathogens will induce distinct iNKT cells effector functions and that 
these effector functions may even change over the course of the infection as the dynamics of 
various activation signals change. These ideas hint at a wealth of new mechanisms to discover 
and high-throughput technologies like the Immgen microarray platform may further expand the 
opportunities to study them14. 
 
iNKT cells and Mtb Infection 
 Ever since mice lacking iNKT cells were shown to be equally resistant to Mtb infection as 
WT mice15, 16, 17, motivation to study a role for iNKT cells during Mtb infection has been restrained. 
Interestingly, the more persuasive evidence to study iNKT cells during Mtb infection comes from 
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human studies. Four independent studies found that iNKT cell frequency and number are 
decreased in the peripheral blood of patients with active TB compared to either household 
contacts, patients on treatment, or healthy controls18, 19, 20, 21. In addition, two studies found a 
change in iNKT cell subset frequency in TB patients, with a decrease in CD4-CD8- (DN) iNKT 
cells and an increase in CD4+ iNKT cell subset in the periphery20, 22. Clearly, Mtb infection alters 
iNKT cell trafficking, but how should these observations be interpreted in the context of iNKT cell 
biology? Is this evidence that iNKT cells are recruited to the lung, the site of infection, during 
disease? Does this suggest that iNKT cells are activated and then deleted? Or, does this indicate 
that iNKT cells are simply “diluted out” by the proliferation of other immune cell subsets 
responding to infection? Only more thorough clinical studies can address these types of 
questions. 
It is possible that the murine model of Mtb is not representative of human disease when it 
comes to nonconventional T cell activity. Interestingly, other non-conventional T cells including 
group I CD1-restricted T cells, MAIT cells, and γδ T cells have all been shown to respond to 
human Mtb-infected macrophages and are found in people during infection, but none of them 
have been shown to be required in mice (note: mice do not possess group I CD1-restricted T 
cells)1, 23, 24, 25, 26, 27. In addition, stimulation of γδ T cells was recently shown to enhance 
resistance of non-human primates during Mtb infection28. Due to the dynamics of chronic infection 
in mice, where antigen burden remains very high over the course of infection, it is possible that 
the murine model is not the right one to assess function of these cell types during infection.  
Despite lack of evidence that iNKT cells are required for infection in the mouse model, 
studies from our group have found that activation of iNKT cells with αGalCer leads to increased 
survival of susceptible mouse strains11 and works in conjunction with antibiotics to improve 
disease outcome29. In addition, iNKT cells are able to inhibit Mtb growth when added during in 
vitro co-cultures and the work in this thesis has now identified that iNKT cells produce GM-CSF in 
response to infection and this is protective12.  
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 How can these data be reconciled? It is clear that iNKT cells, once activated, are 
protective during infection. Then why are they not required for bacterial control in the murine 
model? There are at least two possible explanations. First, their function is redundant with other 
cell types. Work in Chapter 3 revealed that iNKT cells are not the only T cell or innate subset to 
produce GM-CSF in the lung during Mtb infection. If GM-CSF is the dominant iNKT cell effector 
function, it is easy to imagine how GM-CSF coming from other sources would make iNKT cells 
redundant.  
Second, the chronic nature of Mtb may make it a poor fit for iNKT cell-mediated control. 
Many of the infections for which iNKT cells are required for pathogen control (Tables 1-2, 1-3, and 
1-4) are acute infections that are resolved within several days to a week. Because protection 
against Mtb infection requires weeks of function, iNKT cells may participate very early on during 
infection, but become less functional over long periods of activation. A previous study with BCG 
infection found that iNKT cells become anergic over time30. After 7 days of infection, iNKT cells 
started to die, stopped producing cytokines, and became unresponsive to further stimulation, just 
as conventional T cells were starting to proliferate and respond. This timing suggests that iNKT 
cells might serve as a bridge between the innate and adaptive immune system instead of being 
central mediators of control. Further investigation into these immune dynamics should be 
performed. 
 
Antimicrobial role for T cell-derived GM-CSF 
 GM-CSF has long been considered to be a myeloid and granulocyte growth factor. It is 
used at the clinical bedside to rescue chemotherapy-induced neutropenia and at the bench to 
generate bone marrow-derived dendritic cells31, 32. GM-CSF has also recently been recognized as 
a factor driving Th17-induced autoimmune disorders33, 34 and antagonists are now in clinical 
development to treat rheumatoid arthritis and multiple sclerosis32. 
 The identification of T cell-derived GM-CSF as a direct antibacterial factor adds a new 
function to the T cell antimicrobial arsenal and highlights an additional role for GM-CSF. For 
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tuberculosis specifically, recombinant GM-CSF (rGM-CSF) has recently been used successfully 
in murine treatment studies35, 36. Only a single human trial has ever tested rGM-CSF during active 
TB37. Although it was well tolerated, it failed on the endpoints tested. Because few aspects of 
disease were characterized during this trial, it is unclear why it failed. However, an evident 
misstep was the route of administration. In this trial, rGM-CSF was given subcutaneously, but 
previous research found that aerosol but not systemic delivery of GM-CSF restores pulmonary 
function in GM-CSF-/- mice38. It appears that the route of delivery is critical for attaining biological 
effects with rGM-CSF in mice and whether this is also true in people has not yet been tested. 
 While rGM-CSF has many appealing attributes for a potential immunotherapy during 
tuberculosis, the contribution of GM-CSF to autoimmune conditions necessitates caution in 
reviewing the details of how and for how long it would be administered. Like most factors in 
biology, striking an equilibrium between too little and too much GM-CSF is likely to be most 
beneficial for treatments. 
 Due to the short half-life of rGM-CSF and the presumed need to fine-tune the dosage of 
the cytokine in vivo, investigating means to induce T cell production of GM-CSF production 
endogenously may be more effective therapeutically. Because so many T cell subsets are 
capable of producing GM-CSF, this leaves many different therapeutic routes available for future 
investigation.  
 
Effect of lipid content on macrophage antimicrobial activity 
 Because Mtb is an intracellular and chronic pathogen, it works very hard to maintain an 
intracellular niche that allows for persistence, growth, and ultimately replication. It blocks 
phagosome maturation and vesicular acidification39, 40. Mtb utilizes the glyoxylate shunt and 
gluconeogenesis pathways to access carbon sources41, 42. It also expresses sensors like DosRS 
and enzymes like catalase-peroxidase to perceive and repair oxidative stress43, 44. In addition, 
Mtb requires amino acid biosynthesis and/or access to host amino acids for growth45.  
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  Therefore, it is not surprising that immune cytokines might alter host cell metabolism in 
an effort to make these intracellular niches less hospitable. For example, a recent study found 
both IFNγ and LPS stimulation induced host immunoresponsive gene 1 (Irg1) in macrophages 
that generated a host metabolite itaconic acid46, 47. Itaconic acid acted as an isocitrate lyase 
inhibitor, blocking glyoxylate shunt activity and restricting bacterial growth in macrophages. This 
demonstrates that host inflammatory signals can lead to bacterial metabolic pressure that acts as 
an antimicrobial mechanism.   
 The results that GM-CSF leads to an increase in neutral lipid content and an increase in 
cholesterol in combination with studies utilizing Mtb metabolic mutants and chemical inhibitors 
suggest that these pathways may be critical to the antimicrobial function of GM-CSF. The model 
that increased cholesterol quantity within the host cell is detrimental to Mtb growth may at first 
appear counterintuitive. It has been demonstrated that Mtb can utilize cholesterol as a carbon 
source and its growth in cholesterol is normal48. It would appear that increased access to this 
carbon source would allow Mtb to grow even better. However, it has been documented that Mtb is 
highly vulnerable to effects of cholesterol toxicity due to accumulation of propionyl-CoA and other 
metabolites toxic to the cell49, 50, 51. These effects can be rescued by either increased propionyl-
CoA catabolism or increased acetyl-CoA levels. In addition, one hypothesis is that changing the 
access to carbon sources, even if they are increased, may alter Mtb cell wall permeability and 
integrity, leading to inhibited growth.  
 Results of in vivo experiments are much harder to interpret in the context of these 
pathways. For example, a recent study demonstrated that treatment of Mtb-infected mice with 
statins, HMG-CoA reductase inhibitors that lead to lowering of cholesterol levels, were effective in 
reducing bacterial burden in mice52. In addition, hMDM from patients on statin therapy showed 
increased resistance to Mtb growth during in vitro cultures. However, this result must be 
interpreted carefully, because statins have been shown to decrease cholesterol levels in the 
blood leading to subsequent decreased cholesterol efflux from macrophages and potential 
contradictory accumulation of cholesterol in peripheral cells53. It is not clear yet whether the 
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beneficial effect of statins during Mtb infection comes from reduced cholesterol within host cells or 
whether other systemic changes account for the effect. 
 Whether GM-CSF could ever be used therapeutically or induced immunologically to 
control infection remains to be seen. However, examining the metabolic consequences of GM-
CSF both on the host and bacterial sides may reveal other novel and more feasible therapeutic 
targets. For example, both PPARγ and LXR have well-developed agonists and antagonists that 
could be adapted for therapeutic use. Investigation into the antimicrobial role of GM-CSF will 
hopefully provide greater insight into the biology behind the macrophage-Mtb interaction.  
 
 
FUTURE DIRECTIONS 
 
 There are many potential paths of further investigation into the antimicrobial roles for both 
iNKT cells and GM-CSF. In order to better understand the role for iNKT cell activation during Mtb 
infection and link various observations that have been made, it would be important to investigate 
the effector function utilized by iNKT cells to reduce bacterial growth after in vivo αGalCer 
stimulation. Given our in vitro co-culture results using IFNγ-/- iNKT cells and Mtb-infected 
macrophages, we would predict that iNKT cells do not require IFNγ production for this effect and 
in fact produce GM-CSF as the dominant effector function. However, this experimental set-up is 
complicated by the fact that iNKT cells from GM-CSF-/- mice are dysfunctional, likely due to the 
requirement of GM-CSF in the maturation of the cells selecting iNKT cells during development54. 
Therefore, to test this hypothesis, a more complicated transfer experiment will need to be 
performed. In addition, it would be useful to investigate whether iNKT cells can be activated 
therapeutically in people to induce GM-CSF production and restrict bacterial growth.  
 We demonstrated that many of the T cells that produce GM-CSF during infection also 
produce IFNγ. To fully understand the effect of GM-CSF during infection, studies investigating the 
function of GM-CSF in the presence of other cytokines should be undertaken. We have 
preliminary evidence that GM-CSF and IFNγ have additive protective effects in vitro. In addition, 
there are reports that GM-CSF induces the production of pro-inflammatory cytokines like TNF and 
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IL-1β. New evidence that IFNγ signaling in macrophages induces itaconic acid that acts as an 
isocitrate lyase inhibitor also provides preliminary evidence that the protective effects of IFNγ and 
GM-CSF may be linked mechanistically46, 47. 
 Utilizing the Δmce4 Mtb mutant was very informative for testing how GM-CSF stimulation 
affected Mtb growth. There are several other known metabolic mutants that could also be useful 
to test, but a more thorough analysis of bacterial pathways that are affected by this stimulation 
could be accomplished by screening with a transposon mutant library55. This could be 
accomplished either in GM-CSF treated macrophages or in GM-CSF-/- mice compared to 
appropriate controls and provide further insight into both the antimicrobial effects of GM-CSF and 
the transcriptional program utilized by Mtb to counteract host immune stresses. 
 Another area of future investigation is the effect of GM-CSF on human macrophages. In 
Chapter 4, we tested rGM-CSF on hMDM and observed greater heterogeneity in the response of 
human macrophages to GM-CSF than in murine cells. Previous studies that described the 
protective effect of GM-CSF in hMDM did not comment on donor-to-donor variability56, 57, 58. It is 
not yet clear whether this variability is technical or biological. If inducing lipid changes in the host 
macrophage generates the antimicrobial effect of GM-CSF, then one would predict that the host 
lipid status at baseline would influence the magnitude of the effect of GM-CSF. This is a 
consideration at the cellular level and also at the host level. The interaction between host 
metabolism and tuberculosis has gained greater attention in light of the increased susceptibility to 
TB by people with diabetes mellitus and the current epidemiological shift that is bringing these 
two public health epidemics closer together59. In considering future therapeutic approaches using 
GM-CSF, variability in the host response due to conditions of lipid dysregulation, like diabetes, will 
certainly need to be addressed. 
 Lipid droplets have been described during infection as potential sites of both nutrient 
acquisition by pathogens and microbial killing60, 61. Lipid droplets can associate with phagosomes 
and transport of lipid content between these organelles has also been observed. It has been 
hypothesized that lipid droplets could play a role in accelerating phagolysosomal fusion as well as 
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enhancing autophagy pathways62. One hypothesis is that the increase in neutral lipids observed 
after GM-CSF treatment may induce increases in phagosome maturation and autophagy that 
contribute to the inhibition in Mtb growth. The effect of increased lipid content, especially stored in 
lipid droplets, on other cellular processes could be investigated further. 
 Roles for both iNKT cells and GM-CSF during Mtb infection offer many new avenues for 
investigation. A better understanding of both factors will offer greater mechanistic insight into TB 
immunity. This study is just the first step towards addressing these new mechanisms.  
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APPENDIX I: SUPPLEMENTAL FIGURES 
 
GM-CSF antimicrobial mechanism 
 
 
To determine how GM-CSF leads to restriction of bacterial growth in mature 
macrophages, a number of common effector functions and macrophage characteristics were 
analyzed. These included nitric oxide (NO) production, reactive oxygen species (ROS) 
production, phagocytosis rates, cell survival and growth, and cell cycling. Interestingly, GM-CSF 
appeared to have little effect on most of these measurements, with the exception of increased cell 
growth and cell cycling. This is likely because many of the reports of GM-CSF inducing these 
phenotypes may have in fact been measuring the maturation effect of GM-CSF on immature 
monocytes, rather than the effect of GM-CSF on fully mature activated macrophages, as 
observed with our thioglyollate-elicited peritoneal macrophages.  
The following results are included here: 
Supplemental Figure 1. Recombinant GM-CSF does not induce nitric oxide production. 
Supplemental Figure 2. Recombinant GM-CSF does not induce ROS production. 
Supplemental Figure 3. Recombinant GM-CSF increases CD80 and MHC II expression  
but does not increase the rate of phagocytosis. 
Supplemental Figure 4. Recombinant GM-CSF increases cell survival and growth. 
Supplemental Figure 5. Recombinant GM-CSF alters macrophage cell cycling. 
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Supplemental Figure 1. Recombinant GM-CSF does not induce nitric oxide production.  
 
Uninfected or H37Rv-infected WT murine mφ treated after 24 hours with GM-CSF (10 ng/ml) or 
IFNγ (10 U/ml) and TNF (10 ng/ml). Supernatant was harvested at 48 hours post-infection, 24 
hours post-treatment. Nitrite, a stable breakdown product of NO2, was measured by Griess 
reaction. Error bars indicate mean ± SEM. Data is from triplicate samples from one experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2. Recombinant GM-CSF does not induce ROS production.  
 
Uninfected WT murine mφ treated for 24 hours with GM-CSF (10 ng/ml), LPS (5 ng/ml), IFNγ (10 
U/ml) and TNF (10 ng/ml), or PMA as a positive control.  Cells were then stained with 
dihydrorhomdamine (DHR) 123 and fluorescence was measured by flow cytometry. Error bars 
indicate mean ± SEM. Data is from triplicate samples from one experiment. 
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Supplemental Figure 3. Recombinant GM-CSF increases CD80 and MHC II expression but 
does not increase the rate of phagocytosis.  
 
Uninfected WT TGL-elicited peritoneal mφ (TGL-mφ) and bone marrow derived macrophages 
(BMDM) treated for 24 hours with GM-CSF (0.1-10 ng/ml), LPS (1 ug/ml), or LPS/IFNγ (1 ug/ml; 
10 U/ml) as positive controls. (A) % phagocytosis measured after treated mφ were fed 
fluorescently tagged heat-killed E. coli. for 30 mins (B and C). CD80 and MHC II surface 
expression measured by flow cytometry. Error bars indicate mean ± SEM. Data is from duplicate 
samples from one experiment. 
 
 
 
 
	   163	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 4. Recombinant GM-CSF increases cell survival and growth.  
 
WT TGL-elicited peritoneal mφ (TGL-mφ) (A) and PPARγfl/fl; LysM-cre mφ and PPARγfl/fl control 
mφ (B) were either uninfected or infected with H37Rv at varying MOIs and treated on d1 with 
GM-CSF (1-10 ng/ml) or IFNγ (10 U/ml) and TNF (10 ng/ml). Cell survival and growth was 
measured on d5 using the crystal violet assay. Error bars indicate mean ± SEM. Data is 
representative of two experiments (A) or from a single experiment (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 5. Recombinant GM-CSF alters macrophage cell cycling.  
 
WT TGL-elicited peritoneal mφ were treated for 48 hours with GM-CSF (10 ng/ml) and then 
stained with propidium iodide. DNA content was measured by flow cytometry and various DNA 
peaks were isolated to determine cell cycle phase. (A) Representative flow cytometry histograms 
for propidium iodide staining. (B) % of the macrophage population in G1, S, or G2/M phase. Error 
bars indicate mean. Data is representative of a single experiment.   
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APPENDIX II: ADDITIONAL PUBLICATIONS 
 
1. EspA acts as a critical mediator of ESX1-dependent virulence in Mycobacterium tuberculosis  
by affecting bacterial cell wall integrity. 
Garces A, Atmakuri K, Chase MR, Woodworth JS, Krastins B, Rothchild AC, Ramsdell 
TL, Lopez MF, Behar SM, Sarracino DA, Fortune SM. PLoS Pathog. 2010 Jun 24;6(6) 
e1000957.  
The ESX-1 secretion system in Mtb is highly associated with its virulence. However, the 
effects of individual secreted factors by ESX-1 had not been studied separately from the total 
effect of the secretion system, because deletion of any individual component completely inhibited 
all secretion. This study sought to dissociate these virulence factors by utilizing a bacterial mutant 
with a defective form of one of the secreted components, EspA, that is unable to form a disulfide 
bond once secreted. The EspA mutant has decreased virulence during in vivo infection in mice 
and decreased mycobacterial cell wall integrity. Here, I tested the IFNβ response, by both protein 
and mRNA techniques, to determine that the EspA disulfide-bond mutant was not defective in 
eliciting an innate immune response in macrophages.   
 
 
 
2. Critical role for invariant chain in CD1d-mediated selection and maturation of Vα14-invariant  
NKT cells. 
Sillé FC, Martin C, Jayaraman P, Rothchild A, Besra GS, Behar SM, Boes M. . Immunol 
Lett. Sep 30;139(1-2):33-41.  
 
 
3. Requirement for Invariant chain in macrophages for Mycobacterium tuberculosis replication  
and CD1d antigen presentation. 
Sillé FC, Martin C, Jayaraman P, Rothchild A, Fortune S , Besra GS, Behar SM, Boes 
M. Infect. Immun. 2011 Aug;79(8):3053-63. 
These two studies sought to determine the role of invariant chain (Ii) expression during 
Mycobacterium tuberculosis infection. Ii-/- macrophages display early restriction of Mtb growth, yet 
delayed phagosomal maturation. Here, I assessed the rates of cell death and cytokine production 
in Ii-/- macrophages compared to WT macrophages and found no effect of invariant chain 
expression on the cellular response of these macrophages to Mtb infection. In addition, these 
studies found that Ii-/- macrophages do not upregulate CD1d expression and are unable to 
stimulate iNKT cells in co-culture to restrict bacterial growth. The invariant chain was shown to 
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play a role in iNKT cell development and maturation. iNKT cells from Ii-/- mice were defective in 
their cytokine responses and their ability to control Mtb growth in WT macrophages. 
 
 
4. Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse  
TCRs. 
Tatituri RV, Watts GF, Bhowruth V, Barton N, Rothchild A, Hsu FF, Almeida CF, Cox LR, 
Eggeling L, Cardell S, Rossjohn J, Godfrey DI, Behar SM, Besra GS, Brenner MB, Brigl 
M. Proc Natl Acad Sci. 2013 Jan 29;110(5):1827-32 
This study characterized the lipid antigens recognized by diverse iNKT (dNKT) cells. I 
tested the recognition of various dNKT cell hybridomas to in vitro Mtb infection of RAW cells. I 
demonstrated CD1d-dependent recognition of Mtb-infected APCs by the dNKT cell hybridomas 
through measurement of IL-2 production. dNKT cells specifically recognized microbial 
phospholipid antigens found in Mtb and Corynebacterium glutamicum and this recognition 
required antigen presentation and processing by the APC but not separate TLR signaling. In 
addition, mammalian phosphatidylglycerol (PG) and diphosphatidylglycerol (DPG) also activated 
the dNKT cell hybridomas. 
 
 
5. Interfering with mycobacterial metabolism synergizes with immune-mediated killing. 
Zhang YJ, Reddy MC, Ioerger TR, Rothchild AC, Dartois V, Schuster BM, Trauner A, 
Valluru S, Huttenhower C, Sacchettini JC, Behar SM, Rubin EJ. Cell 2013 Dec 
5;155(6):1296-1308.  
 In this study, a tryptophan production pathway was identified as a mycobacterial 
response to the CD4+ T cell immune response through a transposon library screening technique 
(TraSH). Together, Jason Zhang and I tested the hypothesis that blocking tryptophan 
biosynthesis in Mtb, either using Mtb mutants or small molecule inhibitors, would inhibit bacterial 
growth and synergize with IFNγ-mediated protection during in vitro infection of murine 
macrophages. 
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6. In search of a new paradigm for protective immunity to TB 
 Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. Nat  
Rev Micro 2014 Mar 3;12: 289-299. 
In this review, we discussed recent discoveries in mechanisms of immune control during 
Mycobacterium tuberculosis infection, with special emphasis on CD4+ IFNγ-independent 
pathways that may be informative for future vaccine design. My contribution was focused on the 
role of pro-inflammatory cytokines and non-conventional T cells. 
 	  
